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ABSTRACT 
 
Currently, resources that may be spent in health care are limited so it is 
necessary to rationalize their consumption and prioritise their allocation 
to the options with higher health outcome and economic sustainability. It 
is for that reason that economic analyses are increasingly included in 
medicine research as an instrument for evaluating different therapeutic 
strategies. In this thesis, both cost and health outcome are separately 
and jointly evaluated to compare different therapeutic strategies to treat 
diseases in different and specific health areas. The challenge was 
adapting and implementing the methods to reflect the assessed health 
issue. 
The analyses require data, and the main sources to obtain them are 
clinical studies (prospective or retrospective), or simulation models. The 
use of simulations avoids to experiment directly to the system of 
interest, these methods imply a smaller time consumption and cost, and 
any danger can be caused by the experimentation performance. 
However, the simulated data always is going to be an approximation of 
real data. 
Real data of a clinical trial was used in the assessment of the adherence 
to antiretroviral treatment promotion program in HIV infected patients. A 
decision tree was used to study the cost per health gain, measured by 
means of clinical and health related quality of life outcomes.  
The simulation of a Spanish cohort of postmenopausal women and their 
possible osteoporotic fractures was done to assess the performance of 
two treatments for the prevention of vertebral and non-vertebral 
fractures in terms of cost-effectiveness. Simulation by means of a 
Markov model required that the disease evolution and the related events 
were simplified using a finite number of health states and the 
probabilities of moving from one state to another as the time go on. 
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Markov models were adapted to reflect that the risk of suffering an event 
can change over time. This analytical model was applied to elucidate 
whether co-receptors testing is cost-effective to determine patient’s 
suitability to benefit from the use of an antiretroviral treatment that 
includes maraviroc. All HIV strains require binding to CD4 plus at least 
one of the 2 co-receptors CCR5 or CXCR4 to enter human cells. Some 
HIV can use both co-receptors, and some individuals have a mixture of 
strains. Only patients with exclusively CCR5-tropic HIV are considered 
eligible to use the CCR5 antagonist maraviroc. 
A budget impact analyses to assess the economic effects of introducing 
eculizumab for treating the paroxysmal nocturnal hemoglobinuria was 
performed. Direct and indirect costs of this disease treatment were 
estimated and reported from the perspective of the health care system 
and from the societal perspective. 
Most of the published clinical studies are focused on measuring health in 
terms of efficacy and/or safety. But, sometimes the health and well-
being quantification is not a direct measurement. Here, the calculation of 
the burden of disease for osteoporotic women who may suffer from 
fractures done at an individual level was presented in terms of disability 
adjusted life years (DALYs). Few studies of burden of diseases are 
available, and even less for Spanish population and performed using 
individual characteristics. 
The pharmacoeconomic studies can be useful in the health resources 
rationalization, and both budget impact analyses and new health 
measures are complementary tools. The work performed in this thesis 
constitutes a good example of methods application and adaptation to 
answer real clinical questions. 
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Summary Chapter 1. INTRODUCTION 
 
Resources that may be spent in health care are limited so it is necessary 
to rationalize their consumption and prioritise their allocation to the 
options with higher health outcome and economic sustainability. 
Consequently, economic analyses are increasingly included in medicine 
research as an instrument for evaluating different therapeutic strategies. 
In this first chapter we explain the data required to complete a 
pharmacoeconomic study and the techniques available to perform it. 
Analyses require data, and the main sources to obtain them are clinical 
studies (prospective or retrospective), or simulation models. The use of 
simulations avoids to experiment directly to the system of interest, these 
methods imply a smaller time consumption and cost, and avoid dangers 
that could be caused by the experimentation performance. However, 
simulated data is only an approximation of real data. 
The available tools to jointly evaluate the cost and the health outcome 
are: Cost-minimization, cost-effectiveness, cost-utility and cost-benefit, 
the incremental cost-effectiveness ratio (ICER), the cost-effectiveness 
plane and incremental net benefit (INB). For all of their results exist the 
need of discounting to the present when future values are used. A state 
of the art of the different approaches used in the health literature is 
presented. 
The aim of this thesis is to assess both cost and health outcome, 
separately and jointly, to compare different therapeutic strategies to 
treat diseases in different and specific health areas. 
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1. INTRODUCTION 
 
This first chapter contains the description of the framework in which the 
thesis is developed, a summary of the state of the art— containing both 
the data required and its available sources, and methods of analysis— 
and the thesis aims and structure. 
 
 
1.1. Background and motivation 
 
This doctoral thesis attempts to define several tools to assist in the 
rationalization of expenditure in health care, taking into consideration 
costs and health benefits. During the learning process, we used various 
methodologies to answer real questions in a number of health-related 
areas; these constitute the practical aspect of this work.  
The problem of expenditure must be considered in a context that 
comprises public health management of new medical technologies and 
emerging drugs, increasing life expectancy of the population, economic 
and financial circumstances, and existing techniques for joint evaluation 
of cost and health outcome*. 
The main goal of public health is to identify and implement strategies to 
enhance the well-being of the population by promoting health, preventing 
disease, and ensuring recovery of good physical and mental status. 
These goals are achieved by providing health education and reporting the 
benefits of a healthy lifestyle through the media, schools, and primary 
                                                 
* Health Outcomes  are  a  change  in  the  health  status  of  an  individual,  group  or  population which  is 
attributable  to  a  planned  intervention  or  series  of  interventions,  regardless  of  whether  such  an 
intervention was intended to change health status. There are different ways of measuring the outcome 
such  as,  death,  degree  of  disability,  number  of  hospitalizations,  health  related  quality  of  life  or  any 
health marker. The  treatment and analysis of  the health outcome should be chosen according  to  the 
type (continuous, discrete…) of the outcome. 
[Reference: http://definitionofwellness.com/wellness‐dictionary/health‐outcomes/] 
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care centres. Prevention of disease includes primary health interventions 
such as vaccination campaigns and early detection programmes. The 
health services—both primary care centres and hospitals—are 
responsible for a recovery of health in cases where there has been a 
loss.  
Technological progress implies that existing mechanisms of providing 
health care are continually changing. Moore’s law1 states that the 
capacity of a computer increases 100% approximately every 2 years. 
This ongoing improvement generates breakthroughs in science, in 
general, and in medicine, in particular. These advances include the 
following: 
i) Information gathering techniques, where electronic databases are used 
to record a patient's medical history and where medical information is 
shared or searched for using the Internet 
ii) Online databases and more precise instruments of measure that 
improve research procedures 
iii) Development of better treatments  
iv) More powerful communications tools, e.g., health campaigns launched 
through social media2.  
Improvements in technology have made health care much more efficient 
than in the past. Many treatments are cheaper and more readily available 
to the general population, and previously “untreatable” diseases now 
have a cure. Sometimes these advances complicate health care. For 
instance, the possibility of detecting the presence of cancer cells imply 
that the medical community has to make every effort to treat it. A 
relevant example of the improvement in health technology is the change 
in the costs associated with the DNA sequencing of a complete human 
genome, which decreased dramatically from September 2001 
($95,263,072) to January 2008 ($3,063,820) and again in April 2013 
($5,826), thanks to second-generation sequencing platforms3. 
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Information on the human genome makes personalized medicine feasible: 
the common medical prescription based on summary responses from a 
broad population is becoming a lifelong health maintenance strategy 
adapted to a person’s unique genetic constitution. It will, therefore, be 
possible to customize disease-prevention strategies and prescribe 
treatment that is both more effective and free of side effects. Making 
personalized medicine available for the general population can reduce the 
duration, cost, and failure rate of therapeutic strategies and eliminate the 
inefficiencies arising from empirical treatment that inflate health care 
costs and undermine patient care. 
Nanomedicine is a finding that can also be applied in daily clinical 
practice. Its goal is to identify the precise targets—cells and receptors—
associated with specific clinical conditions and ensure delivery of 
treatment to achieve the required responses while minimizing side 
effects and dose, leading to a reduction in health care cost. However, 
further research is needed on design, nanoscale vehicles for site-
specific drug delivery, medical imaging after parenteral administration, 
and associated side effects4.  
Although some improvements in health care are reflected in cheaper 
treatment, the rising cost of health care is a reality. Increasing life 
expectancy in developed countries, active expansion of medical 
technology, and the cost of using effective clinical services mean that the 
demand for health resources exceeds supply.  
The increase in life expectancy often implies an increase in the 
prevalence of chronic diseases. The World Health Organization [WHO] 
defines chronic diseases as “diseases of long duration and generally slow 
progression”5. This type of disease has traditionally included 
cardiovascular disease, diabetes and asthma or chronic obstructive 
pulmonary disease. As survival rates and durations have improved many 
varieties of cancer, HIV/AIDS, mental disorders such as depression, 
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schizophrenia and dementia, and disabilities such as sight impairment and 
arthroses are also included6.  
Most morbidity, mortality and health expenses in Europe are due to 
chronic diseases. They cause 86% of deaths and an expenditure of the 
50-80% of the health budget across the 53 member states in the WHO 
European region7. Projections of future mortality and disease show that 
chronic diseases will continue to be the biggest contributor to mortality 
and disability in high−income countries, and chronic disease will 
increase. The Disability Adjusted Life Years (DALYs)* associated with 
chronic or noncommunicable conditions** in high-income countries is 
projected to rise from 86% in 2005 to 89% in 20306.  
Availability of resources is a crucial area in healthcare. The European 
Union is facing an economic and financial crisis that started between 
2008 and 2009 after a period of general growth and stability. In almost 
all European countries, this crisis has been characterized by a strong 
increase in government deficit*** and public debt****. Hospitals and health 
                                                 
* One measure of the overall burden of disease, developed by WHO,  is the disability‐adjusted  life year 
(DALY).  It  is  designed  to  quantify  the  impact  on  a  population  of  premature  death  and  disability  by 
combining  them  into a single measure. The DALY  relies on  the assumption  that  the most appropriate 
measure  of  the  effects  of  chronic  illness  is  time  either  spent  disabled  by  disease  or  lost  due  to 
premature  death.  One  DALY  equals  one  year  of  healthy  life  lost  [WHO  (2005).  Preventing  chronic 
diseases:  A  vital  investment.  Geneva,  World    Health  Organization  Available  from: 
http://www.who.int/chp/chronic_disease_report/full_report.pdf, accessed 13 May 2014]. 
** A situation  in which outflow of money exceeds  inflow. That  is, a deficit occurs when a government, 
company, or  individual spends more  than he/she/it  receives  in a given period of  time, usually a year. 
One's deficit adds  to one's debt, and, therefore, many analysts believe  that deficits are unsustainable 
over the long‐term. [REFERENCE: http://financial‐dictionary.thefreedictionary.com/] 
*** A non‐communicable disease is a medical condition or disease, which by definition is non‐infectious 
and  non‐transmissible  among  people.  Often,  the  terms  “noncommunicable  disease”  and  “chronic 
disease” are treated as  interchangeable, but given recent advances  in treating communicable diseases 
this use is no longer precise enough. For example, HIV/AIDS treated with modern medicines has become 
a disease of  long duration and generally slow progression  (chronic and communicable disease). WHO 
acknowledge this issue, but nevertheless refer to sources that use noncommunicable disease as a proxy 
for chronic disease if no alternative high‐quality data are available. 
**** The total of all bonds and other debt owed by a government. Most of the time, the national debt 
comes  from  bonds  and  other  debt  securities,  but  some  countries  in  the  developing  world  borrow 
directly from international institutions (such as the World Bank). The national debt may be internal, that 
is,  owed  to  bondholders  and  banks  within  the  country,  or  external,  that  is,  owed  to  foreign 
governments,  institutions,  and/or  individuals.  [REFERENCE:  http://financial‐
dictionary.thefreedictionary.com/] 
 
7 
 
care services are traditionally the primary source of social expenditure 
and have been at the core of many measures aimed at reducing costs and 
increasing efficiency. Some European countries such as Greece, Ireland, 
Italy, Portugal, and Spain, have reduced healthcare spending and 
introduced low ceilings on increases in the healthcare budget. Other 
countries have reduced the operational costs of health services and the 
prices paid to providers for goods, services, and tangible assets*. Some 
of these measures directly affect users in terms of payment for 
treatment, visits, hospitalization, and access to health technologies and 
drugs**, 8, 9.   
Consequently, rationalization of available resources and selection of the 
most beneficial and sustainable therapeutic strategies have become a 
priority10. It is necessary to evaluate the costs and benefits of available 
therapeutic strategies when attempting to make major improvements in 
health care. Indeed, decisions about public health and health care 
delivery increasingly rely on studies that assess the cost-effectiveness 
of medical services11. 
It is clear that a standardized set of methodological tools should be 
developed. The International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) provides a series of healthcare-specific 
economic concepts and facilitates a forum for discussion and guidelines 
for the development of research on healthcare costs and outcomes12. 
Pharmacoeconomics is the scientific discipline that evaluates the clinical, 
economic, and humanistic aspects of health care interventions in order to 
provide health care decision makers, providers, and patients with 
valuable information for allocating resources and obtaining optimal 
                                                 
* Austria, Belgium,  the Czech Republic, Denmark, Estonia, Greece,  Ireland,  the Netherlands, Portugal, 
Spain, Slovenia, and the United Kingdom. 
 
**  The  Czech  Republic,  Denmark,  Estonia,  France,  Greece,  Ireland,  Italy,  the  Netherlands,  Portugal, 
Switzerland –and also the private health insurance in the United States ‐raised user charges. 
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outcomes. The health care interventions include pharmaceutical 
products, diagnostic tools, services, programs, and activities to promote, 
generate, or re-establish health. Pharmacoeconomics incorporates and 
combines economics, clinical evaluations, risk analysis, health related 
quality of life, and epidemiology. It uses statistical and computer-based 
techniques to analyze drugs, medical devices, biotechnology, surgery, 
and disease-prevention services. In this context, the outcome and impact 
of different strategies can be examined by taking into account cost and 
health gain in order to address the following questions: 
 Which health care interventions should be included in the clinical 
care guidelines for a particular disease? 
 Which is the best health care intervention for a particular subset of 
patients? 
 Which is the cost per unit of outcome for a concrete health care 
intervention? 
 Will patient health related quality of life be improved by applying a 
particular health care intervention? 
 
The general aim of this thesis is to assess several methods to answer 
real clinical questions related to health resources rationalization. An 
overview of techniques and illustrations on the evaluation of cost and 
health outcomes to compare different strategies are presented and 
discussed. 
 
The Spanish health care system 
The data discussed here apply to the Spanish population, its health care 
system, and its expenditure on health care. 
In Spain, life expectancy at birth increased by more than two years from 
1995 to 2005 and now stands at 80.23 years (76.96 for men and 83.48 
for women)13. Application of various techniques to project life 
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expectancy in Spain for 2050 reveal values of 81 to 85.38 years for men 
and 87 to 91.97 years for women13-15. It is important to note that all the 
estimations in the studies cited indicated an increase in life expectancy. 
The increase in survival is linked to a larger number of citizens affected 
by a chronic disease. At least one over six Spanish adults (15 years old 
and older) suffers one of them. The lumbar pain (18.6%), arterial 
hypertension (18.5%), arthroses, arthritis and rheumatism (18.3%), high 
cholesterol (16.4%) and cervical pain (15.9%) are the most common16. A 
study published on 2002 reported that the Spanish population older than 
65 years old suffers a mean of 1.8 chronic diseases (Standard 
Deviation=1.2, Minimum=0, Maximum=5). Being the hypertension the 
most prevalent (40.1%), followed by osteoarticular (24.0%) and 
cardiovascular diseases (18.4%) and sight impairment (16.6%)17. 
In order to gain a perspective of the impact of disease on the cost of the 
Spanish Health Care System, we analyzed the following 5 groups of 
diseases: HIV/AIDS, cancer, respiratory diseases, cardiovascular 
diseases, and neurological diseases. For each group, we used various 
sources to obtain information on the number of cases and the 
corresponding costs. The information provided below must be 
interpreted with caution, as the sources are not homogeneous.  
Neurological diseases generate the highest costs for the health care 
system. During 2004, between 6 and 7.5 million people had a 
neurological disease; the cost of treatment to the health system was over 
€10.8 billion*,18. 
This group was followed by cardiovascular diseases, which generated an 
expenditure of more than €9 billion per year19. Cardiovascular diseases 
have a high impact on mortality and cause 31.7% of deaths20. 
                                                 
* Billion is equivalent to a one thousand million, i.e., 109. 
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As for respiratory diseases, asthma affects 2.5 million people and costs 
€1.48 billion, and chronic obstructive pulmonary disease affects 4.8 
million people and costs €3 billion21-23. 
Every year 162,000 of new cases of cancer—excluding skin cancer and 
melanoma—are diagnosed in Spain. In 2003, these generated costs of 
about €1.75 billion (colorectal, breast, prostate, and uterine cancer)24, 25. 
Treatment of HIV/AIDS affects fewer people and costs less than the 
other disease groups. In 2005, the Spanish health care system estimated 
the cost of antiretroviral drugs to be €0.423 billion (i.e., 423 million)26. 
 
1.2. Data sources 
 
Several considerations should be taken into account in an economic 
evaluation. Data (information on cost and health gain per treatment 
strategy) are collected from real sources or generated through 
simulation. The type of the health-economic evaluation performed and 
the input data required depend on the definitions selected for cost and 
health outcome. 
The information used in the economic evaluation is detailed in subsection 
1.2.1. A description of the available methods for obtaining data, namely, 
by real data collection or analytical models and simulation, is given in 
subsections 1.2.2 and 1.2.3, respectively. The Section ends with a 
discussion of the features of the various data sources. 
 
1.2.1. Data requirements 
For a model to enable rationalization of resources and thus produce the 
largest possible gain in health per monetary unit, a series of points must 
be taken into account. These include the population of interest, the 
characteristics of the study cohort, the course of the disease under 
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study, available treatments or health care interventions, treatment 
efficacy*, adverse events, and cost. 
The disease of interest and the cohort characteristics depend on the 
target population, which can be a subset of the patients affected by the 
disease. 
It is necessary to gain knowledge of disease course, incidence, and 
guidelines for diagnosis and treatment. The intervention to treat the 
health problem studied can be a combination of tests, care services, and 
drugs, and it is of interest to analyze both their efficacy and their side 
effects. Efficacy should be measured objectively, i.e., it can be 
expressed in terms of enhanced health related quality of life and self-
sufficiency, number of clinical events avoided, number of patients without 
treatment failure, or even health gain expressed as a monetary value. 
Apart from disease course and therapeutic options, the model should 
include the associated costs of each health care intervention, which are 
expressed in monetary terms. The items and services that are included 
in the cost calculation should be stated in the study plan (e.g., drugs, 
health care, and patient’s travelling expenses). 
The effectiveness (or efficacy) measure chosen and the list of items 
included in the costs of therapy define the type of the pharmacoeconomic 
study (described in subsection 1.3.1). Once the therapeutic strategies to 
be compared have been decided and the terms of the comparison are 
made, the data collection or generation process is designed. 
 
 
 
                                                 
* The terms Efficacy and Effectiveness are going to be used with the following meaning: Efficacy entails 
how a drug performs in an ideal or controlled circumstance, as in the context of a clinical trial. However, 
effectiveness describes a drug's success in real‐world circumstances where the patient population and 
other variables cannot be controlled, i.e. under usual circumstances of health care practice. 
[REFERENCE: http://www.contextmattersinc.com/use‐of‐efficacy‐and‐effectiveness‐often‐misleading‐
and‐may‐skew‐reimbursement‐decisions‐presented‐at‐ispor‐europe‐2012/] 
12 
 
1.2.2. Data collection 
The data needed to build a pharmacoeconomic model can come from 
prospective randomized clinical trials (RCTs) and observational studies, 
retrospective databases or clinical files, expert panels (expert opinion), 
patient surveys, published literature, treatment guidelines, and research 
institute databases, such as those of the World Health Organization27, the 
Statistical Office of the European Communities15, the Instituto Nacional 
de Estadística28, or the Institut d’Estadística de Catalunya29. 
The availability, advantages, and disadvantages of the different types of 
databases are discussed below. 
 
1.2.2.1. Prospective RCTs and observational studies 
In prospective RCTs, patients are randomly allocated to the intervention 
of interest and followed up for a defined period of time. The main goal is 
to evaluate and compare the health outcome, usually efficacy and/or 
safety, of the intervention. Within this framework, monetary cost can be 
easily registered to perform a pharmacoeconomic evaluation30, 31, but the 
utility of the data generated is limited owing to homogeneity in patient 
characteristics, fixed screening and follow-up schedules, and finalization 
of data collection when patients discontinue the study treatments. The 
design of RCTs makes it difficult to evaluate the therapeutic strategies 
for a large variety of patients, since it reduces the chance of unexpected 
outpatient visits and the need for symptom-driven diagnostic procedures 
and implies a lack of information when the patient discontinues the study. 
These restrictions prevent an extrapolation of health cost results for 
patients in daily clinical practice. This limitation is especially important in 
the field of prevention and chronic maintenance therapy. 
 
Observational studies assess patients with similar characteristics who 
differ with respect to the specific factors under study; the health 
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interventions are not controlled. During the follow-up, changes in the 
available therapeutic strategies and guidelines for treatment of a disease 
can vary and invalidate future conclusions, thus leaving them outdated. 
Observational studies have fewer limitations than the pharmacoeconomic 
studies associated with clinical trials; however, both are time-consuming 
and involve cost expenditure. Decision making in healthcare usually 
requires rapid access to information. The data from previous RCTs and 
observational studies can be used, but they have the same drawbacks as 
described above, except for the time and money consumed to obtain 
results. 
 
1.2.2.2. Retrospective databases and clinical files 
Retrospective data analysis measures effectiveness and can provide 
“real-world” data. Cost-effectiveness analyses based on retrospective 
databases or clinical files can provide real-time, relevant, and 
comprehensive decision-making tools. Retrospective analyses are quick 
and relatively inexpensive to perform. They reflect specific populations 
that cannot be easily studied using RCTs. Retrospective databases tend 
to cover more realistic time frames, since they are not constrained by 
the limitations of a set trial period. Existing databases can provide a set 
of variables, and analyses of these data can reveal real-world 
prescribing patterns. The disadvantages of retrospective database 
analyses used for economic evaluations include the fact that some of the 
study variables are not directly precisely recorded32, which reduces the 
quality of the information. 
 
1.2.2.3. Expert panels 
The increase in the number of pharmacoeconomic studies in the last 
decade has promoted the development of guidelines for the conduct of 
economic evaluations in many countries. It is noteworthy that different 
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study designs can impact results. The use of expert judgement in 
decision analytic modelling is one area where design issues may 
influence the findings of a study33. Several researchers have suggested 
that expert judgement can be used successfully in pharmacoeconomic 
studies. Most acknowledge that expert opinion should be used as a last 
resort in pharmacoeconomic studies. Barr and Schumacher support its 
use when ideal data are not available and when, together with 
information from meta-analyses and other trial data, expert opinion can 
serve as a reasonable approximation34. Nuijten et al. also acknowledge 
the weaknesses inherent in the use of expert opinion, although they 
report that its application is not forbidden in modelling studies35. Evans 
suggests that the use of expert opinion need not be avoided as long as 
potential weaknesses are addressed and the techniques are applied 
appropriately36. Similarly, Halpern et al. recognise that expert opinion 
plays an important role in modelling studies but that it is subject to many 
errors and biases37.  
Expert opinions can be obtained by means of Delphi panels, modified 
Delphi panels, and round tables. The Delphi technique is a well-known 
method for consensus building based on a series of questionnaires 
delivered using multiple iterations to collect data from a panel of 
experts38. 
The areas of concern to be considered when obtaining expert opinion 
include the provision of baseline information or seed algorithms to 
panellists, the high attrition rate of panels, the criteria for selecting 
experts, and the definition of consensus36. Despite the difficulties and 
limitations involved in this method, information gathered through an 
expert panel can cover the lack of appropriate information necessary to 
perform pharmacoeconomic studies. 
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1.2.2.4. Patient surveys 
Surveys have been used to understand the value that patients place on 
health care interventions. Understanding patient preferences can help to 
improve adherence and better predict the corresponding health 
outcomes. It is widely accepted that adherence is maximised when a 
treatment or intervention matches the patient’s preferences (World 
Health Organization [WHO]39, National Institute for Health and Clinical 
Excellence [NICE]40). 
Patient surveys have been used to demonstrate patient tradeoffs 
between treatment features and outcomes, and to quantify patient values. 
The approaches used are self-reported adherence and measures such as 
willingness to pay or maximum acceptable risk. The term “willingness to 
pay” is the maximum amount a person would be willing to pay, sacrifice, 
or exchange for a good. The parameter “maximum acceptable risk” was 
proposed by Johnson41. The objective of this approach is to estimate the 
maximum risk patients are willing to accept in order to achieve the 
therapeutic benefits of drug therapy. This maximum acceptable risk can 
then be compared against the actual or expected risk associated with a 
treatment to determine whether a treatment is acceptable to patients. 
 
1.2.2.5. Published literature 
Published literature, treatment guidelines, and research institute 
databases can provide insight into disease outcome, patient 
characteristics, recommended treatment, disease prevalence, and 
treatment efficacy or effectiveness. 
 
1.2.3. Data generation 
Analytical models or procedures based on simulations provide data 
without conducting real experimentation using patients. These methods 
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do not imply costs or danger in their performance, and the results are 
obtained relatively quickly. 
 
1.2.3.1. Analytical models 
Analytical models are symbolic and yield general solutions to a problem. 
The model is constructed following specific rules written in terms of 
mathematical expressions which reflect as closely as possible the real-
world problem. A general solution is obtained, and specific cases might 
be assessed by forcing the variables included in the model to take 
different values. Both the complication of constructing an analytical 
model for dealing with a complex problem and the oversimplification of 
the problem are limitations of this approach. The steps required to define 
an analytical model departing from a real system and applying the 
information obtained to solve it are presented in Figure 1.1. 
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Figure 1.1. The components of an analytical model and the steps required to represent 
and assess a real system by means of modelling are displayed42. 
 
The steps required to define an analytical model departing from a real 
system and applying the information obtained to solve it are presented. 
The use of these models is advisable when the study is relatively simple. 
 
1.2.3.2. Simulation procedures 
Shannon, in 1978, defines simulation as the process of designing a model 
of a real system and conducting experiments with this model for the 
purpose of understanding the behaviour of the system and/or evaluating 
various strategies for the operation of the system43. Another way of 
defining modelling and simulation is by using the concept of “learning by 
doing” or “experimental learning” introduced by the political scientist 
Herbert A. Simon (1916-2001). The process of simulation allows the 
imitation of the operation of a real-world process or system over time. 
The execution of an operation in a designed model generates a history, 
which makes it possible to draw inferences concerning the operating 
features of the real system that is represented44. Simulation-based 
models yield specific solutions and make it possible to test a combination 
of variables and scenarios that would be impossible to study in real life. 
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Thus, the simulation provides a means of learning about a system which 
cannot be observed or experimented with directly. 
Simulation-based models require the use of knowledge and data about 
the real system, and the accuracy of the results depends enormously on 
the quality of the input parameters and the simplifications of the real 
system when constructing the model. Different steps can be identified 
when constructing a simulation model, as follows: 
 
 
 
 
 
 
 
 
 
Figure 1.2. The components of a simulation model and the steps required to represent 
and assess a real system by means of simulation are displayed. 
 
Simulation models can be based on continuous or discrete time45. The 
variables or events that constitute the model can be continuous, discrete, 
or both. Prescriptive models are built to characterize and optimize the 
choice of a treatment, whereas descriptive models study the behavior of 
the disease. Simulation models can be deterministic or 
probabilistic/stochastic. The deterministic simulation model assumes 
point values and do not account for variability, whereas the probabilistic 
model accounts for uncertainty by using random variables to assign the 
values to the system status and its entries46. Autonomous models are 
those that the system users are initially included in the model and they 
evolve through the time function i.e., the patients assessed are already 
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inside the model –also called “closed” models. The non-autonomous 
models have a paradigm to represent the flux of new “patients” entering 
in the system –also referred to them as dynamic or “open” models.  
The most appropriate models for our cost and health outcomes are 
discrete time models, since the recurrence of the disease events and 
medical visits are recorded discretely in a finite number of time points. 
Decision trees, Markov models, and discrete-event simulation use 
discrete-time models, which are the most common in the literature.   
Further details about discrete-event simulation are given in Annex I. 
 
1.2.4. Some remarks on data sources 
The accuracy of model-based pharmacoeconomic estimates depends on 
the quality of input data, validity of surrogate endpoints, and 
appropriateness of modelling assumptions, including model structure, 
length of the simulated time, and ability of the model to differentiate 
between clinically and economically meaningful outcomes. 
 
It would be desirable to find real data collected for the population and 
treatments under study to provide the required information about cost 
and health gain already registered. A prospective study designed with 
this purpose would require time and money investment. The simulation 
requires less time and money to be performed but the results obtained 
have a limited amount of information and are based on assumptions. 
 
Depending on the available means, information can be collected from a 
single source or multiple sources and be combined in order to answer the 
question of interest. For the objectives, it is desirable to have the 
minimum possible data sources that fulfil our cost and efficacy 
requirements in a cohort with characteristics similar to those of our 
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target population. The conclusions obtained will be as accurate as the 
data we use. If the available data cannot answer our question, the gaps 
can be filled in using assumptions; in this case, the conclusions obtained 
will be valid under the assumptions we made. Bodrogi et al. stated the 
following: “These economic evaluation methods are not mutually 
exclusive: in practice, economic analyses often combine data collection 
alongside clinical trials or observational studies with modelling. The need 
for pharmacoeconomic evidence has fundamentally changed the strategic 
imperatives of research and development (R&D). Therefore, 
professionals in pharmaceutical R&D have to be familiar with the 
principles of pharmacoeconomics, including the selection of health 
policy–relevant comparators, analytical techniques, measurement of 
health gain by quality adjusted life-years and strategic pricing of 
pharmaceuticals”47. 
 
 
1.3. Techniques for economic evaluation 
 
This section contains the description of several useful tools to jointly 
evaluate the cost and the health outcome. In the first subsection -1.3.1- 
four techniques selected depending on the cost and health outcome 
measurements definition are described, these definitions are the bases 
for the analysis developed in this thesis. Further calculations and 
graphical displays combining cost and health outcomes can help to 
assess the performance of the therapeutic strategies such as the 
incremental cost-effectiveness ratio (ICER), the cost-effectiveness plane 
and incremental net benefit (INB) (See subsection 1.3.2).  
Finally, in the third subsection, a review of examples of relevant 
economic evaluation techniques and modelling approaches used in the 
health literature is presented. 
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1.3.1. Definitions 
The value of one health-care intervention can be compared to another in 
terms of cost and health outcome. The cost is expressed in monetary 
terms and the effects can be expressed either in terms of monetary 
value, efficacy or enhanced quality of life. Depending on which 
measurement is chosen for the effect, a different type of economic 
evaluation should be performed. Costs and benefits can be assessed 
through cost-minimization, cost-effectiveness, cost-utility and cost-
benefit analysis. 
 
The cost-minimization is the simplest of the pharmacoeconomics tools. It 
is applied when comparing two drugs of equal efficacy and equal 
tolerability. When clinical equivalence is previously proved, a simple 
comparison of cost can suffice to choose between two or more 
therapeutically equivalent treatment alternatives. The weakness of this 
approach lies in the difficulty of proving that the compared treatment 
strategies have the same health impact, or in describing the assumptions 
under which the bioequivalence of treatments become true. 
 
The cost-effectiveness (CE) of a therapeutic or preventive intervention 
is the ratio of the cost of the intervention to a relevant measure of its 
effect. Cost refers to the resource expended for the intervention, usually 
measured in monetary terms such as Euros or Dollars. The measure of 
effects is the units of health improvement, and this depends on the 
intervention being considered. For a given therapeutic strategy the 
number of people cured of a disease, the number of symptom-free days 
experienced by a patient or the number of illness events avoided can be 
of interest. The selection of the appropriate health effect quantification 
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should be based on clinical judgment in the context of the intervention 
being considered. 
 
A special case of CE analysis is cost-utility analysis, where the effects 
are measured in terms of the number of years that a person lives with 
“good health”, using a measure such as quality-adjusted life years or 
disability-adjusted life years. The purpose of the cost-utility studies is 
to estimate the ratio between the cost of a health-related intervention 
and the benefit it produces in terms of the number of years lived in full 
health by the beneficiaries. Cost is measured in monetary units. Benefit 
needs to be expressed in a way that allows health states that are 
considered less preferable to full health to be given smaller quantitative 
values. The utility-related measure is often expressed in quality-
adjusted life years (QALYs). 
A QALY takes into account both quantity and health related quality of life 
generated by healthcare interventions. It is the multiplication of life 
expectancy by the measure of the quality of the remaining life-years. 
Further details about this health measurement are given in Annex II. 
The QALY places a weight on time in different health states. A year of 
perfect health is worth 1; however a year with any health impairment has 
a score less than 1. Death is considered to be equivalent to 0, some 
health states might be considered worse than death and have negative 
scores. These health status scores are known as utilities. 
The cost-utility ratio indicates the additional cost required to generate a 
year of perfect health (one QALY). Comparisons can be made between 
interventions, and priorities can be established based on those 
interventions that are relatively inexpensive (low cost per QALY) and 
those that are relatively expensive (high cost per QALY). However, this 
approach, as a method for assessing interventions, remains controversial, 
because methods for scoring health states require a consensus about 
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how valuations should be made, which valuations should be used, and 
how the valuations of different individuals should be combined. 
 
The cost-benefit analysis measures the impact of an intervention on 
monetary units. The costs and also the benefits are assessed in monetary 
terms, for this reason it is necessary to set money values on health 
outcomes. The therapies are compared using the ratio Cost/Benefit. The 
advantage of this method is its simplicity when comparing between 
treatments; however, the difficulty in setting money values to health 
outcomes and the ethical issues related to a subjective quantification 
entail a scarce use of this type of study on health area. The cost-benefit 
analysis is mainly, but not exclusively, used to assess the value for 
money of very large private and public sector projects. This is because 
such projects tend to include costs and benefits that are less agreeable 
to being expressed in financial or monetary terms (e.g. environmental 
damage), as well as those that can be expressed in monetary terms. 
A small discussion on ethical issues related to the resources allocation is 
presented in Annex III. 
 
Discounting 
Discounting is a procedure that can be applied to all the previous 
analyses. In fact, the results of the measures described above should be 
reported indicating if they are discounted or non-discounted.  
Costs and health outcomes should be discounted to present values when 
they occur in the future, to reflect society’s rate of time preference. 
Accordingly, any costs or outcomes occurring beyond one year should be 
depreciated using standard methods. A common discount rate should be 
used to ensure the comparability of results across evaluations. The 
standard rate for the Reference Case is set at 5% per year. A rate of 0% 
should be used to show the impact of discounting and a 3% discount rate 
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must be used in a sensitivity analysis* for a comparison with published 
evaluations in other jurisdictions. The discount rates are expressed in 
real (constant value) terms, which are consistent with valuing resources 
in real (i.e., constant, inflation-adjusted) monetary units (Euros, dollars, 
etc.)48. 
Some countries have developed their own guidelines to perform 
pharmacoeconomic studies. One of the most complete and frequently 
used as a good example are the NICE guidelines49, where the 
suggestions are to apply a 3.5% of annual discount rate and vary the rate 
between 0% and 6% for the sensitivity analysis if results are potentially 
sensitive to the discount rate. 
The discounting rate applied in the model should be clearly stated in the 
results document. 
In the assessment of the therapeutic strategies by means of cost and 
health outcome, both cost and health measurement should be defined and 
calculated. The following table summarizes the terms of cost and health 
outcome that can be used to compare a health-care intervention. 
 
 
 
 
 
 
 
 
 
 
                                                 
* A sensitivity analysis consists in examining the changes in results when the assumptions in the model 
are  varied.  Generally  an  economic  evaluation  is  based  on  a  number  of  debatable  hypotheses, 
introducing  an  element  of  uncertainty.  Sensitivity  analysis  suggests  vary  the  input  parameters  in 
different ways to calculate and evaluate the robustness of the results under different assumptions. 
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Table 1.1. Summary of the techniques of analysis to jointly evaluate health outcome and 
economical cost. The health outcome units and the calculation required to compare 
between therapies are characterized. 
Method of 
analysis 
Health outcome 
measurement 
Terms used to  
compare between 
therapies 
 
Assumptions and comments 
Cost-
minimization 
Any unit Therapies price Therapies compared have the 
same efficacy and tolerability 
Cost-
effectiveness 
Natural health 
units 
Cost/Effectiveness 
ratio  
The health effect quantification 
should be suitably selected for  
the assessed therapy 
Cost-utility Utility score such 
quality-adjusted 
life years 
(QALYs) 
Cost/Utility ratio  Special case of the Cost-
effectiveness analysis. 
The score per health state can 
be debatable 
Cost-benefit  Monetary units Cost/Benefit Ratio The assignation of monetary 
units to health states can be 
debatable 
Discounting Should be applied to cost and health outcomes involded in the described 
methods of analyses when future values should be discounted to present 
values. The rate of discount should be set up depending on the study aim. 
 
 
 
1.3.2. The ICER, the cost-effectiveness plane and the INB 
Well known and widely used calculations and plots to display the results 
for the cost-effectiveness and cost-benefit analysis are the incremental 
cost-effectiveness ratio (ICER), the cost-effectiveness plane plot and 
the incremental net benefit (INB), which facilitate comparing the costs 
and benefits of new and existing health care interventions. 
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Incremental Cost-Effectiveness Ratio 
In the evaluation of treatments, either by pairs or all of them versus an 
established therapeutic standard of care (SOC), four situations can be 
identified in terms of cost and health outcome: 
 Cost treatment A<Cost treatment B; Effect treatment A>Effect 
treatment; Accept the treatment A, as it is both cheaper and more 
effective than B. It is a situation of dominance. 
 Cost treatment A>Cost treatment B; Effect treatment A<Effect 
treatment B; Reject the treatment A, as it is both more expensive 
and less effective than B. It is a situation of dominance. 
 Cost treatment A>Cost treatment B; Effect treatment A>Effect 
treatment; the magnitude of the additional cost of treatment A 
relative to the additional effectiveness should be considered. 
 Cost treatment A<Cost treatment B; Effect treatment A<Effect 
treatment; the magnitude of the cost saving of therapy A relative 
to its reduced effectiveness should be considered (See also Table 
1.2). 
 
Table 1.2. In the comparison of two treatments, 4 situations are possible according to 
cost (rows) and effect (columns). In two of the combinations, the treatment selection is 
clear, the unclear ones are marked with a question mark. 
 
Cost A<Cost B A selected ? 
Cost A>Cost B ? B selected 
 Effect A>Effect B Effect A<Effect B 
 
As a summary of the previous situations, the cost-effectiveness can be 
expressed as an incremental cost-effectiveness ratio (ICER) defined as 
the ratio of change in costs to the change in effects. 
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BtreatmenttmeasuremenEffectAtreatmenttmeasuremenEffect
BtreatmentCostAtreatmentCostICER 
  
 
The ICER value might be considered as the monetary cost of the 
additional outcome caused by switching from treatment B practice to the 
treatment A. Assuming that the new treatment is more effective and its 
price is low enough, the new strategy is considered "cost-effective” or 
dominant. The ICER value can be directly compared to a pre-specified 
amount of money which represents the maximum cost health payers 
would invest to achieve one clinical benefit unit, and this value is defined 
as the willingness to pay (or ceiling ratio, Rc) benchmark. The advantage 
of ICER is that different interventions are evaluated in the same units and 
decision, between interventions, can be based on the cost/unit of result. 
Its drawback is that the ICER interpretation varies in function on the 
result of the difference between the effects and between the costs of the 
compared treatments. Also, there is a limitation on the confidence 
interval calculations, especially when the the effect of both treatments is 
close to the same measured value50. 
 
Cost-effectiveness plane 
The incremental cost-effectiveness plane represents the incremental 
cost and the incremental effect from a treatment A versus a treatment B 
as coordinates in a plot51. The plane is divided into four quadrants: the 
horizontal axis divides the plane according to the incremental cost 
(positive above, negative below) and the vertical axis divides the plane 
according to the incremental effect (positive to the right, negative to the 
left). The cost-effectiveness plane is presented in Figure 1.352. 
 
 
 
28 
 
NW 
“Dominated”
 NE
“May or may not be CE”
Existing treatment 
dominates 
New treatment more 
effective but more 
costly
     
New treatment costly 
but less effective 
New treatment      
dominates
“May or may not be CE”  “Dominant”
SW 
 
 SE
 
 
Figure 1.3. The cost-effectiveness plane. In the figure, the label and the decision about 
the compared treatments corresponding to each quadrant are indicated. NE = northeast 
quadrant; NW = northwest quadrant; SE = southeast quadrant; SW = southwest 
quadrant. 
 
Each quadrant has a different implication for the decision: 
i) If the ICER is calculated for the new treatment compared to the SOC 
and it falls in the southeast quadrant, with negative costs and positive 
effects, the new treatment would be claimed more effective (larger 
health gain) and less costly than SOC; in this case it can be said that the 
new treatment 'dominates' the SOC. Interventions falling in this 4th 
quadrant are always considered cost-effective. 
ii) If the ICER is located in the northwest quadrant, with positive costs 
and negative effects, the new treatment would be more costly and less 
effective than SOC (i.e., new treatment is 'dominated' by SOC). 
Interventions falling in the 2nd quadrant are never considered cost-
effective. 
iii) If the ICER falls in the northeast (or 1st) quadrant, with positive costs 
and positive effects, or the southwest (also named 3rd) quadrant, with 
negative costs and negative effects, trade-offs between costs and 
effects would need to be considered. The 1st and 3rd quadrants represent 
the situation where the new treatment may be cost-effective compared 
to SOC, depending upon the value at which the ICER is considered good 
Incremental 
Health Effect 
Incremental 
Cost 
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value for money i.e.: compared to the maximum amount that the payer is 
willing to pay for health effects. 
For instance, in the UK, the National Institute of Health and Clinical 
Excellence (NICE) at 2012 uses a threshold between £20,000–30,000 
(€24,557-36,835, using the exchange ratio of 1£ = €1.23) per QALY 
gained when deciding which interventions to approve (interventions 
costing less than £20,000 (€24,557) per QALY gained are more likely to 
be approved than interventions costing more than £30,000 (€36,835) per 
QALY gained)53. In Spain an intervention costing less than €30,000 per 
QALY gained is considered cost-effective54 and the interventions in the 
range of €30,000-€45,000 per QALY are also susceptible to be labelled 
as cost-effective.55 When a treatment is not dominant, deliberations 
about the collateral potential benefits and costs gained or lost, in the 
context of the most efficient use of resources, can help in the election. 
When the ICER shows that the new treatment is less costly and more 
effective than the SOC the concern is to quantify the variability or 
uncertainty of this result. The ICER is usually calculated from point 
estimates of costs and effects without taking into consideration their 
variability. To account for this variability, sensitivity analyses changing 
the input parameters and probabilistic techniques to generate a range of 
input parameters can be used to generate a set of possible results which 
can be taken as a quantification of the uncertainty surrounding the 
estimates of costs and effects. 
There remains considerable debate concerning the presentation of joint 
uncertainty for estimates of cost-effectiveness. The calculation of 
confidence intervals can be complex. The possibility that the numerator 
and/or denominator tend to 0 complicate calculations even more. As a 
result of these challenges, a number of alternative methods for 
calculating confidence intervals have been proposed. These methods 
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include the use of Fieller's theorem and non-parametric bootstrapping56, 
57. 
 
Incremental Net Benefit 
The incremental net benefit (INB) can be defined in terms of health gain, 
known as incremental net health benefit (INHB), or in monetary 
quantification becoming the incremental net monetary benefit (INMB). 
INHBs estimate a treatment's net clinical benefit after accounting for its 
cost increase versus an established SOC. 
Lynd58 has proposed a framework for calculating the incremental net 
health benefits (INHB) of different pharmaceutical treatments. Both 
benefits and adverse events associated with a treatment are quantified 
using available clinical trial or surveillance published data.  
A score reflecting the utility is assigned to each outcome in order to 
express all benefits and all risks in a common scale. The difference 
between the sum of the weighted benefits and the sum of the weighted 
risks of a treatment represent the net health benefits of the treatment. 
INHB is calculated as the difference between the NHB of the treatment 
of interest minus the NHB of an alternative treatment or the standard of 
care. A positive INHB indicates that the net benefits of treatment are 
larger than its competitor59. INMB would be defined analogously. 
 
 
1.3.3. Outline of the approaches used in health research  
Techniques used for pharmacoeconomic evaluations performance in the 
health area and the ones susceptible to be adapted for application to our 
real case studies are described. According to the data source, the models 
were classified in dynamic models, Markov models and models based on 
real. The main methodological differences among studies were allocated 
in the data generation/collection; the provenance of the data on costs and 
31 
 
health outcome can be real or simulated using different methods. The 
data used in the assessment can be collected from clinical records or 
prospectively in the framework of a clinical study. Another difference is 
the numerical summaries and graphical displays chosen to be reported, 
they are based on the research question that should be answered. Some 
examples of models applied to several health area problems are 
described in the following. 
 
Dynamic models 
These models are useful for studying the nature of epidemics or disease 
trends over time. They are typically deterministic and non linear over 
time; they track the changing population and individuals constantly enter 
the model as they are born and exit the model as they die. The 
probabilities of suffering health events change with the time. They are 
difficult to implement and few works used them. Edmunds et al.60 used a 
dynamic model for assessing the cost-effectiveness of vaccination 
programmes on human papillomavirus (HPV). 
 
Markov models 
Markov models, also called health-state transition models, are widely 
used for cohort simulation. In this approach, the transition probabilities 
between health states do not change with time. 
 
In cancer research, Markov models are often used to simulate the 
disease evolution. A brief summary of three representative published 
works is here stated: Van de Velde et al.61 implemented a state 
transitions model to assess the effectiveness of HPV vaccine; 
considering the natural history of infection and disease, the probability of 
a woman of being tested for HPV and the life-long natural immunity. The 
aim of this study was to predict the impact of HPV-6/11/16/18 
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vaccination on the girl’s life time risk of HPV infection. Yang et al.62 used 
a Markov model to evaluate the cost-effectiveness of two available gene 
expression profiling test to learn about the breast cancer recurrence and 
guide the treatment.  
 
Two representative examples of cost-effectiveness studies on coronary 
heart diseases63, 64 used Markov models to simulate the health-states 
previous death. The outcomes measured included costs, life expectancy 
in quality-adjusted life-years (QALYs), incremental cost-effectiveness 
ratios, and events prevented. 
 
In the HIV/AIDS cost-health outcome studies, we identified three 
differentiated cohort simulation models: the implemented by Freedberg 
et al.65-68, the developed by Sanders et al.69 and the developed by Sax et 
al.70. These models have in common a state-transition model framework, 
but they are based on different clinical assumptions. 
Freedberg et al. have developed a mathematical simulation model of HIV 
disease, using the CD4 cell count and HIV RNA level as predictors of the 
progression of the disease. The input information used for modelling the 
course of the disease were the monthly probabilities of clinical events: 
changes in CD4 cell count, changes in HIV RNA level, development of 
opportunistic infections, adverse reactions to medications and death. A 
state-transition model framework was employed; wherein disease 
progression in a patient was characterized as a sequence of monthly 
transitions from one health state to another. Outcome measures included 
life expectancy, life expectancy adjusted for the health related quality of 
life - scale from 0.0 (death) to 1.0 (perfect health), lifetime direct 
medical costs, and cost-effectiveness in dollars per quality-adjusted 
year of life gained. 
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The simulation model previously described, or slightly adapted, was used 
in a long list of published papers of cost-effectiveness assessments. 
Goldie et al.65 also used it to explore the cost-effectiveness of 
interventions to improve adherence to combination antiretroviral therapy 
in patients with HIV infection. Shackman et al.66 examined the societal 
cost-effectiveness and the impact on government payers of earlier 
initiation of antiretroviral therapy for uninsured HIV-infected adults. In 
the work published at AIDS by Walensky et al.67, the value of resistance 
surveillance in influencing recommendations toward effective and cost-
effective sequencing of ART regimens in clinical care in Cote d’Ivoire 
was assessed. In one of the last published works, Morris et al.68 
evaluated the immune response when an immune-enhancing agent was 
added to the initial antiretroviral therapy. 
Sanders et al.69 used the Decision Maker software (version 2003.11.1. 
Prat Medical Group) to develop a Markov model that followed a cohort of 
patients over their lifetime. The HIV infection evolution was defined on 
the basis of CD4 levels and HIV RNA viral load, the change to another 
antiretroviral regimen after virological failure and the virus resistances 
developed. By means of this model, costs, quality of life, and survival 
associated with an HIV-screening program and current practice were 
estimated.  
Sax et al.70 defined a state-transition model of HIV disease to determine 
the clinical impact and cost-effectiveness of genotype resistance testing 
for treatment-naive patients with chronic HIV infection. By using the 
hypothetical cohort of antiretroviral-naive patients with chronic HIV 
infection, the life expectancy, costs, and cost-effectiveness were 
projected. Results were given in terms of incremental cost-effectiveness 
ratio and a sensitivity analyses was performed through wide variations in 
baseline assumptions, including variations in genotype cost, prevalence 
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of resistance overall and to individual drug classes, and sensitivity of 
resistance testing. 
 
In a work published by Greeley et al.71 Markov model simulated data was 
used to assess the economic impact of adding genetic testing to the 
clinical routine in permanent neonatal diabetes, which is an example of 
personalized genetic medicine to other disorders in the future. 
 
Models based on real data 
Cost-effectiveness studies can be done prospectively, using data 
recorded in the framework of a clinical trial or a prospective study; this 
is more often done in programs which outcome can be measured in a 
short period of time. For instance, the cost-effectiveness study done for 
a pulmonary rehabilitation program in which, a cost/utility analysis was 
undertaken jointly with a randomised controlled clinical trial of 
pulmonary rehabilitation versus standard care72.  
Hamel et al.73 performed a prospective cohort study to evaluate the 
clinical outcomes and cost-effectiveness of initiating dialysis or to 
continue aggressive care for patients who suffered a renal failure.  
It is remarkable the use of decision trees to assess the results of the 
study. The decision trees are a graphical display that gives a good 
representation of the health care interventions assessed and their health 
outcomes. In dental health there are programs and treatments susceptible 
to be studied as cost-benefit and cost-effectiveness studies. Two 
examples of them are a prospective study following a cohort of patients 
during 3 years to compare between implant 2 denture prostheses versus 
complete dentures74, and a decision tree to help in the choice of the 
management strategy for symptomatic, disease free mandibular third 
molar75. 
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Dasbach et al.76 used hybrid models, which are a combination of a cohort 
model simulation and a dynamic model. In the cohort simulation the 
probability of transition does not change with time, the dynamic model 
adds flexibility to the model structure by estimating how the probability 
of transition would change with the time for the cohort of interest. The 
complication added by the integration of both models allows reflecting 
more acurately the real system than when the separated model 
structures are used. 
 
 
1.4. Goals and thesis structure 
 
The aim of this thesis is to present a set of models that could favour a 
more rational use of resources in order to achieve the largest gain in 
health per monetary unit spent on health care in a national health system. 
The methods are applied to real clinical questions: two on antiretroviral 
treatment for HIV-infected patients (Decision trees and Markov models 
in n-stages), two on prevention of osteoporotic fractures (Markov 
models and techniques for health benefits quantification), and one on the 
rare disease paroxysmal nocturnal haemoglobinuria (budget impact 
analysis). 
 
The thesis is organized as follows: This first chapter had the aim to 
explain the data required to perform a pharmacoeconomic study and the 
techniques available to carry out an economic evaluation. The next 5 
chapters of the thesis are devoted to 5 different approaches of 
pharmacoeconomic studies; existing methods are adapted, combined 
and/or developed to be applied into real health problems.  
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From a methodological perspective Chapters 2, 3 and 4 compare 
different therapeutic strategies by jointly evaluating cost and health 
outcome, while Chapters 5 and 6 deal with cost and health outcome 
separately, by means of a budget impact analysis and the use of 
techniques to quantify health benefits. Concercing the areas of 
application, Chapters 2 and 4 are devoted to HIV health issues, Chapters 
3 and 6 to osteoporosis disease while Chapter 5 provides an example of 
study for a rare disease, the paroxysmal nocturnal haemoglobinuria 
(PNH). 
Finally, in Chapter 7 and Chapter 8, we discuss the issues raised and 
examine indications for new lines of research. 
Some details about other technical approaches, data input used in the 
clinical applications and the program code for the model, and/or 
statistical analysis —by means of SPSS, R or Microsoft Excel— are 
provided in the Annexes. 
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Summary Chapter 2.  
TREATMENT ADHERENCE PROMOTION STRATEGY IN HIV INFECTED 
PATIENTS. DECISION TREES 
 
Real data of a clinical trial was used in the assessment of the adherence 
to antiretroviral treatment promotion program in HIV infected patients. A 
decision tree was selected to study the cost per health gain, measured 
by means of clinical and health related quality of life outcomes. The 
simplicity of the technique was appropriate to summarize the cost-
effectiveness of the adherence promotion program. A small 
immunological or health related quality of life improvement resulting 
from the new strategy was observed. It was found that an increment of 
the treatment cost in €14.53PPM could generate a 1% of additional 
health outcome. 
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2. TREATMENT ADHERENCE PROMOTION STRATEGY IN HIV 
INFECTED PATIENTS. DECISION TREES 
 
Decision trees are used to describe the possible choices and their 
consequences, in terms of the health outcome and resources 
expenditure. This method was used to assess an HIV antiretroviral 
treatment adherence program. The comparison between the intervention 
group and the standard of care is performed in terms of cost-
effectiveness and using real data collected in the framework of a clinical 
trial. 
 
 
2.1. Decision trees 
 
A decision tree (or tree diagram) is a decision support tool that uses a 
graph of available options and their possible consequences, including 
chance event outcomes, resource costs, and utility. 
The branches off the initial decision node represent all the therapeutic 
strategies that are to be compared. A series of probability nodes of each 
strategy branch can be used to reflect uncertain events, usually within a 
relatively short time frame. The outcomes at the end of each pathway 
are values that reflect both the cost and the health effect associated with 
that pathway. Usually, the outcomes are grouped into health states which 
are characterized by a utility measure and a monetary measure of cost84.  
 
Example: 
The figure 2.1 is a graphic representation of the context of a 
decision and its impact on health results. In this case, the 
potential outcomes are Well, Sick and Dead, which should be 
defined in such a way that they are exhaustive, but 
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exclusive, i.e., they cover all possible outcomes, but a 
patient cannot be in more than one state at a time. The 
available therapeutic strategies to treat the health problem 
are A and B. The probabilities of achieving a health outcome 
for the studied treatments are known and displayed in the 
diagram (p and q). A logical constraint in the final nodes for 
the possible health outcomes is that the sum of the 
probabilities must be 1. 
 
 
 
Figure 2.1. Decision tree structure. This is a graphic representation of 
the context of a decision and its impact on health results. A and B can be 
used as a treatment for the health problem assessed. The potential 
outcomes are Well, Sick and Dead. p and q are the probabilities of 
achieving the fist two health states, 1-p-q is the probability of Death. 
The square indicates a decision node, the circles represent the 
probability of the event, and the triangles indicate a final state. 
 
Health 
problem 
Treat. A 
Treat. B 
pA 
qA 
1-pA-qA 
Well 
Sick 
Dead 
Well 
Sick 
pB 
qB 
1-pB-qB Dead 
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Cost-effectiveness (CE) and incremental cost-effectiveness ratio (ICER) 
can be calculated to compare outcomes between groups. The CE and 
ICER are calculated at the end of the follow-up as described in 
subsection 1.3.2, CE is calculated as the cost divided by efficacy and 
ICER is the difference of cost between the treatment A and treatment B 
divided by their difference in effects. The decision tree offers a static 
portrait of a dynamic process. It is relatively easy to construct and use 
this approach, although it only works for micro-circumstances (i.e., well 
defined systems, described by few and well characterized features and 
usually in a bounded time), where the information does not come from 
different studies or populations, and it is not necessary to adjust for 
factors. Furthermore, duration of follow-up should be the same for all 
patients and branches. The difficulty to represent a disease 
characterized by the repetition of events in the time (such as chronic 
diseases: complications, recurrence and progression) and the 
impossibility to assign utility values to the health states and a discount 
rate to the costs are limitations of this approach. 
 
 
2.2. HIV infection and a promoting adherence program 
 
2.2.1. Clinical background 
HIV infection continues to be a major health epidemic problem. The 
World Health Organization (WHO) estimated that there were 34.0 million 
[31.4 million–35.9 million] people living with HIV worldwide at the end of 
2011. In 2011, an estimated 2.5 million [2.2 million–2.8 million] new HIV 
infections occurred and 1.7 million [1.5 million–1.9 million] annual deaths 
were due to AIDS77. The WHO estimated the number of people living with 
HIV in Spain, among adults aged 15 years and older, to be 150,000 
42 
 
[130,000-160,000], and the prevalence in this setting was 0.4%[0.4-
0.5]78. 
Significant advances in antiretroviral treatment have been made since the 
introduction of zidovudine (AZT) in 1987. With the advent of highly 
active antiretroviral therapy (HAART), HIV-1 infection is now 
manageable as a chronic disease in patients who have access to 
medication and who achieve durable virologic suppression79. 
Accessibility to antiretroviral therapies is general because the Spanish 
health care system provides universal health care free of charge for the 
patients. Nowadays concern is whether patients take the prescribed 
medication, as well as they follow the treatment dosage. Poor adherence 
to combined antiretroviral therapy (cART) has been shown to be an 
important determinant of virologic failure, emergence of drug resistant 
virus, disease progression, hospitalizations, mortality, and, consequently 
health care costs. The challenge is to achieve a high long term 
adherence and break the barriers to optimal adherence. The obstacles to 
overcome may be from individual (biological, socio-cultural, 
behavioural), pharmacological, and societal factors80.  
 
2.2.2. Study characteristics 
A program to promote adherence in HIV naïve patients that start cART 
was established. The experimental group received the standard care of 
treatment and a psychoeducational adherence-based intervention 
consisting in 3 sessions of 1 hour of duration each. The visits were 
performed in the moment of cART starting, 2 weeks and 4 weeks later. 
During these sessions the beliefs of the patient about the HIV disease 
and his/her circumstances that prevent the patient to be adherent to the 
cART, including conceptual, behavioural and motivational areas, were 
discussed and the importance of the adherence was emphasized. The 
control group did not participate in the psychoeducational adherence-
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based intervention program. See the chronogram of the study in figure 
2.2. 
 
Experimental Group                  
0 2 4   12 24 36 48 
PSABI PSABI PSABI       
BBT     MA MA MA MA 
CV     CV CV CV CV 
QoLA      QoLA  QoLA 
                   
Control Group                  
0 2 4   12 24 36 48 
BBT     MA MA MA MA 
CV     CV CV CV CV 
QoLA      QoLA  QoLA 
 
Figure 2.2. Chronogram of the study procedures by branch of health care intervention. 
Time expressed in weeks (w) of follow-up (48w, considered equivalent to 1 year). 
PSABI is the psychoeducational adherence-based intervention. BBT is the Baseline 
blood test, CV is the Clinical visit, MA is the Monitoring analysis and QoLA is Health 
related quality of life questionnaire assessment.  
 
The performance of the program was evaluated in terms of cost-
effectiveness for different health outcomes. Data was collected through a 
prospective clinical trial designed to evaluate the health outcome in 
terms of HIV RNA viral load, CD4 cells count and health related quality 
of life variables at 1 year of follow-up. Forty treatment-naïve 
participants were randomized to the experimental and control groups. 
Clinical, economical and health related quality of life variables were 
assessed from the RCT data base and the direct cost of the hospital 
medical supplies. The numerical variables were expressed as mean 
(Standard deviation, SD) or as median and interquartile range (IQR) and 
compared using the t or Mann-Whitney test. For the categorical 
variables, percentages and/or number of patients were given and 
compared using the χ2 or Fisher exact test (as appropriate). Further 
Time 
(weeks) 
Time 
(weeks) 
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detail on cost and effectiveness input data and calculations are provided 
in Annex IV and Annex V. 
 
 
2.3. Results 
 
Participants were all men with a median (IQR) of 35 (30-45) years old, 
who were infected mainly through sex with other men (90%). The median 
number of cART changes during the study was 2, with a minimum of 0 
and a maximum of 4 changes. Initially, 20 patients were allocated in each 
treatment group but 5 and 2 were lost to follow up in the control and 
experimental groups, respectively. 
 
To assess both cost and the clinical and health related quality of life 
outcomes of interest six decision tree models were built. The first two 
present the results for viremia control and the immune recovery, the 
next ones reflect the quality of live improvements (figure 2.3 and 2.4). 
These models compared the performance of the patients attending the 
adherence program with the individuals receiving the standard of care. 
The mean (SD) cost per patient month (PPM) was €1,252 (460) in the 
experimental group and €1,139 (275) in the control group. The 
percentage of patients that reached the end of the study with virological 
suppression was larger in the experimental group (94.4% versus 86.7%; 
not statistically different, p-value=0.579). The CE indicates that the cost 
per 1% more of patients with virological response is slightly larger in the 
experimental group (€1,326 PPM versus €1,314 PPM). The ICER 
indicates that, per 1% additional in viral suppression outcome, the 
incremental cost is €14.53 PPM. The percentage of individuals that show 
an improvement of 100 or more CD4 cells/mm3 was larger in the control 
group (80% versus 72.2%; not statistically different, p-value=0.699). 
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When this outcome is assessed, the adherence program is not cost-
effective (Figure 2.3). 
 
     
Figure 2.3. Cost-effectiveness decision trees considering clinical variables in 
experimental (EG) and control groups (CG). The ICER for the Undetectable Viral load 
marker is €14.53 and €-14.53 for the CD4 change as an incremental cost per 1% of 
increasement in the health outcome. Decision is represented by the square, the circle is 
a chance node, and triangle represents a final node. 
 
Mental and psychological, and global health scores were favourable to 
the experimental group in comparison with the control group; although 
the differences between groups were not statistically significant for any 
of the scores. Considering the cost added for the adherence promotion 
visits, the minimum cost therapeutic strategy should be chosen in this 
population. The percentage of every outcome and the CE ratios are 
displayed in Figure 2.4. 
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Figure  2.4. Cost-effectiveness decision trees considering health related quality of life 
variables in experimental (EG) and control groups (CG). The ICERs for the Physical 
health, Mental and psychological health, social relationships and global health are €-
11.30, €25.42, €-20.34 and €101.70 respectively. Decision is represented by the 
square, the circle is a chance node, and triangle represents a final node. 
 
 
2.4. Discussion  
 
In our study there were no significant differences in the health outcomes 
between control and experimental programs. In terms of the trend found 
on the descriptive analysis it can be said that the patients in the 
psychoeducational adherence program had a scarce benefit in terms of 
achieving undetectable HIV viral load, compared with the patients in the 
control group. The HIV Unit where the trial was performed stresses the 
need of educating and making the patients aware of the treatment 
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adherence importance; the standard of care include interventions to help 
patients to understand the HIV infection, the drugs role and connect 
these terms with their routine and believings. This might be due to the 
fact that the adherence in our patients is greater than 80%. Then, it can 
be supposed that the standard of care in terms of adherence sensitivity is 
greater than in generalized clinical practice. If the program is 
implemented in units of care without specific interventions to help the 
patient to deal with the disease, a larger improvement in adherence, and 
consequently, in the health outcomes can be expected. 
Increasing the follow-up would be valuable to quantify the changes in 
immunological and health related quality of life scores and characterize 
the program effects in the long term. The health resources used were 
registered using the clinical files and some information on visits and 
prescribed drugs done out of the HIV unit could be ignored in our 
register. We assume that undereporting of resources used was balanced 
between both groups, and this did not significatively affect to our results. 
In spite of the study limitations and the lack of generalization of the 
results to the HIV infected patients visited in other clinical units, it was 
an asset to manage the intern available resources in the unit where the 
study was performed. The conclusions of this work are similar to what 
Goldie et al.65 reported, where they mention that in spite of improving the 
patients’ health related quality of life “the cost of the programme 
represented a key variable”. 
The decision trees are very useful to describe situations where a simple 
choice and the set of possible outcomes are not very extense. The 
simplicity of this technique has the limitation of not reflecting the 
evolution of the health outcomes over time, in this method the value at 
the end of follow-up is used as an indicator of success or failure. 
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Conclusion 
The study performed can guide the selection of the therapeutic 
strategies applied to the clinical practice. The program to promote the 
HIV treatment adherence resulted in a few immunological or health 
related quality of life improvement, it seems cost-effective in terms of 
virological suppression if the decision-makers on health resources 
allocation consider worthy increasing the treatment cost. In our setting 
the increase estimated is of €14.53PPM to obtain a 1% of additional 
health outcome. 
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Summary Chapter 3.  
COST-EFFECTIVENESS STUDY FOR COMPARISON OF BAZEDOXIFENE 
WITH RALOXIFENE IN OSTEOPOROSIS PREVENTION. MARKOV MODEL 
 
The simulation of a Spanish cohort of postmenopausal women and their 
possible osteoporotic fractures was done to assess the performance of 
two treatments for the prevention of vertebral and non-vertebral 
fractures in terms of cost-effectiveness. Simulation by means of a 
Markov model required that: 
i) the disease evolution and the related events were simplified using a 
finite number of health states and 
ii) the probabilities of moving from one state to another as the time goes 
on were defined. 
Probability sensitivity analysis (PSA) was also performed to assess the 
uncertainty of the results. It was observed that the use of bazedoxifene 
slightly increases the patients QALYs and the cost of the treatment (0.02 
QALYs, 445€). In the PSA, the deterministic results were confirmed in 
52% of the realizations; with a willingness to pay for an additional QALY 
gained ranging from 0 to a maximum of €50,000 In this context, the 
decision between treatments should be reinforced with other clinical 
features not included in the model. 
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 3. COST-EFFECTIVENESS STUDY FOR COMPARISON OF 
BAZEDOXIFENE WITH RALOXIFENE IN OSTEOPOROSIS PREVENTION. 
MARKOV MODEL  
 
Markov models are used to simulate a cohort of patients at a population 
level and their path towards different health states. As a result, the cost 
and health parameters obtained allow performing a comparison between 
treatments to prevent osteoporosis in menopausal women. 
 
 
3.1. Markov model 
 
Markov models are a commonly used tool in medical decision analysis. 
They are especially appropriate when the disease of interest is 
characterised by the recurrence of specific events and when these 
events are based on continuous risk over time81. 
The simulated cohort of patients is divided into a finite number of states 
based on, for example, the current health status of the patient. The 
states are supposed to be mutually exclusive and collectively exhaustive 
and they can be defined as transient or absorbing states. It is said that a 
state is absorbing when the individuals in the model cannot leave this 
state and transient otherwise. Suppose we are observing random 
variables X0, X1, X2… which are the successive states of a system with 
some sort of random functioning. And suppose also that the states can be 
numbered 1, 2, …. We call this system a Markov chain if the probabilities 
passing into the next state are completely determined by the present 
state of the system. More precisely, in a discrete setting, the sequence 
X0, X1, X2 … will be called a Markov chain if for any sequence of states 
x0, x1, ..., xn+1 
P(Xn+1= xn+1| Xn= xn,…, X0= x0)= P(Xn+1= xn+1| Xn= xn). 
52 
 
In other words, the probability of moving from the nth state xn to the 
(n+1)st state xn+1 does not depend on how we got the nth state; that is, 
does not depend on x1,…,xn-1. This property is called Markovian property 
and refers to the memoryless property of a stochastic process82. The 
conditional probabilities 
P(Xn+1=j|Xn=i) 
of moving to state j at time n+1 given that we were in state i at time n 
are called the transition probabilities for the process and are denoted by  
pn(j|i). 
The possible values of Xi form a countable set S called the state space of 
the chain. 
 Example: 
A simple example of a three-state Markov model to simulate 
a cohort of patients at a population level and their path 
towards different health states is provided in figure 3.1. 
Time is handled as discrete periods of the same length 
(cycles). The state space of the chain is S={Well, Sick, 
Dead}, with 2 transient states -Well and Sick- and 1 
absorbing state –Dead-. 
                 
Figure 3.1. Representation of a simple Markov model. The arrows 
represent possible transitions between health states (ovals) in a cycle. 
Transitions between health states with probability 0 are not connected 
by arrows. 
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The Markov models can be represented by a decision tree with many 
branches while every cycle the patient has the chance to remain in the 
same health state or switch to any of the others which probability of 
transition is different from 0 (see Figure 3.2).  
 
 Example: 
The previous Markov model with 3 health states (Well, Sick 
and Dead) can be represented using a tree structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Decision tree structure for the Markov Model in Figure 3.1. 
The circles represent the probability of the event and the triangles 
indicate a final state. Well, and Sick are transient states, and Dead is an 
absorbing state. 
 pW 
pS 
 pD 
Well 
Sick 
Dead 
pWW 
pWS 
pWD 
Well 
Sick 
Dead 
pSW 
pSS 
 pSD 
Well 
Sick 
Dead 
Cycle 0 Cycle 1 
 pDD 
Dead 
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The health states can be transient or absorbing. This can be stated 
formally as pn(i|i)=1 and pn(j|i)=0 for i≠j.  
The elements of the matrix of transition probabilities (pij) indicate the 
probability to travel from the current health (i) state to the next (j) in one 
cycle, i.e., from time t to time t+1 -named pij(t). It is required that the 
sum of probabilities in a row equals 1. The structure of a transition 
probabilities matrix, A, using the examplecase is shown in Figure 3.383. 
 
Example: 
The transition probabilities for the Markov model with 3 
health states (Well, Sick and Dead) are represented using a 
matrix structure. The matrix cells contain the probabilities of 
being in the state i move to state j in one clyce, i.e., pij. 
 
 
 
 
 
 
 
Figure 3.3. Structure of a transition probabilities matrix for a three-state 
Markov model. The probabilities are different from 0 when a transition 
between health states is possible. Transitions between health states with 
probability 0 are not feasible, such as the ones starting in the health 
state Dead. 
*Example of probabilities estimated by difference. 
  
From a given state, for instance Well, after 1 cycle, and once 
the probabilities of going to Sick state and Dead state have 
been calculated (pWS and pWD), the probability of staying Well 
 
From 
To 
Well Sick Dead 
Well pWW=1-(pWS + pWD)* pWS pWD 
Sick pSW pSS==1-(pSW + pSD)* pSD 
Dead 0 0 pDD=1
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is the “residual probability” computed as the difference from 
1 of pWS+pWD (see figure 3.3). This method allows obtaining 
information that is not usually reported in published health 
studies (research papers, epidemiological tables, etc.).  
 
The model is initially filled by distributing the simulated individuals 
across a number of starting health states according to parameters 
defining the probability of being in each of these states. These 
parameters can be extrapolated from the sickness prevalence in the 
population of interest. This is done by specifying the dimension of the set 
of states, which is 1×s, where s is the total number of health states in the 
Markov model and the starting vector P0, which contains the probability 
of the patients of starting in each health state. 
The proportion of the initial cohort in each of the three states after one 
cycle (P1) can be calculated by multiplying P1 by the matrix of transition 
probabilities, A. More generally the proportion of the initial cohort in 
each state after k cycles becomes Pk= Pk-1*A, where Pk -with dimension 
1×s- display the proportion of the cohort contained in the defined states 
at cycle k.  
The structure for a Markov model will depend on the clinical application, 
the available data and how many simplifying assumptions are made. 
However, there are a number of essential steps to follow when 
constructing a Markov model: 
i) Specify the Markov states to reflect the relevant states of health and 
resources expenditure associated with the disease and treatment over 
time 
 ii) Choose the cycle length to be used in the simulation, which must be a 
constant increment of time. The selected elapse of time should be short 
enough to consider the changes of clinical effects and resource use in 
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patients between the cycles. The time horizon for the analysis also 
should be chosen 
iii) A cost and utility should be assigned to each health state. In order to 
calculate discounted utility or cost, they should be divided by (1+r)k, 
where r is the discount rate corresponding to the cycle length and k is 
the cycle index84 
iv) A set of transition probabilities must be specified. They indicate the 
chance of the individuals in the model to move from one health state to 
another. They can be defined as a function of time. For that purpose, a 
different matrix Ak for each cycle k should be defined to provide a 
transition probability linked to be health states and incorporate the time 
elapsed after an event. Introducing a statistical distribution (e.g., the 
exponential) or temporary and tunnel states can accomplish this purpose. 
The temporary states are used when a health situation has a short 
duration but has an important effect in costs or outcomes; the patients 
can only stay at the state for, at most, one cycle; their use enables the 
model users to assign state specific transition probabilities and adjust 
utilities and costs. The tunnel state, in which patients can only transit in 
a fixed sequence, is analogous (given the nature of life-threatening 
disease) to passing through a tunnel, and would be used when a 
temporary state would last more than one cycle85. 
 
The cohort simulation at the population level procedure consists on a 
hypothetical cohort of people who begin the process with some 
determined distribution among the states (P0). In the next cycle, the 
cohort is divided between the states according to the probability of 
transition, thus yielding a new distribution of the cohort between the 
states. This will continue in the subsequent cycles until the process has 
reached a cycle limit. The movement of the cohort through the health 
states during the simulated time produces estimations for the cumulative 
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utilities and costs. Table 3.1 illustrates the Markov trace for the first 2 
cycles for the 3-state model used as an example (a numerical example 
can be followed in Annex VI). The simulation is run until the entire initial 
cohort resides in an absorbing state or until the upper limit of time that 
was considered clinically reasonable for the assessed health problem is 
reached. 
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Example: 
Markov model trace for the two first cycles is displayed 
below: 
Table 3.1. Two-cycle Markov trace for a 3-state Markov model with 
health states: Well, Sick and Dead. Utility scores for the health states are 
uW, uS, uD, respectively. Costs are defined analogously using the c as 
notation. P0=(1,0,0), i.e., P0=(p0W, p0S, p0D). Column 1 show the cycle 
number (k), columns 2 to 5 show the proportion of the cohort in each of 
the 3 health states at each cycle k (Pk), the last 2 columns show the 
utility and the cost contribution in each cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#At cycle 0, the utility and the cost can be multiplied by 0.5 to take into 
account that some individuals transit in the middle of the cycle, which is 
known as the half-cycle correction. 
¤ To obtain discounted expected utility (or cost) values the cycle utility 
(or cost) would be divided by its discount factor (1+r)k. 
Cycle 
(k) 
Well Sick Dead Cycle 
utility 
Cycle 
cost¤ 
0 1 0 0 1* or 0.5* 
(pkW*uW+ 
pkS*uS+ 
pkS*uD)# 
1* or 0.5*
(pkW*cW+ 
pkS*cS+ 
pkS*cD)# 
1 p0W * 
pWW+ 
p0S * 
pSW 
p0S * 
pSS+ 
p0W * 
pWS 
p0D * 
pDD+ 
p0W * 
pWD+ p0S 
* pSD 
(pkW*uW+ 
pkS*uS+ 
pkS*uD) 
(pkW*cW+ 
pkS*cS+ 
pkS*cD) 
2 pk-1W * 
pWW+ 
p k-1S * 
pSW 
pk-1S 
* 
pSS+ 
pk-1W 
* pWS 
pk-1D * 
pDD+ pk-
1W * 
pWD+ p 
k-1S * pSD
(pkW*uw+ 
pkS*us+ 
pkS*uD) 
(pkW*cw+ 
pkS*cs+ 
pkS*cD) 
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To draw a cohort simulation at the individual level we 
perform a first-order Monte Carlo simulation. The individual 
track is simulated, one at a time, through the tree of possible 
states. The first individual would start in the “Well” health 
state, based on P0, the next cycle visited will be determined 
using a random number drawn from a Uniform[0,1] and using 
the ordered cumulative probabilities for the cycle 1, i.e.: 
P1=(p1W, p1S, p1D) 
Assuming that p1W>p1S>p1D, in case of equality the order can 
be decided at random. 
Then, the value in the [0, 1] obtained from a uniform 
distribution to allocate the individual in a health state for the 
cycle 1 is used as follows: 
If the uniform drawn value is in the [0, p1D] range the 
individual is going fall in the Dead health state (D). If it is in 
the [p1D, p1D+p1S] the health state is going to be Sick (S). 
Otherwhise (in the [p1D+p1S, 1]) the individual will reside, at 
least for the cycle 1, in the Well state. The simulation will be 
repeated for an individual until the dead state or the end of 
simulation time is reached; individual tracks would be 
performed up to the sample size wished for the cohort. The 
quality-adjusted life years (or cost) are calculated by taking 
the average of all the quality-adjusted life (or cost) spans in 
the cohort. 
 
The individual simulation has the advantage that conditional factors can 
be set up (e.g., conditional adherence) because the simulation is 
performed for individuals rather than for a full cohort. This approach 
offers plenty of flexibilities but often requires a very large number of 
simulations for accuracy of estimates. The standard error of the sample 
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mean can be estimated from a preliminary sample of, say n=1000. Since 
the standard error is quasi-proportional to the square root of n, the 
standard error with sample size N would be estimated to be roughly 
Sn*(n/N)1/2. The required sample size, N, depends on the magnitudes of 
the transition probabilities, the differences in utilities between states, and 
the effect sizes of interest. The HIV model by Freedberg et al. uses 
N=1,000,000 in order to obtain reliable estimates of cost-effectiveness 
ratios86. 
 
To seize parameter uncertainty for a cohort at population or individual 
level a probabilistic sensitivity analysis or a second-order Monte Carlo 
can be used. Both procedures require the input values to be extracted 
from a probability distribution. The results of the sensitivity analysis 
account for the variability in the input parameters. Even other 
distribution can fit the input parameters; cost can be drawn from a 
Gamma distribution, probabilities can be draw from a Beta or a Uniform 
distribution and utilities can be distributed as a Lognormal, Beta, or 
Uniform law. Several simulations are run using different input 
parameters. The analysis of the outputs obtained from these simulations 
provide a broad view of how much the variation in the inputs might affect 
the results and acts as a tool to check whether the assumptions made in 
the model definition are reasonable and do not influence the result. Both 
the cost-effectiveness acceptability curves (CEACs) and the scattered 
plot in the incremental cost-effectiveness plane are a good summary for 
the outputs of the sensitivity analysis and show the uncertainty of the 
model results. 
The CEACs depict the probability that each scenario is the most cost-
effective at any particular willingness to pay (or ceiling ratio) per unit of 
health gained. They are constructed by plotting the proportion of cohort 
simulations were each of the treatments assessed were cost-effective 
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for many ceiling ratios. It is noteworthy that the sum of the plotted 
proportions for every ceiling ratio value is 1. 
The other figure is obtained by displaying the pairs of cost and 
effectiveness values for every simulation over an incremental cost-
effectiveness plane. As it was described in Subsection 1.3.2. 
Usually, the scatter plot covers all four quadrants, indicating uncertainty 
about whether or not the intervention is cost-effective, and at what value 
it is cost-effective. The purpose of the CEAC is to summarise this 
uncertainty87.  
 
 
3.2. Introduction to osteoporosis disease 
 
Thirty percent of the postmenopausal women suffer osteoporosis in 
Spain175. This diseases is characterized by low bone mass and structural 
deterioration of bone tissue, leading to bone fragility and an increased 
susceptibility to fractures, especially of the hip, spine and forearm, with 
vertebral fractures, although any bone can be affected88-90. Of all 
patients that developed a vertebral fracture, it is estimated that 20% will 
suffer a new vertebral fracture within a year91. Of all osteoporotic 
fractures, hip fractures are the most dangerous with an elevated 
mortality risk as well as a high hospital burden in Spain92. Osteoporosis 
has a negative impact on the health related quality of life (HRQoL) of the 
affected individual93. The increasing number of fractures due to 
osteoporosis in the past 20 years combined with the development of 
novel agents for the prevention or treatment of osteoporosis results in a 
health resources allocation problem94. 
Various treatments are approved for the prevention of osteoporotic 
fractures. Although they have been considered effective for the 
treatment of postmenopausal osteoporosis, some of them are not 
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appropriate for all women because of safety and/or tolerability issues95, 
96. The selective estrogen receptor modulator (SERM) therapies, both 
raloxifene and bazedoxifene, had shown to reduce the risk of vertebral 
fractures in postmenopausal women97. Bazedoxifene has also associated 
with a favourable endometrial, ovarian, and breast safety profile in a 2-
year, phase 3 study of postmenopausal women at risk for osteoporosis98-
100.  
In Spain, approximately 2 million women101 were estimated to have 
osteoporosis in 2010. Treating this population is associated with a high 
socioeconomic burden and both clinical and economic implications should 
be taken into consideration to build a model to compare the treatment 
options to achieve higher long-term benefits of fractures risk reduction.  
Many models have been developed to study the socioeconomic impact of 
osteoporosis treatments for the Spanish National Health Service, as well 
as for patients102-105. Different tools are being used to estimate fracture 
risk which, at the same time, can vary significantly between countries105, 
these items can influence the results of any cost-effectiveness analysis. 
A recently published cost-effectiveness analysis comparing bazedoxifene 
with placebo used the FRAX® algorithm that provides fracture 
probabilities for specific populations105. Although FRAX® can be used to 
predict the probability of hip or other major osteoporotic fractures, the 
criteria should not be generalized to other countries having different 
fracture incidence rates and health care106. Therefore, when comparing 
the cost-effectiveness of bazedoxifene with raloxifene for Spanish 
osteoporotic women, it is important to take into account that the 
incidence of fractures is different for Southern European countries than 
countries in the Scandinavian region107, 108. 
The objective is to build a model to evaluate the cost-effectiveness of 
bazedoxifene and raloxifene for the prevention of vertebral and non-
vertebral fractures among women diagnosed with osteoporosis, 
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accommodating the special characteristics of the disease in the Spanish 
setting. 
 
 
3.3. Model to estimate the cost-effectiveness of bazedoxifene versus 
raloxifene 
 
Cost-Effectiveness analysis  
Our work sought to assess the cost-effectiveness of the available SERM 
treatments in terms of cost per QALY. The clinical evolution of the 
disease was based on the Osteoporosis Study109 and applied to the 
Spanish setting. The simulation model is implemented in Microsoft® Excel 
to calculate cost-effectiveness using an updated Markov model that has 
been used previously to estimate the cost-effectiveness of bazedoxifene 
incorporating the FRAX® algorithm using a European perspective105. 
The assessment was performed from the perspective of Spanish National 
Health Service and the time-horizon considered was 27 years, from 55 
years old to 82 years old. The starting age was based on women 
recruited for bazedoxifene’s 3-year treatment clinical trial109 and 82 
years old correspond to the life expectancy of a Spanish women110.  
QALYs gained was included as an effectiveness measure to allow us to 
compare the value of the interventions across different disease states. 
The incremental cost-effectiveness ratio (ICER), which is a measure of 
the added cost per QALY gained, is given as an output of this model. 
 
Decision analytic model 
The model evaluated the cost-efficacy of receiving bazedoxifene or 
raloxifene during this 27 year time. It was assumed that no patient 
discontinued treatment because of adverse effects. 
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Model specification 
The model simulated the transition of postmenopausal osteoporotic 
women through six defined health states (represented by ovals in figure 
3.4) based on yearly transition probabilities. All patients began in the 
well-health state or no event state. In each cycle, a patient had a 
probability of sustaining a fracture, remaining healthy, or dying. After 
one year in any fracture state, the patient had a risk of sustaining a new 
fracture or dying. When a woman passes away, she would continue into 
the dead-health state for the rest of the simulation. After one year, the 
patient moved to the corresponding post-fracture state if no additional 
fracture occurred. The patient would automatically remain in the post-
fracture state (shown as a circular arrow) if she did not die or sustain a 
new fracture. Fractures could be vertebral or non-vertebral, consisting 
half of hip fractures and half of wrist fractures. After a non-vertebral 
fracture, it was possible to suffer a vertebral fracture or another non-
vertebral fracture (Figure 3.4). 
 
Figure 3.4. Graphic representation of the simulation model. Ovals represent the health 
states and the arrows the possible transitions among them. 
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The travelling between health states are made following the probabilities 
reported in the probability transition matrices for the patients treated 
with bazedoxifene or raloxifene, respectively. The efficacy and mortality 
data were obtained from published clinical trials and population 
demographics. 
In Annex VII, the input parameters and their sources are detailed. The 
cohort simulation was run to obtain 2 cohorts of 100,000 women treated 
with bazedoxifene or raloxifene. For the cohort path in the disease 
evolution, cost and utility values were assigned according to the time of 
permanence in every health state.  The values for cost and utilities were 
calculated accounting for the adverse events (also detailed in Annex VII). 
 
 
3.4. Results 
 
Results from the Markov model simulation using the input parameters in 
a deterministic way and a simulation of 1,000 trials using input 
parameters drawn from a theoretical probability distribution with 2 
cohorts of 100,000 women are reported. The model validation is done by 
means of probabilistic simulation (see the model worksheets in Annex 
VIII). 
Costs are reported in 2010€ and both costs and benefits are discounted 
at a 3% rate. 
 
Deterministic analysis results 
Deterministic results using a 27-year horizon and a 2 cohort of 100,000 
women revealed that the expected cost per patient was 445€ higher in 
the raloxifene cohort compared with the bazedoxifene cohort (€13,436 
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vs. €13,881). The estimated QALYs gain was slightly higher in the 
bazedoxifene treatment branch than in the raloxifene one (14.56 vs. 
14.54 QALYs). Their Incremental Cost-effectiveness Ratio (ICER) was 
estimated to be -22,250 €/QALY. In absolute terms, it can be said that 
bazedoxifene was the dominant treatment strategy, being less costly and 
more effective than treatment with raloxifene (Table 3.2 and Figure 3.5). 
 
Table 3.2. Total Cost, Incremental Costs, QALY, QALYs Gained, and ICER 
Treatment Cost Incremental costs QALY 
QALYs 
gained 
Bazedoxifene  13,436 € -445 € 14.56 +0.02 
Raloxifene  13,881 €  14.54  
QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio. 
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Figure 3.5. Cost efficacy plot for the two evaluated treatments. The values for cost and 
quality-adjusted life years (QALYs) are displayed. 
 
Probabilistic analysis results 
Beta and gamma distributions were used for probabilities and utilities, 
and costs to generate the values employed in the simulation. The model 
was run 1,000 times with all these three parameters varying 
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simultaneously. The results were presented as cost-effectiveness 
acceptability curves (CEACs) and as a scattered plot in the incremental 
cost-effectiveness plane. 
 
The cost-effectiveness acceptability curves (CEACs) depict the 
probability that Bazedoxifene or Raloxifene are cost-effective, given the 
observed data, for a range of maximum monetary values that a decision-
maker might be willing to pay for one QALY gain. It can be seen that 
bazedoxifene had a slightly higher probability of being cost-effective 
than raloxifene for a willingness to pay value ranging from 0 to €50,000 
per an additional QALY gained (Figure 3.6). This range includes the 
commonly accepted willingness-to-pay threshold of €30,000 for a QALY 
in the health care sector in Spain111, showing that bazedoxifene can be a 
cost-effective option for the Spanish National Health Service. 
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Figure 3.6. Cost-effectiveness acceptability curves: bazedoxifene versus raloxifene. 
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The mean incremental QALY and cost gain were estimated to be 0.16 and 
€–428, respectively, which showed that bazedoxifene was the dominant 
treatment strategy (Figure 3.7). It can be observed a large variability in 
the results: the dots that conform the ellipse fall within all of the 
quadrants, being the majority contained within the north-east (NE) and 
south-west (SW) quadrant. Realizations falling in the NE quadrant 
correspond to simulations that resulted in treatment more costly and 
more effective; the ones falling in the SW with the majority contained 
within the SW quadrant shown to be less costly and less effective. A 52% 
of observations were allocated in the south quadrants (below the X-axis) 
indicating that, in these cases, bazedoxifene was cheaper than raloxifene. 
The observations located on the east quadrants (right of the Y-axis) 
indicated that the 51% of the realizations showed that a greater QALY for 
bazedoxifene than for raloxifene. 
 
 
Figure 3.7. Cost-effectiveness of bazedoxifene versus raloxifene in postmenopausal 
osteoporotic women. Quality-adjusted life years (QALY). The large dot indicates the 
mean incremental cost and incremental QALY gain. 
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Model validation 
The probability analysis was used also as a sensitivity analysis, as it was 
said, it accommodates the variation of the input parameters. It was 
observed that bazedoxifene generated slightly greater health benefit in 
terms of QALYs gained, but for some input parameters combination 
raloxifene could be preferable. As the difference between treatment cost 
and utilities is small a few variation among these input parameters can 
change the result in terms of labelling the dominant treatment, even the 
relative difference in cost and health outcome remain small. 
 
 
3.5. Discussion and conclusion  
 
Discussion 
The accuracy of the results of the model depends on the quality of the 
input parameters, as always happen for these models. All of the 
parameters used where extracted from published studies. We selected 
the ones that reflect more closely the Spanish patient’s characteristics 
and the clinical practice. One of considerable strengths of this study is 
that data on event incidences, post-event mortality, and costs were 
country-specific. The lack of specific data can be addressed assuming 
conservative scenarios and by including a probabilistic sensitivity 
analysis to assess possible deviations from the base-case analysis. 
The disease evolution simplification can produce results separated from 
what could happen in reality and can be considered study limitations: 
i) No treatment effect was assumed on non-vertebral fractures as the 
fracture incidence did not differ significantly from bazedoxifene 
treatment and placebo97, 109, and raloxifene with placebo 
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ii) The adverse event considered relevant were extracted from the 
published paper. To increase or reduce this list with other possible 
adverse events could modify the results obtained 
iii) The presence of adverse events did not result in treatment 
discontinuation 
iv) The adverse events were assumed to decrease a 10% of the HRQoL 
for the first year and subsequent years based on assumption as 
appropriate estimates found on the utility loss was lacking in the 
literature. The assumption of 10% of utility loss due to leg cramps and 
breast cyst or fibrocystic breast disease could differ from the reality. 
These assumptions matter because once the utilities were corrected for 
HRQoL loss, QALY gain was slightly higher for the bazedoxifene cohort 
leading to a better cost-effectiveness. The change in the estimates of 
HRQoL loss could influence cost-effectiveness ratios. This can be 
controversial and arguable, although these parameters were varied into 
the probability analysis 
v) The situation of multiple fractures simultaneously was not considered 
in the model and costs and HRQoL was not evaluated in this case. 
Furthermore, no data on patients sustained multiple fractures 
simultaneously was found in the literature 
vi) The probability of suffering fractures is constant in time. This is one 
feature of the Markov models, even it can be solved, it is not 
straightforward to implement different transition probabilities depending 
on patients’ age or another characteristic. In addition, most of the times 
the description of the change of the probabilities cannot be found or 
derived from the information in the literature 
vii) The cost of bazedoxifene and raloxifene in the Spanish market was 
assumed to be the same. A time after the assessment performance –in 
November 2012- raloxifene was offered as generic which reduced its 
price112. The cost parameters in the model were established to the 
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nowadays drugs cost (€286.52 and €171.86 per bazedoxifene and 
raloxifene treatment per patient year) and the results obtained show that 
the expected cost per patient was 1,292€ higher in the bazedoxifene 
cohort compared with the raloxifene cohort. The estimated QALYs gain 
was slightly higher in the bazedoxifene treatment branch than in the 
raloxifene one (0.02 QALYs). The PSA shows that bazedoxifene and 
raloxifene are almost equal in their probability of cost-effectiveness. 
 
The model was implemented using Microsoft® Excel Office 2007. It was 
built allowing the user to restore the original default parameters easily 
and to evaluate different possible scenarios, all input parameters were 
presented on one input worksheet and outputs displayed in several 
worksheets in a logical manner that summarizes the findings for the user, 
displaying tables and plots. The introductory worksheets describe the 
structure and the assumptions. These properties make this tool available 
and easy to use for the health care managers that should choose the best 
health care options. 
Other software options are available for implementing the Markov models 
for simmulation, such as R or Matlab. More specific programs designed 
with the aim of using decision trees and Markov models for decisions in 
an applied environment are also in the market –for instance, TreeAge©- 
but they are not simple enough to allow a basic user to change the input 
parameters to calculate the results for different scenarios. 
 
Conclusion 
This study investigated the cost-effectiveness of bazedoxifene compared 
with raloxifene in Spanish postmenopausal osteoporotic women and 
indicated that bazedoxifene was the dominant treatment strategy 
compared with raloxifene for the prevention of vertebral and non-
vertebral fractures in postmenopausal osteoporotic women aged 55 to 82 
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years. The probabilistic sensitivity analysis that accounted for parameter 
uncertainty confirmed the deterministic results in a 52% of the 
realizations and did not create an evidence to select between treatments. 
The use of bazedoxifene supposes a small gain in terms of cost and 
QALYs and the decision between treatments should be reinforced with 
other clinical features not included in the model, such can be safety and 
tolerability113. 
Raloxifene was available later (November 2012), as a generic, for a 
lower cost than bazedoxifene. The cost-effectiveness analysis with the 
current prices showed that it can be a cost-effectiveness option when 
compared with bazedoxifene (Data not shown). 
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Summary Chapter 4.  
HIV TROPISM TESTING FOR MARAVIROC ALLOCATION. MARKOV 
MODEL IN N-STAGES 
 
Markov models were adapted to reflect that the risk of suffering an event 
can change over time. This analytical model was applied to elucidate 
which of 3 available co-receptors tests is cost-effective to determine 
patient’s suitability to benefit from the use of an antiretroviral treatment 
that includes maraviroc. All HIV strains require binding to CD4 plus at 
least one of the 2 co-receptors CCR5 or CXCR4 to enter human cells. 
Some HIV patients can use both co-receptors, and some individuals have 
a mixture of strains. Only patients with exclusively CCR5-tropic HIV are 
eligible to use the CCR5 antagonist maraviroc. 
The co-receptor assessment with 454 test or PS is nearly equal in 
effectiveness to Trofile-ES test but less expensive. Their Incremental 
Cost-effectiveness Ratios (ICER) were estimated to be 68,185 €/utility 
and 77,482 €/utility. There is not a dominating strategy; the expensive 
strategies also have a higher health outcome. The results of the PSA 
showed that the differences between tests are very small and we cannot 
claim the superiority of any of them. The choice will depend on the 
maximum that the health service is prepared to pay per additional unit of 
utility gained. 
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4. HIV TROPISM TESTING FOR MARAVIROC ALLOCATION. MARKOV 
MODEL IN N-STAGES 
 
The HIV/AIDS is a major health problem but antiretroviral (ART) 
regimens proved to be effective in decreasing HIV plasma viral load, 
improving CD4 cell counts, and have substantially altered the natural 
history of HIV infection. The introduction of new antiretroviral agents 
has broadened the number of active agents available for treatment of 
patients with infection due to HIV virus with certain particularities such 
as, its co-receptor type and/or the presence of drug resistance 
mutations. The new drugs in combination with new tools for the diagnosis 
have improved the success rate of therapy. In the case of the maraviroc, 
only patients with exclusively CCR5 HIV co-receptor (not CXCR4 either 
mixed-tropic virus) are considered eligible to use the CCR5 antagonist 
maraviroc. 
The objective of our work is to compare the cost-effectiveness of three 
different tests to determine HIV co-receptor usage (CCR5 and/or 
CXCR4) in order to select candidates for maraviroc. Markov models are 
used to simulate a cohort of patients at a population level and its path 
through different health states to calculate cost and health parameters. 
The resulting cohort will be used to assess the performance of diagnostic 
tests in HIV antiretroviral treatment allocation. This is an adaptation of 
the available methodology implemented to add flexibility to the Markov 
models. 
 
 
4.1. HIV antiretroviral treatment and HIV co-receptor usage tests  
 
The HIV/AIDS is considered a pandemic, a disease outbreak that is not 
only present over a large area but is actively spreading114. Standard ART 
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therapy consists of the combination of at least three ART drugs to 
maximally suppress the HIV virus and stop the progression of HIV 
disease. Raltegravir, darunavir, maraviroc, and etravirine are new drugs 
frequently considered for use, particularly in ART experienced patients. 
Limited information exists regarding optimal combinations of these 
agents for the treatment. Selection of treatments combinations is often 
based on resistance testing results, prior treatment history, and any 
intolerance. 
Maraviroc was shown to be cost-effective, particularly in individuals 
with limited options for active antiretroviral therapy115. However, the 
role of maraviroc in this setting has been limited because of the high 
frequency of dual/mixed-tropic or CXCR4-tropic virus in patients with 
long-standing HIV infection and the necessity for expensive tropism 
assay testing116. Various strains of HIV use one of two co-receptors -
CCR5 or CXCR4- along with the CD4 receptor to enter human cells. 
Some HIV can use both co-receptors, and some individuals have a mix of 
strains (known as mixed-tropic virus). Only patients with exclusively 
CCR5-tropic HIV are considered eligible to use the CCR5 antagonist 
maraviroc, which blocks the virus from using this co-receptor.  
Patients susceptible to be treated by the drug are screened using a 
phenotypic viral tropism assay, the standard of care is the called 
Enhanced sensitivity Trofile test. As the MERIT-ES study demonstrated, 
accurate identification of patients with CCR5-tropic virus is an important 
predictor of treatment response117, 118. Recently, researchers have shown 
that a genotypic tropism test -the 454 sequencing-, or Population 
Sequencing test -PS- may perform well in predicting which patients will 
respond to maraviroc and other drugs in its class. Genotypic tests (which 
look at viral genetic sequences) are easier to perform than phenotypic 
tests (which look at how the virus behaves in a test tube), and therefore 
are usually less expensive (see characteristics in figure 4.1). 
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Figure 4.1. Description of the available tropism tests grouped by phenotypic and 
genotypic procedure. Their characteristics and their accuracy in virus detection are 
reported. 
 
Investigators retrospectively analyzed stored samples from a subset of 
572 participants in the MOTIVATE-1 trial, which evaluated maraviroc 
versus placebo, combined with an optimized background regimen, in 
treatment-experienced patients119. They compared treatment response 
rates between patients identified as having CCR5 virus according to the 
genotypic test and the Trofile assay. Note that this study used the 
original Trofile test, not the enhanced sensitivity assay used in the 
MERIT-ES re-analysis. 
The genotypic test looked at the V3 loop of the HIV-1 gp120 protein, 
which plays a role in interactions between the viral envelope and host 
cell co-receptors. 
V3 genotype and standard Trofile were comparable in predicting antiviral 
responses to maraviroc in treatment experienced patients120. Despite 
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apparently poor sensitivity of standard genotyping for predicting non-
CCR5 HIV relative to standard Trofile, these findings suggest the 
potential of genotyping as an accessible assay to select candidates for 
maraviroc. 
HIV V3 genotyping shows promise as a significantly faster and more 
cost-effective way to correctly identify patients who would benefit from 
CCR5 antagonists. Furthermore, the genotypic test is based on methods 
that are already widely used through the same labs that provide HIV drug 
resistance testing; this approach could become broadly available and be 
conducted at the same time as resistance testing to determine 
susceptibility to all drugs, including maraviroc. 
The model should be realistic and reflect all the variability that the test 
selection implies in the daily clinical practice, furthermore than the 
accuracy, the cost of the tests and the possibility to extend their use for 
all patients should be considered. We adapt the simulation based on 
Markov models allowing different phases of the evolution of the disease 
process characterized by different transitions probabilities matrices. The 
full program for cost-effectiveness and sensitivity analysis was 
implemented in R (see Annex IX). 
 
4.2. Markov models in n-stages  
 
Markov models are a simulation tool frequently used in medical decision 
analysis. These models are especially appropriate when the disease of 
interest is characterized by the recurrence of particular events and when 
these are associated with a continuous risk over time81. The basic 
feature of the Markov model is that future events only depend on the 
current state that the patient is in, and not on prior events. A disease is 
characterized by using a finite number of health states and time is 
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handled as discrete periods of the same length. The implementation of 
the models is done assuming that the probability of travelling between 
health states is the same over time; flexibility can be added by 
introducing tunnel states and tolls, which make the model more complex. 
 
For some of the biological parameters assessed in cost-effectiveness 
studies, it is relevant to consider various phases on the evolution, which 
can be characterized for different probabilities of transition among the 
health stages defined in the structure of the Markov model. A 2-phase 
evolution process can be observed in several biological parameters such 
as the control of the HIV viral load, the recovery of CD4, CD8 or 
lymphocyte cells under active ART therapy or the serologic course of 
Hepatitis A-E virus infection under treatment121-125. The model 
adaptation performed in this thesis allows considering different matrices 
of transition probabilities to describe different phases of evolution for the 
disease course.  
The cohort simulation at a population level considers a hypothetical 
cohort of people were all members begin the process with some 
determined distribution among the states, usually designated according to 
the characteristics of our population of interest and/or the information 
found on the literature. In the next cycle, the cohort is divided among the 
states according to transition probabilities, which yields a new 
distribution of the cohort among the states. This continues in subsequent 
cycles until the process has reached the horizon time or the entire cohort 
reaches an absorbing state. 
For the model building several elements must be defined: 
i) A finite number of informative and realistic health states that can result 
from the evaluated therapies. The states should be mutually exclusive 
and collectively exhaustive 
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ii) The cycle length and the study horizon time. The time horizon should 
be equal to the sum of the lengths of the different phases considered 
iii) Costs and utilities assigned to every health state 
iv) The transition probabilities matrices must be specified. The number 
of transiton matrices is function of the number of therapeutic strategies 
assessed and they correspond to the number of Markov process to run. 
The performance of one Markov process was described in Section 3.1. 
When several phases of outcome evolution are considered, the 
probability of travelling between health states depend on the phase; this 
is reflected in the model by using different transition probability 
matrices. 
Example: 
A simulation by a Markov model in 2-phases is illustrated 
below, the 3 health states model introduced previously is 
used. Figure 4.2 represents the procedure of simulation to 
be run for every assessed therapeutic strategy. 
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Figure 4.2. Representation of a 2-stage Markov model. The arrows 
represent possible transitions between health states (ovals) in a cycle. 
Arrows do not connect health states with transition probability equal to 
0. ds1 and ds2 are the cycles duration of stage 1 and stage 2, 
respectively. P0Stage1 and P0Stage2 are the proportions of the cohort in each 
state at time 0 and at the starting time of the Stage 2. MStage1 and MStage2 
are the transition probabilities matrices associated to each evolution 
stage. 
  
The proportion of patients allocated in each health state at 
cycle 0 is defined initially and the distribution for next stages 
start is taken from the model, i.e., P at the end of stage 1 
(time=ds1) is going to be used as starting proportion for the 
stage 2, considering a cohort with n individuals: 
Pds1=(number patients in Well state at ds1/n, number patients 
in Sick state at ds1/n, number patients in Dead state at 
ds1/n, number patients in Sick state at ds1/n). The simulation 
is run up to the horizon time or all the cohort is death. 
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The model validation by means of sensitivity analyses and probabilistic 
study can be performed using the corresponding transition probabilities 
matrices and proportions of cohort at the starting time for the different 
stages. This adaptation of the procedure also works for the simulations 
performed at individual level, where the patients, one by one, travel in 
the different health states. 
  
 
4.3. Model definition for the HIV co-receptors testing 
 
The cohort simulation model was build to reflect the 2-phases of 
evolution of the outcome studied: the proportion of patients that achieve 
the control of the HIV viral load (HIV RNA VL≤50 copies/mL). The 
issues that have to be addressed are: 
i) Definition and selection of the parameters needed in the simulation 
(transition probabilities matrices, utilities and cost for a patient being in a 
health status for a cycle, horizon time) 
ii) definition of the structure of the Markov model 
iii) selection of the summaries for reporting cost-effectiveness score of 
the evaluated strategies 
iv) sensitivity analyses performance to explore the impact of taking 
alternative assumptions for the input values on the results. 
 
Cost-Effectiveness analysis 
Our study uses data about the target population, sensitivity and 
specificity of the evaluated tests and effectiveness of the intervention 
measured by means of utilities. 
The interest of this work is restricted to the patients that have shown a 
Non X4 co-receptor and the use of maraviroc. The cost of tropism 
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testing for the patients whose test shows a X4 tropism is not considered 
as they are not in the studied therapeutic strategy: tropism testing plus 
treatment which includes maraviroc. 
We simulate a cohort as described in section 4.2 of HIV infected whose 
characteristics are similar to those in MOTIVATE119 or MERIT trial117. 
The simulation was performed up to 3 years of lifetime horizon126. The 
analysis was conducted from the perspective of the health care payer in 
Spain. 
Cost-effectiveness was analyzed by estimating incremental cost and 
effectiveness. 
 
Decision analytic model 
In the situation of an HIV infected patient, maraviroc can be a therapeutic 
option. To assess whether the patient is susceptible to benefit from the 
treatment and if it can save resources, it is required to test the HIV co-
receptor. The interest of this work is restricted to the patients that have 
shown a Non X4 co-receptor and the use of maraviroc (See Figure 4.3). 
The proportion of patients within each group can be calculated taking 
into consideration the prevalence of each co-receptor and the sensibility 
and specificity of the test to detect the co-receptor.  
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Figure 4.3. Flow chart for the tropism test result and treatment allocation. The 
assessment is focused on the patients receiving maraviroc, framed by a rectangle. 
 
The evaluated tests to determine the HIV co-receptor were the 
Enhanced Sensitivity Trofile (Trofile-ES), the 454 test and population 
sequencing test (PS). The sensitivity and specificity of these tests are 
given in Table 4.1. 
 
Table 4.1. Sensitivity, specificity of the assessed co-receptor tests are displayed. 
 Trofile-ES 454 sequencing PS 
Sensitivity 100 73 60 
Specificity 100 95 100 
 
 
The prevalence of HIV infected patients with X4 co-receptor drive to the 
proportion of patients that receive MRV properly or improperly. For the 
study, null efficacy on virological control was assumed when prescribing 
maraviroc to patients with X4 co-receptor.  
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Model specification 
The actual model contains the following health states: HIV RNA viral load 
(VL) under control (undetectable VL, i.e.: VL≤50 copies/mL), HIV RNA 
viral load detectable (VL>50 copies/mL) and death. The graphic 
representation of the health states and outcomes is shown in figure 4.4. 
 
 
Figure 4.4. Graphic representation of the different health states included in the Markov 
model. Ovals represent the health states and the arrows the possible transitions among 
them. The utility scores are indicated into the oval in a scale from 0 (death) to 1 
(perfect health). 
 
A hypothetical group of patients starts in one of the Markov health states 
(ovals) and has a specified rate of transition (arrows) to other Markov 
states. 
Two phases of achieving undetectability where considered121. The 
probability of travelling between health states is different for the period 
from week 0 to 24 weeks and over 24 weeks (Figure 4.5); this is 
reflected in by using different transition probability matrix. 
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Figure 4.5. Graphic representation of the percentage of individuals achieving 
indetectability over time, results from the MERIT-ES study. Two phases were 
distinguished: from week 0 to 24 and from 24 to 48 weeks-depicted using the dashed 
line118. 
 
There were 6 Markov processes: 
 patients allocated to Trofile-ES test, 
 those allocated to the 454 and  
 the population sequencing 
all separated by the time (from week 0 to 24 and over 24 weeks). Table 
X.1 in Annex X shows the probability of travelling through the health-
states in 1 cycle (3 months) by co receptor test; notated as MT1, MT2, 
MG1, MG2, MPS1 and MPS2, respectively118. 
Three hypothetical cohorts of 10,000 patients were assumed to be tested 
by Trofile-ES, 454 and PS tests. In order to assess the potential clinical 
and economic impact of the treatment alternatives, 3-month treatment 
cycles were estimated for each strategy. The cycles finished with 3 
years of follow-up or death, which is an absorbing state. 
All patients are assumed to begin in the Markov state “VL>50” 
equivalent to detectable HIV viral load. 
Efficacy data and health-state utilities were obtained from published 
studies (See details in Annex X). 
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Costs were reported from the third party health care payer perspective, 
acknowledging that Spain has universal health care coverage that 
includes tests and prescript antiretroviral ART drugs for this patient’s 
group (see disclosure in Table X.2). Considering the proportion of 
patients with adverse events (MERIT-ES study) the mean cost per 
patient/cycle were €3,161.13 for patients allocated to the Trofile-ES 
test, €3,067.38 for the patients allocated to the 454 test and €3,051.13 
for the PS test group. 
 
The utilities related to the states of Undetectable, Detectable and Death 
were 0.83, 0.79 and 0, respectively. 
Cost and effectiveness annual discount rates were both set at 3%. 
 
 
4.4. Results 
 
Analytical results 
The results were based on deterministic model calculations. The model 
estimated the average costs and utilities per patient of the lifetime 
horizon for the three groups of testing. 
The utility for patients screened with Trofile-ES test was similar to 
patients screened with 454 or PS test (10.67, 10.66, and 10.65 
respectively; equivalently 3.557, 3.553 and 3.550 utilities per year). The 
utilities gained were less than 0.1 utilities. This indicates that all co-
receptor tests have a very similar performance in guiding the therapeutic 
strategy. 
The expected cost per patient per 3 years of treatment was higher in 
patients tested with Trofile-ES test (€41,037; €13,679 per year) in 
comparison with patients in 454 test cohort (€39,821; €13,274 per year) 
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and the PS test (€39,609; €13,203 per year) with a difference of €1,216 
and €1,428 (equivalent to €405 and €476 per year). This indicates that 
testing patients with the Trofile-ES test leads to more expensive 
treatment under the assumed conditions (Figure 4.6). 
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Figure 4.6. Cost efficacy plot for the three therapeutic strategies evaluated. The values 
for cost and utility for a year of simulation are displayed. 
 
Therefore, the testing with 454 test or PS is nearly equal in 
effectiveness as Trofile-ES test but less expensive. Their Incremental 
Cost-effectiveness Ratios (ICER) were estimated to be 68,185 €/utility 
and 77,482 €/utility. There is not a dominating strategy; the expensive 
strategies also have a higher economical cost. 
 
Model validation 
The results produced by a model are as reliable as the quality of the data 
used to generate the results. In the Markov cohort model, the estimated 
average effects (Utilities) and costs are the direct outcome measures, 
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but they are ultimately dependent on the accuracy of the HIV-tropism 
test. The model’s ability to translate test accuracy into patients with 
undetectable VLs is instrumental in the calculation of the ICER, which is 
the primary outcome measure that incorporates both costs and utilities. A 
penalization for the fact that a patient has to wait to know the HIV-
tropism was introduced in the model by decreasing the utility in a 5% for 
every week of turn-around test result (Scenario 8 in the Table 4.2). 
To assess the consequences of using concrete input parameters, the 
base case output was compared to the model output under a range of 
input parameters. A series of deterministic one and two-way sensitivity 
analyses were conducted to explore the impact on the ICERs of 
alternative assumptions for the values of key input parameters. The 
parameters and values tested generate a list of possible scenarios, which 
are described in the Table 4.2. 
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Table 4.2. Fifteen scenarios were created changing the input parameters to perform a 
sensitivity analysis. The Scenarios 1 to 8 are one-way analysis, and the following ones 
are two-way analysis 
 Test 
Sensitivity 
Costs Utilities Comments 
Scenario 1  454,  from 
250€ to 150€ 
  
Scenario 2  454, from 
250€ to 100€ 
  
Scenario 3 454, from  
73% to 63% 
   
Scenario 4 454, from  
73% to 83% 
   
Scenario 5 PS, from  
60% to 50% 
   
Scenario 6 PS, from  
60% to 70% 
   
Scenario 7   VL>50  from 0.79 to 0.69  
Scenario 8   Trofile-ES, VL≤50: 0.622;VL>50: 
0.592 
454, VL≤50: 0.705;VL>50: 0.671 
PS, VL≤50: 0.746;VL>50: 0.710 
The utilities are reduced 
to penalize for the turn-
around test. A week of 
waiting time reduces 5% 
the utility. Trofile-ES: 5 
weeks; 454: 3 weeks; 
PS: 2 weeks.  
Scenario 9  454, from 
250€ to 150€ 
Trofile-ES, VL≤50: 0.622;VL>50: 
0.592 
454, VL≤50: 0.705;VL>50: 0.671 
PS, VL≤50: 0.746;VL>50: 0.710 
Two-way sensitivity 
analysis: Scenario 
1+Scenario 8 
Scenario 10  454, from 
250€ to 100€ 
Trofile-ES, VL≤50: 0.622;VL>50: 
0.592 
454, VL≤50: 0.705;VL>50: 0.671 
PS, VL≤50: 0.746;VL>50: 0.710 
Two-way sensitivity 
analysis: Scenario 
2+Scenario 8 
Scenario 11 454, from  
73% to 63% 
 Trofile-ES, VL≤50: 0.622;VL>50: 
0.592 
454, VL≤50: 0.705;VL>50: 0.671 
PS, VL≤50: 0.746;VL>50: 0.710 
Two-way sensitivity 
analysis: Scenario 
3+Scenario 8 
Scenario 12 454, from  
73% to 83% 
 Trofile-ES VL≤50: 0.622;VL>50: 0.592 
454, VL≤50: 0.705;VL>50: 0.671 
PS, VL≤50: 0.746;VL>50: 0.710 
Two-way sensitivity 
analysis: Scenario 
4+Scenario 8 
Scenario 13 PS, from  
60% to 50% 
 Trofile-ES, VL≤50: 0.622;VL>50: 
0.592 
454, VL≤50: 0.705;VL>50: 0.671 
PS, VL≤50: 0.746;VL>50: 0.710 
Two-way sensitivity 
analysis: Scenario 
5+Scenario 8 
Scenario 14 PS, from  
60% to 70% 
 Trofile-ES, VL≤50: 0.622;VL>50: 
0.592 
454, VL≤50: 0.705;VL>50: 0.671 
PS, VL≤50: 0.746;VL>50: 0.710 
Two-way sensitivity 
analysis: Scenario 
6+Scenario 8 
Scenario 15   Trofile-ES, VL≤50: 0.622;VL>50: 
0.517 
454, VL≤50: 0.705;VL>50: 0.586 
PS, VL≤50: 0.746;VL>50: 0.620 
Two-way sensitivity 
analysis: Scenario 
7+Scenario 8 
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The results of the series of sensitivity analysis performed to explore the 
impact of taking alternative assumptions for the input values on the 
results are displayed in the Table 4.3. 
 
Table 4.3. Results of the cost-effectiveness study, in terms of cost-
effectiveness ratios (ICERs), according to the various possible scenarios (units 
given in 2010 Euros) 
 
Analysis  
Trofile test Genotypic 454 
test 
PS ICER 
Total 
Cost 
Total 
Utilities 
Total 
Cost 
Total 
Utilities 
Total 
Cost 
Total 
Utilities 
Trofile 
vs 454 
Trofile 
vs PS 
454 vs 
PS 
Base-case 41037 10.67 39821 10.66 39609 10.65 68185 77482 353767 
Scenario 1 41037 10.67 39659 10.66 39609 10.65 77287 77482 83300 
Scenario 2 41037 10.67 39578 10.66 39609 10.65 81837 77482 -51933 
Scenario 3 41037 10.67 39821 10.66 39609 10.65 67504 77482 505381 
Scenario 4 41037 10.67 39821 10.66 39609 10.65 68377 77482 326554 
Scenario 5 41037 10.67 39821 10.66 39609 10.65 68185 75998 221104 
Scenario 6 41037 10.67 39821 10.66 39609 10.65 68185 78418 558564 
Scenario 7 41037 10.42 39821 10.36 39609 10.35 19209 22129 171177 
Scenario 8 41037 8.42 39821 9.05 39609 9.58 -1916 -1231 -404 
Scenario 9 41037 8.42 39659 9.05 39609 9.58 -2186 -1235 -95 
Scenario 10 41037 8.42 39578 9.05 39609 9.58 -2314 -1235 59 
Scenario 11 41037 8.42 39821 9.05 39609 9.58 -1916 -1231 -404 
Scenario 12 41037 8.42 39821 9.05 39609 9.58 -1916 -1231 -404 
Scenario 13 41037 8.42 39821 9.05 39609 9.58 -1916 -1231 -404 
Scenario 14 41037 8.42 39821 9.05 39609 9.58 -1916 -1230 -404 
Scenario 15 41037 7.81 39821 8.80 39609 9.31 -1230 -953 -416 
Note: Values in black represent the changes with respect to the base-case analysis. 
A negative ICER means that the 2nd therapeutic strategy improves the utility and 
reduces the cost. 
 
A great variability can be observed from the results obtained for the 
different scenarios. As a summary, it can be said that, for a 46.7% (7/15) 
of the cases, the Trofile test showed to be more costly and more 
effective than the 454 test (ICER>0). In a 46.7% (7/15), the Trofile-ES 
was more costly and more effective than the PS test and for a 46.7% 
(7/15) the 454 test was more costly and more effective than the PS test. 
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In addition to the deterministic sensitivity analyses, a probabilistic 
sensitivity analysis was conducted. 
 
Probabilistic sensitivity analysis (PSA) 
The probabilistic simulation was performed by drawing each model 
parameter value from a specific probability distribution reflecting either 
patient’s individual characteristics or parameter uncertainty.  
The Beta distribution was used to generate the transition probabilities, 
and the utility values, the Gamma distribution was used for the costs. 
The distributions’parameters was computed by using the base-case 
value and its standard deviation assigned to be the 10% of the value, 
since these data were not available127. 
The utilities and cost of the 1,000 simulated trials per each of the three 
therapeutic strategies were computed. The cost-effectiveness ratios 
were plotted on the cost-effectiveness plane, and the cost-effectiveness 
acceptability curves were derived. 
 
It is required to define the ceiling Ratio and compute the net monetary 
benefit for each therapeutic strategy in order to plot the acceptability 
curve. The ceiling ratio indicates the amount of Euros that is worth to 
pay for the gain of one unit of health, 1 unit of utility in our case. The net 
monetary benefit for each therapeutic strategy was computed per every 
trial as the utility multiplied by the ceiling ratio minus the cost, and this 
value was used to assign a 1 to the therapeutic strategy that has the 
larger benefit, and a 0 to the other 2.  
A range of values of the ceiling ratio was used in order to plot the 
probability of each therapeutic strategy to show a larger benefit than the 
others. 
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The PSA showed results in which all treatments can be cost-effective 
since the density of the point estimates were spread in all quadrants of 
the cost-effectiveness plane (Figure 4.7). Regarding the mean of the 
incremental cost and utilities for the comparisons two by two it can be 
said that, in mean, the Trofile-ES test was dominated compared to the 
454 test (Incremental cost=987.57, Incremental utility=-0.07); and also 
when it was compared with the PS test (Incremental cost=1,304.71, 
Incremental utility=-0.02). When comparing the 454 test and the PS, the 
first had a larger cost and a larger gain in health (Incremental 
cost=317.14, Incremental utility=0.04). 
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Figure 4.7. Cost-effectiveness plane for the comparison between therapeutic 
strategies. A=Trofile-ES, B=454 test and C=PS. 
 
The figure 4.8 shows the probability that a treatment is the most 
effective of the three therapeutic strategies at a different threshold 
values for cost-effectiveness (ceiling ratio). For small willingness to pay 
quantities (under €10,000) the differences are small and the cheapest 
test seems preferable. For ceiling ratios from 10,000 onwards the 
difference between tests are very small and we cannot claim the 
superiority of any of them. 
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Figure 4.8. Cost-effectiveness acceptability curve for the three therapeutic 
strategies by different values of the ceiling ratio. 
 
 
4.5. Discussion and conclusion 
 
The limitations and the strengths of the model are detailed, the 
contextualization of these issues allow us to understand better the 
relevance and applicability of the conclusions.  
 
Study limitations 
There are several gaps in empirical data that need to be filled. 
Information is lacking, for instance, on the relation between test accuracy 
and treatment allocation. The hypothesis that a wrong treatment 
allocation drives to treatment failure is not right in 100% of the cases, 
since the ART treatment is composed by 3 or 4 antiretroviral drugs, even 
MRV is not active the other drugs can control the virus replication 
leading to an HIV-RNA undetectable viral load. This assumption avoided 
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adding the probability of failure as a parameter in the model. Treatment 
efficacy reduction due to poor compliance and aspects such as treatment 
switching were not included in the model.  
The sensitivity analysis tried to account for the variability generated by 
the previously described terms and other unknow ones, while extra-
assumptions about them were not added in the base-case analysis. 
A higher-order Markov model can include historical information on 
several patients’ health states in the probabilities of moving next into a 
health state or another 128. In addition, microsimulation models, which 
during the last 20 years have been increasingly applied in qualitative and 
quantitative analysis of public policies, can solve this issue. Their 
technique would let each patient start the simulation at a different risk of 
becoming undetectable and this risk changes over time129. The 
microsimulation requires a larger set of input parameters than the cohort 
simulation and, it usually, gives similar results. 
The efficacy data used in this analysis were taken from a North-
American population. Compliance with treatment recommendations and 
consistency of refilling are also likely to differ between health-care 
systems and cultural settings. It was shown that insurance coverage for 
prescription drugs increases the probability of use130. Thus, the 
availability of country-specific data when evaluating the cost-
effectiveness is of relevance. 
 
Strengths of the model 
The implemented model could accommodate 2-phases of evolution of the 
outcome studied, emulating what happens in “real” life. It was a useful 
tool to learn about the cost-effectiveness of the three assessed tests to 
determine the HIV co-receptor without the need of doing a prospective 
clinical study. 
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Discussion 
The use of HAART had reduced the viral replication and reconstituted 
immunity, leading to longer periods of symptom-free disease and 
survival after AIDS diagnosis, and to changes in the natural history of 
HIV-associated illnesses. This encompasses an increase in the number 
of individuals that require treatment, taking into account the limited 
resources that can be spent on health services, the economic assessment 
for new antiretroviral medications are of interest for the health decision-
makers to optimize the use of health care resources. 
Cost-effectiveness analysis aim to provide information on the value of a 
new co-receptor test compared to the standard intervention. Cost-
effectiveness does not necessarily mean cost-saving; the total cost of a 
therapeutic strategy can be higher, but still considered good value for 
money if it enhances significantly the health outcome relative to the 
current standard.  
The model performed is an attempt to simulate a real world process 
using input data describing physical characteristics of the system, a set 
of algorithms to transform input data to output parameters of interest and 
simplifying assumptions to limit the scope of the model. The accuracy of 
the output measures depends on the quality of the input parameters and 
the structure of the model.  
The input parameters are estimations that have an implicit variability, 
which was not considered in the modelling process, but sensitivity 
analysis measured how this uncertainty can affect the results. 
The time horizon was settled to 3 years, longer simulation times can be 
unrealistic for the following reasons: 
 the patient’s characteristics change over the time,  
 therapeutic strategies and SOC can evolve,  
 and new variables of decision to allocate test and treatment can be 
identified as relevant. 
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The current economic evaluation applies to the Spanish situation. The 
inputs for the model have been obtained from published literature review. 
The scope of the analysis was to compare the performance of three HIV 
co-receptor tests. The study was performed from the payer’s 
perspective, in which only direct medical costs were included. 
 
Conclusion 
The deterministic incremental analysis showed that the 454 test could be 
considered cost effective when compared to the gold standard test. The 
cost of the therapeutic strategy that includes the 454 test is cheaper than 
the one including the Trofile-ES test, and the obtained utilities are very 
similar. The Population Sequencing test showed a smaller health benefit, 
but it is cheaper than the other two options. The probability sensitivity 
analyses have shown that all tests can be considered cost-effective 
when the ceiling ratio of 10,000 is surpassed. The relevant point is to fix 
the maximum that the health service is prepared to pay per additional 
unit of utility gained.  
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Summary Chapter 5.  
COST OF A NEW TREATMENT FOR THE PAROXYSMAL NOCTURNAL 
HEMOGLOBINURIA (PNH). BUDGET IMPACT ANALYSIS 
 
Chapter 5 provides an example of cost study for a rare disease, the 
paroxysmal nocturnal haemoglobinuria (PNH). A budget impact analyses 
was performed to assess the economic effects of introducing eculizumab 
for treating the PNH. Direct and indirect costs of this disease treatment 
were estimated and reported from the perspective of the health care 
system and from the societal perspective. The use of eculizumab for 
treating the PNH would imply an incremental yearly cost of €300,650 per 
patient compared to standard of care, but would provide larger societal 
benefits and an improvement in health related quality of life of the PNH 
affected patients leading to overall savings. 
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5. COST OF A NEW TREATMENT FOR THE PAROXYSMAL NOCTURNAL 
HEMOGLOBINURIA (PNH). BUDGET IMPACT ANALYSIS 
 
Interest in cost analyses has accompanied concerns about rising health 
care costs, pressures on health care policymakers to allocate resources, 
and the need for health product makers, and other technology advocates, 
to demonstrate the economic benefits of their technologies131. 
Accordingly, assessing such costs with accuracy and building a 
predictive model for future medical costs are of interest. The budget 
impact analysis (BIA), also called financial model, is a methodology for 
the estimation of the economical cost and consequences of adopting a 
new health-care intervention within a specific health-care setting or 
system.  
Studies of costs and related economic implications comprise a major 
group of methods used in health technology assessment. These studies 
can involve attributes of primary data collection and/or integrative 
methods, i.e., cost data can be collected as part of RCTs and other 
clinical studies, and also through administrative databases used in health 
care payment131. Cost data from one or more such sources often are 
combined with data from primary clinical studies, epidemiological studies, 
and other sources to conduct cost-effectiveness analyses and other cost 
studies that involve evaluating health and economic impacts of health 
technology. 
The objectives in this chapter are to estimate the direct, and indirect, 
costs of extending a new therapy (eculizumab) for a rare disease such as 
paroxysmal nocturnal hemoglobinuria (PNH), compared to the standard 
care and to provide a prediction of the cost impact for the next 5 years. 
Moreover, this evaluation was conducted from the perspectives of the 
health care system and the societal care system. 
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Section 5.1 explains the methodological approach used to perform a BIA. 
In section 5.2, the clinical background of the PNH is described, next the 
model details to perform this analysis for the PNH treatment are given 
(Section 5.3). The results, and the final discussion and conclusions are 
displayed in sections 5.4 and 5.5. 
 
 
5.1. Budget impact analysis (BIA) 
 
The BIA has two goals: the estimation of the average cost of different 
therapy strategies used to treat a health condition and the prediction of 
how a change in treatment will influence the trajectory of spending on 
that health issue. This analysis can be used for budget planning, 
forecasting and for calculating the impact of health technology changes 
on health-care guidelines; it could be a good complement to the cost-
effectiveness analysis (CEA), which accounts for the cost per unit of 
health improvement132. National regulatory agencies of several regions in 
the world including Australia, North America (Canada, United States), 
Europe (England and Wales, Ireland, Belgium, France, Hungary, Italy, 
Poland) and the Middle East (Israel), have included a request for BIA 
alongside the CEA, when submitting evidence to support national or local 
formulary approval or reimbursement of the new health-care 
interventions. Other countries have typically performed their own BIA 
(The Netherlands) rather than requesting it from the manufacturer, 
although voluntary submission is permitted. Country-specific guidelines 
for constructing BIAs are also available 133-143. These guidelines are 
variable in terms of defining what constitutes a BIA and most of them 
provide only limited details on the important factors. An exception are 
the Polish guidelines142, which provide precise recommendations on 
perspective, time horizon, reliability of data sources, reporting of results, 
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rates of adoption of new therapies and sensitivity analysis. The Spanish 
national regulatory agency does not have any guidelines or 
recommendations. 
A literature review published in 2005 by Mauskofp et al.144 indicate that 
the number of studies in peer-reviewed journals is limited and varied 
greatly in the methods they used. Estimations of the financial impact for 
different timeframes and/or target patients were described: 
i) for a timeframe of 1 to 3 years 
ii) for lifetime costs for a specific cohort  
iii) for a set of representative individuals being started on competing 
treatments.  
A more limited number of published studies attempt to explicitly estimate 
the financial and health-care service impact of a new therapeutic 
strategy for a well-defined national or health plan population. 
 
Instead of publication, budget impact analyses are more frequently 
presented directly to decision makers as interactive computer programs 
designed to calculate the financial impact for specific health plans. There 
is also the ongoing debate about whether a BIAs should be totally or 
partially publicly available for review. 
 
BIA methods 
Whereas an economic analysis addresses the additional health benefit 
gained from the resources invested in health, the BIA addresses the 
affordability of a new therapeutic strategy. Several factors, which are not 
generally needed for cost-effectiveness analysis, should be part of a 
comprehensive budget impact analysis including the size of the treated 
population, second-order costs, market diffusion rates for the new drug, 
and off-label use137. See in Figure 5.1 how the information of BIA and the 
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incremental cost-effectiveness ratio (ICER) as a summary of a cost-
effectiveness analysis (CEA) can be obtained. 
 
 
Figure 5.1. Schematic representations of the budget impact and ICER computation. Both 
approaches compare the current environment with a new one –which can include a new 
therapeutic strategy-. BIA reflects resources use and the ICER considers both costs 
and health outcome. Adapted from Brosa et al.145. MD stands for medical doctor.  
 
The quantification of the affected population out of the total and the 
definition of the target population that can be benefited from the use of 
the health care intervention assessed is relevant, these numbers are 
going to frame the cost analysis. For instance, if the interest is to assess 
the congenital toxoplasmosis, the population of interest should be 
reduced to pregnant women. The epidemiologic information, the 
demographic data, and some risk factors should be taken into account to 
form the right frame for the study. 
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The resources used to treat a particular health condition should be listed 
as detailed as possible, but the cost assessment will be quantified for 
some selected items (or all) according to the cost component (or 
components) and the perspective of interest. 
Costs in health care can be subdivided into three components: Direct 
costs, indirect costs, and intangible costs. The items included in each 
component are described as follows: 
 The direct costs reflect the amount of money spent on medical 
products and/or services as a direct result of an illness 
 The indirect costs are the lost potential productivity resulting from 
illness-related absences or impaired performance at the workplace 
and at patient’s normal life activities 
 The intangible costs include humanistic measures of changes in 
health status such as health related quality of life, joy, and 
satisfaction or the cost of worries, pain, and suffering. These items 
are often included in the health outcome quantification by means of 
a health related quality of life or utility score. 
Further definitions about cost are given in Annex XI. 
 
The direct costs are relatively easy to measure. The indirect costs are 
considered costs from the perspective of society as a whole. Many of 
these are difficult to measure, and there is some controversy over which 
ones to include in the list and how to measure them. For instance, the UK 
National Institute for Clinical Excellence, NICE, adopts a limited societal 
perspective in its evaluations and considers the direct costs falling on the 
UK National Health Services, and those indirect costs funded by the state 
such as unemployment and sickness benefits146. 
Two perspectives can defined in terms of the view point of the analysis: 
If the health care payer point of view is selected, the study only accounts 
for the direct costs of health care for this specific payer and if the study 
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is conducted from the perspective of the society as a whole, direct, and 
indirect cost are both important. In general, the societal perspective is 
considered the most appropriate, but a health care manager with a 
limited budget might be tempted to ignore the societal view and consider 
only the costs that affect his own budget. An example of this situation is 
a study of migraine performed under the health service perspective only 
suggested that sumatriptan in migraine (an expensive drug in comparison 
with a cheaper treatment as the standard of care) was highly undesirable, 
but a study taking a societal perspective came to the opposite 
conclusion147. This example drives us to note that the comparison 
between 2 or more treatment scenarios is possible by repeating the cost 
calculations under the current environment and under the environment 
where the new treatment strategy is used, which is displayed in the last 
column of the figure 5.1, labelled as “New environment”. 
 
Two important concepts are the opportunity cost and the marginal cost. 
The opportunity cost is defined as the benefit foregone when selecting 
one alternative intervention (treatment A) over the next best alternative 
(treatment B). The opportunity cost of investing in a healthcare 
intervention (treatment A) is best measured by the health benefits that 
could have been achieved if the same amount of money had been spent 
on the next best alternative intervention (treatment B). The marginal cost 
is the resource cost associated with the use of treatment A in spite of 
treatment B, being an indicator of the amount of additional resources that 
must be expended or can saved (see detailed explanations in Annex XI). 
 
The perspective and items included in the analysis should be defined 
clearly and the data collection needs to be reflecting values as updated 
and accurate as possible. The validity of the results depends on the 
quality of this data. 
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The first models on value of health were developed in the insurance 
industry to assess and to characterize both the risk of suffering a 
disease, and the population health-care cost. The data used in the 
modelling was the recorded by the health insurance claims. During the 
last years, the study and prediction of the cost became an important 
subject of research to guide the health resources allocation; some of the 
authors have applied different statistical techniques to do the estimations 
and prediction148. Some published examples of budget impact analyses 
are described in the review by Mauskopf et al144. As time goes by, more 
data derived from administrative databases and/or expert opinion is 
available. 
In order to predict the financial impact the most common approaches are 
 to estimate the direct costs of the treatment of a health condition 
by assuming a linear behaviour in the cost for the near-term 
years and updating the proportion on the target population. 
 Alternatively to impose a tax of increase of target population into a 
Markov model incorporating clinical and epidemiological data to 
simulate the target population throughout the timeframe analysis. 
This method is suitable for diseases with rapid evolution. 
 Regression models are also used to characterize the cost as 
dependent variable in function of a set of independent variables 
selected by their clinical and economical relevance. The use of 
the coefficient estimated by the model can be used to predict the 
mean cost for next years. 
 Data mining tools were the newest and accurate approach that 
Bertsimas et al. applied to provide predictions of future health-
care costs. With the use of decision trees and clustering 
algorithms along with claims data from over 1,000,000 insured 
individuals over three years discovered that the pattern of past 
cost data is a strong predictor of future costs and medical 
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information provides an accurate prediction of medical costs 
particularly on high-risk members148. 
 
 
5.2. The paroxysmal nocturnal hemoglobinuria 
 
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, genetically 
acquired blood disorder characterised by chronic intravascular hemolysis 
(destruction of red blood cells). PNH is clinically defined by the lack of 
the complement inhibitory protein CD59 on the surface of red blood cells. 
CD59 normally blocks the formation of the terminal complement complex 
on the surface of the red blood cell, which prevents hemolysis. The list 
of signs and symptoms of PNH include hemoglobinuria (presence of 
blood in the urine), anaemia, fatigue, difficulty swallowing, abdominal 
pain, erectile dysfunction in men and thrombosis149-151. PNH is most 
common among men in their 20s, but it occurs in both genders and at any 
age, causing high morbidity and mortality. 
It is estimated that rare diseases -those whose frequency is under 5 
cases / 10,000 people- affect about 6% of the European population. The 
PNH is considered a rare disease which affects an annual rate of 1-2 
cases per million152. Hill et al.157 estimated that the annual incidence is 
1.3 cases per million, and the prevalence is of 15.9 cases per million of 
inhabitants. Men and women are affected equally and PNH may occur at 
any age but it frequently is found among young adults with a median age 
at the time of diagnosis of around 42 years (range, 16-75 years). This 
disease process is insidious and has a chronic course, with a median 
survival of about 10.3 years after the diagnoses153. 
PNH is the only hemolytic anaemia caused by an acquired intrinsic defect 
in the cell membrane. In the field of anaemia, 1% of couples are at risk of 
having a newborn with a severe syndrome of haemoglobin such are 
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sickle-cell disease or thalassemia. More than 330,000 children are born 
worldwide each year affected by one of these disorders. In Spain, the 
average risk of having a newborn with a rare or unusual anaemia has 
increased due to African immigration154. 
Treatment of PNH consists on supportive care measures including 
corticosteroids, androgen hormones, iron and folate supplementation, 
sometimes transfusions (generally reserved for crises) and allogenic 
stem cell transplantation which have been successful in a small number 
of cases until the development of a new drug known as eculizumab. This 
is a recombinant humanized monoclonal antibody that works by binding to 
complement protein C5, inhibiting its enzymatic cleavage, blocking the 
formation of the terminal complement complex, and thus preventing red 
cell lysis*. In 2007, the drug (eculizumab, Soliris™; Alexion 
Pharmaceuticals, Inc., Cheshire, CT), received approval as an orphan 
drug by the U.S. Food and Drug Administration (FDA) and by the 
European Medicines Agency (EMEA) for the treatment of patients with 
PNH to reduce hemolysis155. The FDA approval was based mainly on a 
randomized, double-blind, placebo-controlled, clinical trial in 87 RBC 
transfusion-dependent adult PNH patients, with supportive evidence 
from two observational studies: 
 A phase II pilot study involving 11 PNH transfusion-dependent 
patients, and 
 a 52-week, open-label, non-placebo-controlled, single-arm study 
in 96 PNH patients156. 
Two clinical trials to study the efficacy of eculizumab were published; 
Sheperd165 and Triumph162, both has shown that eculizumab reduces 
intravascular hemolysis after the first week of treatment. The control of 
the hemolysis reports anaemia diminution and consequently the required 
                                                 
* Lysis is defined as destruction or decomposition, as of a cell or other substance, under 
influence of a specific agent. 
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blood transfusions were reduced by 51%. Fatigue was also reduced after 
a few weeks of treatment, and the release was maintained up to the end 
of the study. Also, 3 phase II* studies concluded that eculizumab 
treatment leads to less blood transfusions need and a reduction on risk of 
thrombosis events157, 158. 
 
The aim of this study was to assess the budgetary impact in Spain of 
using eculizumab as a newly approved pharmacotherapy for PNH 
compared to the standard of care. Two perspectives were used: the 
health care system and the societal care system considering the cost of 
the comorbidities and the patient’s inability to work and perform a 
“normal life”. 
 
 
5.3. Model for assessing the PNH treatment 
 
Model 
A budgetary impact model using Microsoft Excel Office 2007 following 
the international recommendations has been elaborated to estimate 
healthcare costs of the extended use of eculizumab as a treatment for 
PNH. The model was implemented allowing the user to restore the 
original default parameters easily and to evaluate different possible 
combinations. All input parameters were presented on one input 
worksheet and outputs were displayed in several worksheets that 
summarize the findings for the user, displaying tables and plots. The 
introductory worksheets describe the structure, assumptions, and use of 
                                                 
* There are 5 phases for describing the clinical trial of a drug based on the study's characteristics. Phase 2 
studies gather preliminary data on effectiveness (whether the drug works in people who have a certain 
disease or condition). For example, participants receiving the drug may be compared with similar 
participants receiving a different treatment, usually an inactive substance (called a placebo) or a different 
drug. Safety continues to be evaluated, and short-term adverse events are studied. [Reference: 
http://www.clinicaltrials.gov/ct2/info/glossary#P] 
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the model furthermore than all sources and assumptions associated with 
the input (see Annex XII and Annex XIII). 
Published clinical guidelines, clinical literature and expert opinion were 
employed to describe the required treatment and progress-over-time of 
patients affected by PNH. The analytical model was built as a flexible 
tool to predict the potential financial impact when changing some input 
parameters. 
 
Population 
The eligible population was obtained from estimates of the number of 
Spanish citizens affected by PNH.  
 
Treatment options 
Two therapeutic strategies are applied in the Spanish region: the 
standard of care consisting in blood transfusion, anticoagulant 
treatments, hematopoietic stem cell transplantation and/or bone marrow 
transplantation and the new treatment with eculizumab, which was the 
only treatment approved for the PNH159, 160. The standard of care has a 
limited and variable efficacy a non ignorable amount of adverse events 
that require continuous concomitant treatments complicate tackling the 
disease159, 161. Two scenarios were compared in the analysis: patients 
treated with blood transfusion versus the eculizumab treatment. These 
are the two common therapeutic strategies used in practice. 
An expected 15%, 35%, 55%, 70%, 85% and 100% of patients receiving 
eculizumab treatment were considered in the model in the first, second 
third, fourth and fifth year, respectively. It was assumed that patients 
with PNH are going to switch progressively from the standard of care 
treatment to eculizumab.  
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Time horizon, perspective, and discounting 
The analysis was performed with a 5-year time projection from the 
public payer and societal perspective. The costs were in Euros (EUR, 
2010) and were reported with and without discounting by a 5% annual 
rate135, 136. The undiscounted values are given because in the good 
practices of the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) reports is stated that budget impact 
analyses present financial streams over time and it is not necessary to 
discount the costs. However, some national guidelines published for BIA 
performances advise to apply a discount 6% annual rate, instead of 5% as 
we did. 
 
Resources and costs 
The model has been developed considering the costs associated to the 
standard of care and eculizumab treatments using the evolution of the 
disease and treatment efficacy and adverse event described in the 
Hillmen et al.162-164, Brodsky et al.165 and Kelly et al.166 research papers. 
The base-case analysis was defined as the eculizumab treatment and the 
alternative scenario was defined as the standard of care, mainly based in 
blood transfusions. 
The following resources and treatment components were identified and 
quantified as direct costs: drug costs, dispensing and administrating 
costs, the cost of treating the adverse and PNH related events. In the 
indirect cost setting, patients’ traveling expenses to attend to the health 
center and the loss of production due to PNH were included. 
Eculizumab should be administrated in doses of 600mg per week during 
the first 4 weeks of treatment, 900mg in the 5th week and after the 6th 
week 1 dose of 900mg every 2 weeks166. The cost of eculizumab for the 
first year is 342,650€ and for the 2nd and consecutive ones is of 
320,400€ per patient year (PPY). The mean cost PPY is 315,479€. 
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Costs of treatment administration and visits to the clinic where also 
quantified. For both treatments, associated costs of medical supervision, 
screening and transfusions cost were considered. For the standard 
treatment the same cost where considered. For the eculizumab treatment 
the cost of drug doses administration by nursing staff were also added. 
Input parameters are displayed in the Annex XII: data for adverse events, 
direct and indirect costs related to PNH. 
 
Sensitivity analysis 
One-way sensitivity analyses were performed to test the robustness of 
the model. Direct and indirect costs in addition to the survival time used 
as input parameters in the base case analysis were modified one at a 
time to see the differences in the results obtained when changing the 
data. 
 
 
5.4. Results 
 
Base-case analysis 
In the base-case analysis (eculizumab), the estimated drug cost was 
€318,842, a 88.05% higher than in the case of the alternative scenario 
(Standard of care). The administration costs were of €559, a 34.54% 
higher than in the standard of care. The cost of the adverse events were 
estimated to be €72, a 7.17% lower than in the standard of care.  
It is remarkable the difference between the prevalence of thrombotic 
episodes in both treatment groups: a 3% for patients treated with 
eculizumab and a 27% for the standard of care. In addition, a higher 
number of chronic kidney disease in stages 1-3 is observed in the 
standard of care (59% versus 34%). The higher cost to deal with an 
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adverse event is the treatment for the chronic kidney disease in stages 
4-5, with a cost of €62.4, in the base-case assuming the need of 5 
dialysis per year167. 
The direct total costs for 1 year of eculizumab treatment were estimated 
to be €319,473, being superior to the costs of the standard of care. The 
difference is due to the drug and administration cost, the other costs are 
favorable to eculizumab.  
The indirect costs rise to €104 plus €130 for the travelling to the 
medical visits and for the drug administration. The total cost per loss of 
production is non-existent, the losses were due to the time required for 
drug administration €4,693, being €5,197 the total indirect cost 
associated to eculizumab treatment versus €384,662 for the standard of 
care. This large difference is due to the larger survival (mean survival 
time for patients treated with eculizumab is 25 years larger than the 
survival receiving the standard of care) and, consequently non-
productivity loss for patients treated with eculizumab (see Table 5.1 
below, and tables XII. 2 and XII.3 in Annex XII). 
 
Table 5.1. Summary of direct, indirect and total costs per patient year by treatment 
group (2010 Euros) 
 Eculizumab Standard of care Difference 
Direct Costs  
Drug costs 318,842 18,468 300,374 
Administration costs 559 272 287 
AE and events related to PNH cost 72 83 -11 
Total Direct Costs 319,473 18,823 300,650 
Indirect Costs 5,197 384,662 -379,465 
Total Costs 324,670 403,485 -78,815 
 
 
 
 
Alternative scenario 
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The direct drug cost for the standard of care treatment amounted to 
€18,468, while administration cost were €272, the cost of treating the 
adverse-events were €83, and the cost per chronic kidney disease in 
stage 4-5 was €60.72. The total amount of direct costs per patient year 
was €18,823. A large difference in drug costs favorable to the standard 
of care is observable. 
The indirect costs for travelling expenses were €520 (€208 for medical 
visits plus €312 for drug administration), the cost of the administration 
time amounted to €22,846 and the loss of productivity was estimated in 
€361,296. The loss of productivity due to drug administration is higher 
for the standard of care in comparison to eculizumab. 
Even the direct costs for the eculizumab treatment are higher than the 
costs in the standard therapy; the indirect costs show the inverse 
situation. In the indirect costs items, the loss of productivity, the loss of 
working time, and the travelling costs are higher for the standard of care. 
The computation of the different items of costs can be summarized in 
two values: the societal total cost for eculizumab treatment was 
€324,383 per patient year, and the cost for the standard of care was 
€403,484. The treatment with eculizumab represent a saving of €79,102 
relative to the standard of care (See Figure 5.2). 
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Figure 5.2. Direct and indirect total costs for the Eculizumab treatment and the standard 
of care. 
 
Sensitivity analysis  
One-way sensitivity analyses were performed to test the robustness of 
the model. Base-case values were modified for the following parameters: 
 Direct costs. Differences of adding and subtracting a 10% in cost 
were tested. These were labelled as Scenario A1 and A2 
 Indirect costs. Differences of ± 10% in cost were tested (Scenarios 
B1 and B2) 
 Survival time after diagnoses: Influence of adding and subtracting a 
10% of mean survival to the PNH patients were evaluated 
(Scenarios C1 and C2). 
The sensitivity analysis had shown that the results for the assessed 
scenarios agree with those obtained in the base-case analysis. It was 
seen that the higher cost could reach a total of €356,265 in the 
eculizumab treatment and a total of €445,172 in the Standard of care. 
The largest difference between treatment arms was seen when the 
scenario C2, where the incremental cost for using eculizumab amount to 
€120,790 more than in the standard of care. Detailed results are shown 
in Table 5.2 and in Figure 5.3. 
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Table 5.2. Direct and indirect costs are displayed by the different scenarios and by 
treatment group (2010 Euros) 
Scenario and treatment Direct Costs  Indirect Costs  Total costs 
A1‐Eculizumab  351357  4910  356267 
A1‐Standard of care  20669  384662  405331 
A2‐Eculizumab  287588  4910  292498 
A2‐Standard of care  16976  384662  401637 
B1‐Eculizumab  319473  5401  324874 
B1‐Standard of care  18823  423128  441950 
B2‐Eculizumab  319473  4419  323892 
B2‐Standard of care  18823  346195  365018 
C1‐Eculizumab  319473  4910  324383 
C1‐Standard of care  18823  342974  361796 
C2‐Eculizumab  319473  4910  324383 
C2‐Standard of care  18823  426350  445172 
  
 
 
Figure 5.3. Diagram indicating the direct and indirect costs for the different scenarios of 
the sensitivity analysis.  
 
Budget impact analysis 
The budget impact analysis provides and estimation of the cost of the 
substitution of the standard of care by the eculizumab treatment. The 
percentages of patients treated with eculizumab are 15%, 35%, 55%, 
Expected  € 
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70%, 85% and 100% at five years. The calculations are done taking into 
account the total direct costs per patient. 
Total budgetary impact for a hypothetical population of 100 patients with 
an annual growing tax of 1% for 5 years of time horizon has shown an 
increase on PNH treatment expenditure when the number of patients 
treated with eculizumab is larger. The expenditure is calculated in 2010€ 
with a 5% of discount tax, see Table 5.3 and Figure 5.4. 
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Table 5.3. Budget impact analysis of the use of eculizumab versus the standard of care 
for 5 years 
% Patients Treated Now 1st year 2nd year 3rd year 4th year 5th year 
Eculizumab 15% 35% 55% 70% 85% 100% 
Standard of care 85% 65% 45% 30% 15% 0% 
       
Total annual direct and indirect  
costs Now 1st year 2nd year 3rd year 4th year 5th year 
Eculizumab € 4,865,739 € 11,466,926 € 18,199,649 € 23,394,822 € 28,692,078 € 34,092,940 
Standard of care € 34,296,158 € 26,488,739 € 18,521,741 € 12,471,306 € 6,298,009 € 0 
       
Discounted total annual costs Now 1st year 2nd year 3rd year 4th year 5th year 
Eculizumab € 4,865,739 € 10,893,579 € 16,425,183 € 20,058,135 € 23,369,877 € 26,380,467 
Standard of care € 34,296,158 € 25,164,302 € 16,715,871 € 10,692,586 € 5,129,768 € 0 
 
 
 
       Standard of care                        Eculizumab 
 
Figure 5.4. Budget impact of the use of eculizumab versus the standard of care for 5 
years while the percentage of patients treated with eculizumab increases over time. 
 
Treating patients suffering from PNH with eculizumab instead of the 
Standard of care resulted in a reduction in total societal costs of €79,102 
per patient year, even the direct costs are larger when treating patients 
with eculizumab. 
 
 
 
    Now        1st year       2nd year     3rd year      4th year      5th year 
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5.5. Discussion and conclusion 
 
Discussion 
The present work is an update of the current situation in terms of a 
number of patients and costs of the PNH. The goal is to provide details 
of the resource consumption and more accurate estimates of the 
budgetary impact, based on data following the complete clinical situation, 
including adverse events and events related to the studied disease. 
There are several limitations to be considered in this model, including 
the very limited number of published reports regarding resource 
consumption in PNH treatment. Prospective studies conducted under 
standard clinical practice, designed to collect resources and costs data 
associated to PNH would be desirable and could provide reliable 
information to be used in further economic evaluations168. Potential 
improvements in health related quality of life and benefits resulting from 
better health at a social level were included in the present model, but 
future works could be even more useful if a health score would be added, 
such can be the utility or a burden of disease score. 
An increase in the number of patients under PNH seems to be realistic; 
this was reflected in the budget impact analysis for 5 years using the 1% 
of patients growing tax. 
 
Conclusion 
The introduction of new (and expensive) pharmaceutical products is one 
of the major challenges for health systems169. The use of eculizumab for 
treating the PNH would imply an incremental yearly cost of €300,650 per 
patient compared to standard of care, but would provide larger societal 
benefits and an improvement in health related quality of life of the PNH 
affected patients leading to overall savings. These results would help the 
Regional, and National Authorities to perform a better allocation of 
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available resources, decisions in incorporating the new treatments to the 
guidelines and into the new standard of care can be taken with objective 
information.
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Summary Chapter 6.  
DALYS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. HEALTH 
BENEFITS QUANTIFICATION 
 
Most of the published clinical studies are focused on measuring health in 
terms of efficacy and/or safety. Sometimes health and well-being 
quantification is not a direct measurement. The calculation of the burden 
of disease for osteoporotic women who may suffer from fractures done 
at an individual level was presented in terms of disability adjusted life 
years (DALYs). It was quantified that Mean (SD) overall undiscounted 
DALYs lost per woman were 6.1 (4.3), with a significantly higher loss in 
women with severe osteoporosis with prior bone fracture (BF); 7.8 (4.9) 
compared with osteoporotic women (5.8 (4.2)) or postmenopausal women 
with a BMD >-2.5 T-score after receiving a drug-based therapy (6.2 
(4.3)).  Factors explaining the variation in the levels of health were the 
alcohol consumption, having rheumatoid arthritis, previous osteoporotic 
bone fracture, family history of osteoporosis, using corticosteroids and a 
lower BD revealed to be linked to a larger DALYs lost. Few studies of 
burden of diseases are available, and even less for Spanish population 
and performed using individual characteristics. The identification of risk 
factors can improve the clinical practice by guiding the concerns that 
should be considered in the osteoporosis prevention. 
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6. DALYS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS. 
HEALTH BENEFITS QUANTIFICATION *  
 
Different approaches are available for measuring the health benefit of 
any therapeutic strategy or any intervention performed. Historically, 
mortality rates have been used to describe health status across 
communities. These measures do not fully account for the burden of 
premature mortality, an important indicator of a population health. In fact, 
since most deaths occur among persons in older age groups, mortality 
rates are dominated by the underlying disease processes of the 
elderly170. Premature mortality entails estimating the average time a 
person would have lived if he or she had not died prematurely. This 
estimation inherently incorporates age and death, rather than merely the 
occurrence of death itself171. Over the last decades the need of measure 
the health outcome has increased. The introduction of an objective 
summary to quantify the health status is needed to better explain health 
across populations and to compare different treatments and/or individual 
groups (see further definitions in Annex II).  
When morbidity is taken into account, the two dominating summary 
measures are the Quality Adjusted Life Years (QALYs), and the Disability 
Adjusted Life Years (DALYs). QALYs and DALYs represent an implicit 
trade-off between quantity for quality of well-being. In QALYs, 
premature death is combined with morbidity by attaching a weight to 
each health state such that value 0 represents death, while value 1 
represents full health. The number of QALYs for a health profile is found 
by multiplying the health related quality of life weight (HRQoL) of the 
health state, with the duration of the health state. Like the QALY, the 
DALY measure facilitates comparisons of all types of health outcomes by 
                                                 
* The DALY calculations and some of the statistical analysis presented in this chapter have been 
performed along with Lisette Kaskens 
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attaching disease weights were value 0 represents full health and value 1 
represents death. Note that these disease weights are the opposite of the 
HRQoL weights in the QALY. A DALY can therefore be seen as an 
inverse QALY172. 
 
The goal of this chapter is to assess the burden of disease of the 
osteoporosis in postmenopausal women. DALYs are computed using 
individual information. Section 6.1 describes how the DALYs can be 
calculated. Section 6.2 contains the details of the calculation of the 
DALYs for the postmenopausal women with osteoporosis, the details of 
the available data and the statistical analysis. The description of the 
health quantification by means of DALYs and the factors associated to a 
higher burden of disease are given in section 6.3. The discussion and 
conclusions are displayed in the last section. 
 
 
6.1. DALYs calculation  
 
The description of the characteristics of the disability-adjusted life year 
(DALY) for individual data is presented in the followoing. DALYs can be 
calculated according to Fox-Rushby et al.173. 
Previous to the DALYs computation we must state some definitions: 
K is the standard age-weighting modulation factor; 
C is a constant; 
r is the discount rate, usually r=0 or 0.03; 
a is the age of death or the age of onset of disability, for the 
calculation of Years of life lost (YLLs) and Years of life lived with 
disability (YLDs), repectively;  
β is the parameter from the age weighting function 
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L is the standard expectation of life at age a or the duration of the 
disability for the calculation of YLLs and YLDs, repectively;  
D is the disability weight. 
Calculations done using the individual data of the subjects in the sample: 
1) Utility (U) and disutility (D) values: 
UD 1  
The disutility value can be used in the following formulas as the disability 
weight. 
 
2) Years of life lost (YLLs): 
The term YLLs is calculated using the following formula: 
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3) Years of life lived with disability (YLD) is equivalent to the YLLs 
(adapting the definition of a and L) multiplied by the disability weight, in 
the formula noted as D: 
    ,,,, KrYLLDKrYLDs   
 
4) Life expectancy (LE) at a particular age is 
  aLEaLE   
 
5) And years of life lived with disability at age a is the product of 
disability weight and duration of disability at age a, i.e.  
    DadisabilitywithlivedLifeaYLD * . 
 
6) DALY equals to the sum of YLLs and YLDs. 
YLDsYLLsDALYs  . 
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For the calculations at steps 2 and 3: The values introduced for r, K, and 
β were the ones recommended by Murray et al.196: r=0.03, K=1 and 
β=0.04. C is a constant with value 0.1658. These values constitute the 
base case analysis. The YLLs and YLDs can be computed without a 
discount rate (r=0) and without age weighting (K=0). 
The life expectancy, LE, was extracted from the Spanish national 
statistics database174. The information of the individuals recorded in the 
data set was used in the YLLs and YLDs calculations. The onset of the 
disease, life expectancy at a particular age and the disability weight were 
included in the formulas in order to obtain a particular value for each 
individual. 
It is noteworthy that 4 values for the DALY can be computed for every 
individual in the data set, depending on the discounting and age weighting 
combinations: Discounted, weighted by age; Discounted, non-weighted 
by age; Non discounted, weighted by age and Non discounted, non-
weighted by age. 
The DALYs calculation using individual information is illustrated in the 
case of a sample of postmenopausal women. The reported DALYs are 
with and without a discount rate and without age weighting. Once 
calculated, the DALY values are analyzed as a dependent variable with 
the goals to estimate and describe the burden of the disease. 
 
 
6.2. DALYs calculation for postmenopausal women with osteoporosis using 
individual information  
 
The osteoporosis disease and its clinical importance was described in 
section 3.2.  
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The burden of osteoporosis in Spanish postmenopausal women has not 
been established. Osteoporosis is a very common disease; about three 
million people have this health problem in Spain, most of which are 
women. Approximately 30 out of every 100 women suffer of 
osteoporosis after menopause. Every year osteoporosis causes more 
than 1.3 million fractures of vertebrae, hips, and wrists in the world. 
Most of the fractures require a delicate and expensive surgical operation 
that does not ensure perfect patient recovery. It was found that fractures 
caused by osteoporosis cause a substantial hospital burden in Spain175. 
 
6.2.1. Data  
The data used for the DALYs calculations belong to a cross-sectional, 
epidemiological one-visit study that enrolled 4,157 postmenopausal 
women (at least 12-month after last menstrual period) with osteoporosis, 
who were attending outpatient clinics of Gynecology in Spain. The 
patients’ clinical characteristics, bone densitometry and health related 
quality of life (HRQoL) data were recorded. The DALYs could be 
computed in 2,782 (67% out of 4,157) Spanish postmenopausal women 
with a diagnosis of osteoporosis (spinal bone mineral density –BMD- T-
score < -2,5 according to WHO criteria and identified by DXA) within the 
last two years with information on BMD, date of diagnosis and HRQoL at 
the time of data collection.  
The groups of interest were defined by using the T-score value and the 
fact of having suffered an osteoporotic bone fracture: Osteoporotic 
women with bone fracture (BF), Osteoporotic women without BF and T-
score > -2.5176. 
 
Demographics and clinical details of women (2,782) who were included in 
the DALY analyses are summarized in Table 6.1. The total sample has 
9.8% of the women in the osteoporotic with bone fracture group, 70.4% 
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in the osteoporotic without bone fracture and 19.8% in the osteopenic 
group. The respective mean ages are 63, 61 and 60 years old, and 
28.3%, 41.3% and 45.1% of each of them are working. The body mass 
index (BMI) mean of the studied women are 25.6 kg/m2 for the 
osteoporotic with BF, 25.8 kg/m2 for the women in the osteoporotic 
without BF group and 25.7 kg/m2 for those with osteopenia. The clinical 
characteristics show significative differences between groups on age, the 
presence of comorbidities such as diabetes mellitus, hypertension, 
rheumatoid arthritis, and malabsorption syndrome and osteoporosis 
disease data. Also the employment situation and educational level is 
related to the prevalence of osteoporosis177-179. 
Relative to background therapies used among the studied groups, calcium 
supplement and vitamin D are the most used therapies (approximately 
80% of the women use it), followed by the Biphosphonates (approx. 
50%). The Selective Estrogen Receptor Modulators (SERM) is used in 
more than 40% of the women belonging to osteoporotic women and 
women with osteoporosis without BF, and a 26.5% of the women with 
osteoporosis with BF. 
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Table 6.1. Socio-demographics, clinical characteristics and participant background for 
all included women and by study group 
Variable All (n=2782) 
Study group by BMD  
Severe 
osteoporosis 
with prior BF  
(n=272) 
Osteoporosis  
(n=1958) 
T-score >-2.5      
(n=552) 
F or Chi-2  (p 
value)₤ 
Socio-demographic data      
Age (years) 61.0±7.3 63.3±7.3 60.9±7.4 59.9±6.6 20.3 (p<0.001) 
Age group (%)      
≤44 0.4 0.0 0.5 0.2 38.4 (p<0.001) 
45-49 3.6 1.5 3.7 4.2  
50-54 13.8 9.6 13.6 16.8  
55-59 28.3 21.7 28.4 31.0  
60-64 25.3 28.7 24.9 25.0  
≥65 28.6 38.6 28.9 22.8  
Employment situation (%)      
Working 40.7 28.3 41.3 45.1 37.4 (p<0.001) 
Transitory sick leave 2.3 4.0 2.2 1.6  
Permanent disability 0.8 1.5 0.7 0.5  
Unemployment 3.2 3.3 3.6 2.0  
Retired 20.3 29.0 20.1 16.7  
Housewife 32.6 33.8 32.1 34.1  
Education level (%)      
None 6.8 12.2 6.5 5.3 23.7 (p=0.003) 
Primary 35.3 39.6 34.4 36.6  
Secondary 28.8 25.2 29.3 28.8  
Undergraduate 15.9 13.3 16.7 14.5  
Degree 13.2 9.6 13.2 14.9  
Environment (%)      
Rural 10.9 16.6 9.9 11.6 0.1 (p=0.702) 
Semi-urban 22.1 21.8 22.7 20.1  
Urban 39.6 34.3 38.8 45.0  
Metropolitan 27.4 27.3 28.6 23.2  
Clinical characteristics      
BMI (kg/m2) 25.6±4.3 25.8±4.1 25.6±4.3 25.7±4.4 0.4 (p=0.675) 
Cigarettes/day 1.7±0.7 1.6±0.7 1.6±0.7 1.8±0.7 2.2 (p=0.113) 
Smoking (%)      
Non-smoker 67.4 67.3 67.7 66.7 1.1 (p=0.889) 
Former smoker 17.7 16.2 17.8 18.2  
Smoker 14.9 16.5 14.6 15.1  
Alcohol consumption, any (%)  18.2 22.2 17.5 18.7 3.7 (p=0.156) 
Alcohol consumption > 30gr/day (%) 1 1.9 0.8 1.5 4.2 (p=0.125) 
Background of co-morbidities(%)      
Diabetes mellitus       
No 92.3 81.0 93.2 94.5 51.9 (p<0.001) 
Type I 1.7 3.7 1.2 2.6  
Type II 6 15.3 5.6 2.9  
Hypertension (%) 23.6 37.8 21.9 22.7 33.2 (p<0.001) 
Rheumatoid arthritis  4.5 7.6 4.3 3.7 6.9 (p=0.031) 
Anorexia nervosa  0.3 0.4 0.3 0.4 0.1 (p=0.968) 
Hyperparathyroidism  0.4 0.8 0.3 0.4 1.0 (p=0.602) 
Hyperthyroidism  2.4 3.8 2.5 1.3 5.1 (p=0.078) 
Chronic liver diseases  0.6 0.8 0.7 0.4 0.8 (p=0.664) 
Malabsorption syndrome 0.4 1.9 0.2 0.6 10.0 (p=0.007) 
Osteoporosis data      
Age at diagnosis (years) 58.8±6.8 59.9±6.8 58.9±6.9 58±6.4 8.7 (p<0.001) 
BMD (DXA) -2.5±1.2 -2.9±0.4 -2.8±0.5 -0.9+1.9 990.3 (p<0.001) 
# of risk factors for osteoporotic BF 0.7±0.8 1.9±0.8 0.5±0.7 0.5±0.7 495.7 (p<0.001) 
# of risk factors for osteoporosis 5.1±1.8 6.9±0.3 5.0±1.8 4.9±1.8 172.9 (p<0.001) 
Time from diagnosis (years) 2.25±2.9 3.4±3.8 2.1±2.8 2.1±2.8 24.0 (p<0.001) 
Note: Values are mean (standard deviation) or percentage relative to total in the group.₤Chi2 may be lineal 
for trend or likelihood ratio. Environment; rural (<10,000 inhabitants), semi-urban (>10,000 to <30,000 
inhabitants), urban (>30,000 to <200,000 inhabitants) and metropolitan (>200,000 inhabitants). BMD=Bone 
Mineral Density; BF=Bone fracture. 
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6.2.2. Missing data study 
Missingness can contain information. In order to be sure that missing 
data could not be allocated to a special group of participants, 
characteristics of the participants with a value for DALYs were compared 
univariatedly with participants without a DALY value by means of chi-
square or t-test. 
No significant differences between groups were observed in age, 
smoking and the BMI categorized by 20 kg/m2. Henceforth, the 
mechanism for the missing data was assumed to be missing at random. In 
this case the available information of the outcome and covariates 
combined is representative of the information that is not observed or 
registered. Under this assumption the results obtained are valid even 
they are underpowered due to the reduction in the sample size because 
the used models are likelihood based. This seems to be a plausible 
assumption as long as the features of the women used in the DALYs 
calculation do not differ from the total sample included in the study. 
  
 
6.2.3. Utility and disutility weight  
The HRQoL was assessed using the generic Medical Outcomes Study 
(MOS)–Short Form (SF) with 12 items questionnaire (SF-12v2)180, which 
was used to derive disutility values (see Annex XIV).  
Numbers derived from SF) surveys or other health profiles generally 
cannot be used directly for cost-effectiveness analyses. Preference-
based approaches, such as the EuroQol EQ-5D181. The EQ-5D is a 
standardised, non-disease-specific instrument for describing and valuing 
health. It yield interval level scores anchored at 0 (death) and 1 (perfect 
health) that represent preferences for particular health states, 
characteristics essential for use in cost-effectiveness analyses182. 
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Thus, although SF and other instruments for valuing health have distinct 
uses, researchers seeking to reduce respondent burden in primary data 
collection and those relying on existing data for secondary analyses may 
benefit from the ability to translate between profile measure scores and 
preference scores. 
The work published by Franks et al.183 presented the coefficients of a 
second-degree polynomial model that allows the EQ-5D calculation by 
using the SF-12 scores.  
The SF-12 survey is combined to generate physical component summary 
(PCS) and mental component summary (MCS) scales. The PCS is derived 
from questions on physical functioning, the physical part of role 
functioning, pain, and general health; the MCS is derived from questions 
of vitality, social functioning, the emotional part of role functioning and 
mental health.  
The PCS and MCS values for each individual were centered by 
subtracting the mean of each variable for the total sample (in the studied 
dataset, 43.09 and 47.57 units respectively). 
The EQ-5D was calculated using the formula that includes PCS, MCS 
main effects and interaction, also second degree variables: 
,00015.000015.000009.0008.0013.0847.05 21
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2
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121  XXXXXXDEQ  
where X1 are the PCS centered, i.e., the PCS is observed value minus the 
PCS sample mean. And X2 is the analogous for the MCS. 
Then,  
DEQIndexUtility 5  
and 
DEQIndexD 51  . 
 
6.2.4. YLLs and YLDs  
For the calculation of years of life lost (YLLs) the value of 84.6 years of 
life expectancy for Spanish women with a low mortality rate and 
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mortality data associated with osteoporosis was used to determine the 
value of L, being L= 84.6-a. 
 
In the calculation of years of life lived with disability (YLDs) L took the 
value of the difference between the life expectancy and the age of 
diagnosis of osteoporosis. 
 
6.2.5. Data analysis 
The DALYs were compared by group (Osteoporotic women with bone 
fracture (BF), Osteoporotic women without BF and T-score > -2.5) by 
means of analyses of variance and covariance (ANOVA and ANCOVA). 
The null hypothesis is that the mean DALYs are all equal for all the 
assessed groups: 
OtOWBFOBFH  :0  
vs. 
differentismeanstheofoneleastAtHA : . 
 
A MANCOVA or multivariate linear regression models were adjusted to 
assess the effect of the following factors on the mean DALYs: 
Bone Density, BMI above 20 kg/m2, previous osteoporotic fracture, 
active smoking, alcohol consumption above or equal to 30g/day, 
rheumatoid arthritis, presence of family antecedents of osteoporosis and 
the use of corticosteroids therapy was done. 
 
Subsequently, paired-comparison analyses were completed for factors 
showing significant group differences in univariate ANOVA, in order to 
further evaluate specific group contrasts Games-Howell correction184 
was made to give an overall significance level of alpha = 0.05. 
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The SPSS code for the data analysis and DALYs calculation is provided 
in Annex XV. 
 
 
6.3. Results 
 
The overall DALYs both undiscounted and discounted by the study 
groups are shown in Figure 6. 1. The mean (SD) undiscounted and 
discounted years loss are 6.1(4.3) and 4.2(2.9) for the entire sample. 
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Figure 6.1. Mean (95% confidence interval) DALYs loss, undiscounted (white bars) and 
discounted (grey bars) per group and for the total population; OBF=Osteoporosis with 
BF, OWBF=Osteoporosis without BF, Ot=Osteopenic with a BD >-2.5. 
 
There are significative differences in the DALYs between groups 
(ANOVA, p-value<0.001), when the comparison is made by pairs the 
differences are placed in the mean DALYs for osteoporotic women with 
BF and without BF (7.8 (4.9) and 5.8 (4.2) respectively) and on the 
osteoporotic women with BF and the osteopenic ones (6.2 (4.3)). 
The same differences (and p-values<0.001) were observed for the 
discounted DALYs, being the mean values of 5.5 (3.3), 4.0 (2.8) and 4.2 
(2.8). 
The same evaluation was done separating by the women’s age, grouped 
in younger than 65 years and with 65 years old and older. According to 
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the criteria for treatment recommendations in primary prevention in 
Spain185. 
The DALYs values were significatively higher for the younger, with a 
mean of 6.4 (4.7) versus the 5.1 (3.1) of the elderly group, also in the 
discounted values 4.3 (3.1) versus 3.9 (2.3), (p-value for undiscounted 
DALY comparison <0.001 and 0.03 for the discounted values). 
In the group younger than 65 years old there were significant differences 
between osteoporotic with BF and without BF (p-value<0.001) and 
between osteoporotic with BF and osteopenic women (p-value<0.001), 
both for the undiscounted and discounted DALYs lost (Figure 6.2. A). 
In the group with 65 years old and older the differences that achieve 
signification were between osteoporotic with BF and without BF with p-
values of 0.010 and 0.006 for undiscounted and discounted DALYs.  The 
differences between osteoporotic with BF and osteopenic women were 
significant when the discounted DALYs were compared (p-value=0.034) 
but it lost the significance in the undiscounted values (p-value=0.062) 
(Figure 6.2 B). 
137 
 
 
D
A
LY
s-
Y
ea
rs
 lo
st
 
0
2
4
6
8
10
OBF OWBF Ot All OBF OWBF Ot All
Undiscounted
Discounted
 
A)  Postmenopausal women <65 years of age 
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B) Postmenopausal women ≥ 65 years of age. 
 
Figure 6.2. Mean (95% confidence interval) DALYs loss, undiscounted (white bars) and 
discounted (grey bars) per group (OBF=Osteoporosis with BF, OWBF=Osteoporosis 
without BF, Ot=Osteopenic with a BD >-2.5.) and for the total population < 65 years of 
age and ≥ 65 years.  
 
When the relationship between the mean value of DALYs loss and the 
number of risk factors that a patient account for (0, 1 or 2 or more with 
mean values of 5.5 (4.0), 6.1 (4.2) and 6.4 (4.9)) was assessed 
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significative differences were observed between the group with 0 and 1 
risk factors (p-value=0.014) and nearly significative differences between 
the group with 0 and 2 or more risk factors (p-value=0.056). Significance 
was lost when the discounted DALYs were evaluated (none versus 1 p-
value=0.071 and none versus 2 or more p-value=0.220). 
The mean DALY loss and its 95% confidence interval (CI) are larger for 
those who consume alcohol, have rheumatoid arthritis, family 
antecedents of osteoporosis and use of corticosteroids (Table 6.2). 
 
Table 6.2. Mean (95% confidence interval) DALYs loss, undiscounted and discounted by 
the presence of a risk factor. 
 
The same risk factors showed statistical signification in the model when 
adjusting by BD and previous osteoporosis fracture, both for 
undiscounted and discounted DALY loss. When the multivariate model 
was build, the factors that remain significant were rheumatoid arthritis, 
family antecedents of osteoporosis and use of corticosteroids, which 
absence reduce the mean undiscounted DALY loss (14.6 years) by 2.8, 
0.4 and 3.6 years respectively. A similar model was found for the mean 
discounted DALYs which included the rheumatoid arthritis and use of 
    Undiscounted  Discounted 
 
 
   
Mean 
95% CI 
Lower 
 
Upper 
 
Mean 
95% CI 
Lower 
 
Upper 
BMI ≥ 20 kg/m2 6.05 5.89 6.22 4.20 4.09 4.31 
  < 20 kg/m2 6.06 5.25 6.88 4.06 3.54 4.59 
Smoking Non-smoker 6.02 5.85 6.20 4.20 4.09 4.32 
  Smoker 6.26 5.81 6.71 4.17 3.87 4.47 
Alcohol consumption <30g/day 6.03 5.87 6.20 4.19 4.08 4.30 
  ≥30g/day 8.64 6.59 10.69 5.76 4.48 7.05 
Rheumatoid arthritis  Absence 5.92 5.76 6.08 4.10 3.99 4.21 
  Presence 8.92 8.02 9.82 6.36 5.76 6.96 
Family antecedents of 
osteoporosis 
Absence 
5.76 5.55 5.97 4.00 3.86 4.15 
  Presence 6.49 6.24 6.75 4.48 4.31 4.65 
Corticosteroids Non-use 6.04 5.88 6.20 4.19 4.08 4.29 
  Use 9.84 6.63 13.04 6.68 4.62 8.74 
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corticosteroids, with a overall mean of 10.0 and a 2.1 and 2.2 of mean 
reduction for the non-rheumatic women and non-corticosteroids 
consumers (Table 6.3). 
 
Table 6.3. Variables associated with DALY loss, undiscounted and discounted; adjusted 
by BD and previous osteoporosis BF 
Undiscounted DALYs      95% CI   95% CI 
Parameter (category considered) Estimate p-value Lower Upper§ Estimate p-value Lower Upper£ 
BD 0.12 0.066 -0.01 0.25 0.20 0.004 0.06 0.33 
Prior osteoporosis BF (No) -1.96 <0.001 -2.50 -1.42 -1.78 <0.001 -2.34 -1.22 
BMI<20 kg/m2 (No) 0.05 0.898 -0.68 0.78     
Smoking status (Non-smoker) -0.22 0.336 -0.68 0.23     
Alcohol consumption ≥30g/day (No) -2.44 0.003 -4.04 -0.84     
Rheumatoid arthritis (No) -2.87 <0.001 -3.64 -2.09 -2.76 <0.001 -3.55 -1.98 
Family antecedents of osteoporosis (No) -0.39 0.033 -0.75 -0.03 -0.44 0.016 -0.80 -0.08 
Use of corticosteroids (No) -3.61 0.002 -5.87 -1.36 -3.56 0.003 -5.89 -1.23 
Discounted DALYs         
BD 0.07 0.102 -0.01 0.16 0.13 0.004 0.04 0.22 
Prior osteoporosis BF (No) -1.48 <0.001 -1.84 -1.12 -1.44 <0.001 -1.81 -1.08 
BMI<20 kg/m2 (No) 0.18 0.462 -0.31 0.67     
Smoking status (Non-smoker) 0.04 0.793 -0.26 0.34     
Alcohol consumption ≥30g/day (No) -1.45 0.008 -2.52 -0.39     
Rheumatoid arthritis (No) -2.15 <0.001 -2.67 -1.63 -2.09 <0.001 -2.61 -1.57 
Family antecedents of osteoporosis (No) -0.18 0.132 -0.42 0.06     
Use of corticosteroids (No) -2.35 0.002 -3.86 -0.84 -2.15 0.007 -3.71 -0.60 
§Model build for each factor adjusted by BD and prior osteoporotic BF. 
£Model calculated with all the factors at the same time. 
The global mean (95%CI) for the undiscounted DALYs multivariate model was 14.61 (12.16; 17.07) 
and 9.95 (8.32; 11.58) for the discounted DALYs. 
 
 
6.4. Discussion and conclusion 
 
The use of the DALYs as a measure of health is controversial; this health 
outcome has two main components: the quality of life reduced to a 
disability and the lifetime lost due to premature mortality. The methods 
used to assign disability weightings to life years are critical such it 
requires diagnostic group’s definition and, in function of the relative 
severity of their disease, a disability weight should be assigned. In this 
case, the matter was solved by using individual data collected through a 
validated survey. 
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The DALYs can be reevaluated by applying a discount and weighting by 
age. The first option gives higher value of the present years than to the 
future ones, and the second option modifies the DALYs giving less value 
to the children and old people life years. The calculations were 
performed for undiscounted and discounted DALYs and it is remarkable 
that both drive to the same conclusions. The age weighting was not 
applied since the population of interest is elderly women.  
A limiting factor of this study concerns the methodology used to 
determine the EQ-5D used as disability weight since it is made by using 
a formula that explains the 63% of the variability. However, it ensures a 
utility weight calculation already validated and published. Another 
limitation is the fact that the enrolled individuals are women attending 
outpatient gynecology clinics, which have fewer comorbidities and a 
different life style than inpatients, this may have introduce some 
selection bias. 
These results represent the first DALYs loss quantification for 
osteoporosis disease in Spain, which was reported in general terms and 
for different groups of interest. It was found that alcohol consumption, 
having rheumatoid arthritis, previous osteoporotic bone fracture, family 
antecedents of osteoporosis, using corticosteroids and a lower BD 
revealed to be linked to a larger DALYs lost. The identification of risk 
factors can improve the clinical practice by guiding the concerns that 
should be considered in the osteoporosis prevention. 
141 
 
7. CONCLUSIONS  
 
Based on the work developed on this thesis, the following conclusions 
and goals were achieved: 
1. Data recorded in the framework of a prospective clinical trial fail to 
reflect the patients’ diversity and have a limited time horizon. To 
improve the accuracy, data collection should continue after the 
patient’s study treatment discontinuation. 
2. A cohort simulation avoid to experiment directly with patients, it is a 
cheaper and a faster method than prospective studies to gain 
knowledge about the available therapeutic strategies. A sensitivity 
analysis varying he input parameters and using probabilistic 
techniques should be performed to inform about the variability and the 
uncertainty of the results.  
3. Markov models were adapted to reflect the fact that the risk of 
suffering an event can change over time. The deterministic 
incremental analysis and the probabilistic sensitivity method were 
implemented in R software. 
4. A budget impact analysis requires being clear on the items considered 
as resources used under the study perspective applied and need to be 
filled with realistic and precise clinical practice procedures and 
resource prices. 
5. Epidemiological estimations of incidence, prevalence, and mortality 
rates due to a specific disease do not capture the burden of disease 
that cause in the population. The target of interest is the measure of 
the population health and well-being. The known indicators, such as 
DALYs and QALYs are based on utilities for a year of life in a health 
status. Usually, the utilities are derived from a patient’s health related 
quality of life survey and the desirable is to use specific population 
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and country data when available. Although choosing same parameters’ 
value is discussable and makes these measurements controversial. 
6. The adherence promoting program in HIV infected patients has a 
positive impact on the health outcome, even its implantation would 
depend on the willingness to pay per additional unit of health gained. 
7.  A Markov model with 2-phases was used to study the suitability of 
diagnostic test to guide the use of maraviroc. The analysis showed 
that the 454 test to assess the HIV coreceptor could be cost effective 
when compared to the Trofile test; the Population Sequencing test 
showed a smaller health benefit. However, it is cheaper than the other 
two tests. The choice will depend on the maximum that the health 
service is prepared to pay per additional unit of utility gained. 
8. A Markov model was built to assess the cost-effectiveness of two 
treatments to prevent osteoporosis fractures in postmenopausal 
women. The new treatment was shown to be equal in probability of 
cost-effectiveness than the SOC.  
9. The calculation of the burden of disease for osteoporotic women who 
may suffer from fractures done at an individual level was performed. 
Few studies of burden of disease are available and even less for 
Spanish population and/or performed using individual characteristics. 
10. The use of eculizumab for treating the PNH would imply an 
incremental yearly cost of €300,650 per patient compared to standard 
of care but would provide larger societal benefits. 
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8. FUTURE RESEARCH 
 
Based on the work developed on this thesis, the following research 
issues are suggested: 
1. The challenge remains in adapting the methods to reflect complex 
systems and implement them. Other models of simulation besides 
those described in this thesis are available. For instance, the dynamic 
population modelling could be a good approach to model highly 
infectious and/or communicable diseases impact in an entire 
population; including both the diseased and healthy citizens could be 
useful to do a cost-effectiveness analysis. Another approach to 
perform a simulation is the based on discrete-events. This method 
seems appropriate to model diseases were the change between health 
states can be assigned to discrete points in time, HIV disease 
evolution is susceptible to be modelled using these mechanism. 
2. We are working to estimate the differences in the results for a cost-
effectiveness evaluation analysis using a simulated cohort or using 
real data.  
3. The calculation of confidence intervals for the ICER can be complex, 
and the possibility that the numerator and/or denominator tend to 0 
complicate the calculations even further. Because of these challenges, 
a number of alternative methods for calculating confidence intervals 
have been proposed. These methods include the use of Fieller's 
theorem and non-parametric bootstrapping186, 187. We would like to 
explore the methods that can help to quantify the ICER variability and 
uncertainty and we plan to continue our research along this aspect. 
4. Other possible summaries for the performance of therapeutic 
strategies are the incremental net health benefit (INHB) and the 
incremental net monetary benefit (INMB) were the cost and health 
outcome are assessed in terms of health and money, respectively.  
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Both measures depend on the willingness to pay per unit of outcome 
gained. A future work would be to study these options. 
5. The consideration of directional statistics to deal with the limitations 
of the ICER. This technique uses unit vectors (possibly with unknown 
sign) as observations in the plane or in 3-dimensional space, being 
the sample space a circle or a sphere. The research on special 
directional methods for the analysis of unit vectors would be a next 
step. 
6. The simulation models implemented in this thesis were done using the 
cohort approach, which differs from the individual simulation for the 
fact that subgroups of patients travel together through the health 
states. In the individual simulation, every patient travels alone through 
the health states, this is computationally more costly, but it can reflect 
some variability that can be closer to reality. Even some studies 
already mentioned that differences between cohort and individual 
simulation are small; it is of our interest to go deep in the 
quantification of the advantages and disadvantages associated to the 
individual simulation. The next step would be to work on the 
implementation of models for individual simulation in R software. The 
acquired knowledge will help in the technique selection for future 
studies. 
7. We are eager to use the model with n-stages of simulation in other 
health areas, which has the good feature of allowing a simulating 
process using different transition probabilities matrix for the n stages 
defined in the disease evolution. 
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Annex I: Discrete-event simulation. Another technique for model building 
 
In the following, we introduce the discrete-event simulation approach 
that can be used in decision analysis to represent and simulate the 
natural history of the disease under study. 
 
Discrete-event simulation has been extensively used to address various 
industrial problems. Interest in the application of this technique is 
increasing, even though Markov models are the most popular approach in 
the evaluation of health care technology and products188. 
Modelling based on discrete-event simulation is characterized by the fact 
that the state variables only change at discrete points in time at which 
events occur, for example, in a transition between health states. Events 
occur as a consequence of activity times and delays. Entities, i.e., 
patients in our clinical framework, move through the states of the system 
and may join queues while waiting for the next state to occur. Activity 
and delay times may "hold" entities for periods of time. A discrete-event 
simulation model is conducted over time by a mechanism that moves 
simulated time forward. The system state is updated at each event along 
with capturing and occupancy of states that may occur at that time189. 
The figure I.1 shows the time flow in a discrete-event simulation for N 
patients that move through 3 possible heath states: Well, Sick, or Dead. It 
is noteworthy that the simulation skips inactivity periods. Each node 
represents an occurring event, and the system is refreshed when an 
event occurs, i.e., at times t+u, t+v, and t+w.  
 
148 
 
 
 
Figure  I.1. Representation of a simple discrete-event simulation process for N patients 
in three health states: Well, Sick, and Dead. Based on the work by Overeinder et al.190. 
 
Discrete-event simulation is not commonly used in clinical research, 
although it could prove to be a promising technique in cohort simulations. 
The main challenge with this approach lies in the specification of system 
attributes and constraints in the transition between states, i.e., 
specification of the different health states and the rules for assessing 
disease outcome. 
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Annex II: Health outcome measures 
 
The score of health or burden of disease can be produced considering 
two different approaches depending on the interest in measure the health 
of a community or in quantify the individual health. In the application 
developed here the individual health score is calculated using 
disaggregated person’s information, for this reason, a larger description 
is given for these techniques. 
 
The summary measures of population health combine information on 
mortality and non-fatal health outcomes to describe the health of a 
particular community as a single number191. The simplest and most 
widely used method for producing population health statistics is to 
aggregate data on individuals in order to generate summaries like the 
proportion of the population (or of a particular age–sex group) suffering 
from a particular health problem or in a particular health state. When the 
concern is to measure the individual health, non-aggregated information 
should be considered; this evaluation can be done using the direct health 
outcomes or combining some of them into new scores. 
 
In the context of individual health measures, the assessment can be 
performed in randomized clinical trials (RCTs), cohort of patients or in 
some health services administrative data sets. The outcome can be 
measured by using natural units of health (e.g. mortality, number of 
individuals with viremia under control, units of cholesterol reduced), 
effects can be expressed in monetary units or by means of people’s 
preferences on the trade-off between length of life and subjective levels 
of well-being associated with health states.  
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In order to construct scores that allow the comparison of: health 
conditions between various health problems, populations or time points, a 
common metric is the key to provide objective information for the 
economic evaluation of interventions and to set priorities for health 
resources192,193.  
 
Summary measures can be classified according to health expectancies or 
health gaps. Both types use time (lived in health states or lost through 
premature death) as an appropriate common metric for measuring the 
impact of mortality and non-fatal health outcomes. These two classes of 
measures are complementary (see Figure II.2). 
 
 
 
Figure  II.2. Survivor curves for a population and the time lived in optimal health and the 
areas defined by these curves that allow illustrating different summaries for measures 
of population health. Area under the curve A represents time lived in optimal health, 
area B time lived in suboptimal health, and area C represents time lost due to mortality. 
The total life expectancy (LE) at birth is given by the area under the bold 
curve (Area A plus Area B): 
LE = A + B 
      Survival of a population 
       Survival in optimal health 
% Surviving 
Age 
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Health expectancies (HE) are population indicators that account for the 
average time that a person could expect to live in a defined state of 
health. Examples include disability-free life expectancy (DFLE), active 
life expectancy and disability-adjusted life expectancy. These extend the 
concept of life expectancy to refer to expectations of different states of 
health. In terms of Figure II.2, health expectancy is given by: 
HE = A + f(B),  
where f( ) is some function that assigns weights to years lived in 
suboptimal health, usually, optimal health has a weight of 1 and the worst 
health state has weight 0. As summary measures of the burden of 
disability from all causes in a community, healthy life expectancy and 
health-adjusted life expectancy (HALE) has the advantage of being 
meaningful by themselves and being understandable concepts to a non-
technical audience. 
Assesment of potential years of life lost due to premature mortality are 
used to measure the mortality burden of different causes of death. These 
all measure the gap in years between age at death and some arbitrary 
standard, i.e., the difference between actual population health and some 
specified norm or goal. 
Health gap = C + g(B) 
where g( ) is some function that assigns weights to health states lived 
during period B, assigning weight 1 to time lived in a health state 
equivalent to death. 
Following the pioneering work of Dempsey (1947)194, several measures 
of years of life lost due to premature mortality have been proposed (Area 
labeled C in Figure II.2). Health gaps extend the notion of mortality gaps 
to include time lived in states of suboptimal health (Area labeled B in 
Figure II.2). 
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The central feature defining a health gap measure is the population norm 
(age) chosen to define the period before which death or disability is 
considered premature. For some types of health gap measures, the 
implied target age may vary as the mortality level change, which is a 
highly undesirable property for comparisons. 
Methods for defining health states and for obtaining health state 
evaluations affect the calculation and interpretation of health gaps and 
health expectancies. The incorporation of social values and their weight 
in the calculation also affect the result, and it can be controversial. 
 
The best known utility measure is the quality-adjusted life year (QALY), 
which, in turn, is tightly linked to the term “utility”195. The utility score 
ranges from 0 to 1, being the larger values related to a higher degree of 
functionality and independence. The utility values can be converted into 
QALYs by multiplying the years spent in a particular health state by the 
utility of the concrete health state. The DALY measurement for a health 
outcome appeared in the 1990s, in the Quality Adjusted Life Years 
(QALY) framework196. The DALY is primarily a measure of disease 
burden (disability weights measure loss of functioning) and its used in 
economic evaluations is relatively general. The DALY incorporates an 
age-weighting function assigning different weights to life years lived at 
different ages, and the origins of disability and health related quality of 
life weights differ significatively197. 
 
The previously defined health measures can be computed for a 
population or for individual data, with the corresponding adjustments. 
 
The fundamental goals in constructing summary measures are to 
describe the relative magnitude of many health problems and to identify 
risk factors for losing life and/or health expectancy. 
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Annex III: Ethical considerations in the use of the pharmacoeconomic 
studies 
 
The methodological development and its correct application should be 
our goal. Although good tools for pharmacoeconomics evaluations are 
available other problems can limit the application of the results obtained 
in the cost-effectiveness studies to the daily clinical practice198:  
 Sometimes the results are under suspicion because the study can 
be funded by pharmaceutical companies and it can be used as a 
marketing tool. 
 Doctors may tend to think that is not ethical to base clinical 
decisions in cost-effectiveness results. If the reasoning is done 
thinking in the waste of resources when a most cost-effective 
option is not prescribed, this can reduce the ability to give care to 
a larger number of patients, which can be labelled as unethical. 
 Sometimes the cost-effective option requires a present large 
investment to obtain long term savings, and this spending is not 
affordable. For instance, the purchase of a screening machine to 
detect a disease in early stages, it is a big investment that will 
save money and increase the long term population’s health. 
 The budgets are decided in isolation, and it is not easy to move 
money from one to another. For instance, the prescription of a 
drug that can avoid a considerable number of hospital admissions. 
Usually pharmacy and hospital services have a different budget 
and one is not going to promote an expenditure that does not 
revert in their own efficacy numbers. 
Despite these problems, economic evaluations of therapeutic strategies 
are increasingly important in decision making for health care resources 
allocation to promote efficiency and effectiveness of choices. 
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Annex IV:  Input parameters for ProAdh study in HIV infected patients 
 
Costs 
The direct costs linked to the treatment options were measured as the 
total cost of drug treatment, blood analysis and human resources for 
health. The total cost of combined antiretroviral therapy (cART), the 
blood tests and the human resources were obtained from the medical 
supplies of the hospital where the study was performed; the concomitant 
treatment was priced using the PVL reported in the web site. The costs, 
in Euros 2010, are reported in Table IV.1. The trial neither intervened in 
the cART prescribed nor in the concomitant treatment, i.e., the listed 
drug treatments were the ones decided by the medical doctors for the 
care of each patient who participated in the trial.  
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Table IV.1. Cost per item (Euros 2010) 
Item Units Cost(EUR)2010 
Antiretroviral treatment  
NORVIR/100-24,PREZISTA400/800-24 Patient/day 15.58
VIRAMUNE/200-12,KIVEXA/1-24 Patient/day 19.13
TRUVADA/1-24,VIRAMUNE/200-12 Patient/day 21.42
KIVEXA/1-24,SUSTIVA 600/600-24 Patient/day 21.52
ATRIPLA/1-24 Patient/day 23.62
SUSTIVA 600/600-24,TRUVADA/1-24 Patient/day 23.81
VIRAMUNE/400-24,KIVEXA/1-24 Patient/day 25.93
NORVIR/100-24,TRUVADA/1-24,PREZISTA600/600-
24 Patient/day 26.51
NORVIR/100-24,KIVEXA/1-24,PREZISTA400/800-24 Patient/day 27.91
TRUVADA/1-24,VIRAMUNE/400-24 Patient/day 28.22
NORVIR/100-24, TRUVADA/1-24, 
PREZISTA400/800-24 Patient/day 30.20
ETRAVIRINA/1-24,TRUVADA/1-24 Patient/day 30.22
KIVEXA/1-24,ISENTRESS/99-12 Patient/day 36.25
TRUVADA/1-24,ISENTRESS/99-12 Patient/day 38.54
TRUVADA/1-24,ISENTRESS/400-12 Patient/day 38.54
PREZISTA400/800-24,NORVIR/100-24,TRUVADA/1-
24,ISENTRESS/400-12 Patient/day 54.12
CELSENTRI 300 MG COMP/300-12,TRUVADA/1-
24,ISENTRESS/400-12 Patient/day 66.28
   
Concomitant treatment  
Enalaprim and pravastatin Patient/day 0.14
Captopril and hidrosaluteril 25mg/day 0.19
Atorvastatin 20mg/day 0.33
Insulin (supposed the need of 1 vial per month) Patient/day 0.33
Metformin Patient/day 0.70
Risperdal Patient/day 3.16
  
Human resources  
Nurse visit 1 50
Visit to specialist physician, dietician or psychologist 1 100
Psychoeducational intervention visit 1 150
  
Blood tests  
Baseline analyses 1 421.22
Monitoring analyses 1 131.14
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Health outcome assessment 
The clinical performance was evaluated using two outcomes: the 
percentage of individuals in each group that achieved undetectable RNA 
HIV viral load and the increment of 100 CD4 cells/mm3 at the end of 1 
year of follow-up. 
The health related quality of life was measured using the Medical 
Outcomes Study (MOS), which is a brief questionnaire to assess the 
health status. The MOS-HIV (MOS validated for HIV infected patients) 
questionnaire is one of the most widely used to evaluate the health 
related quality of life in HIV clinical trials199. 
The health related quality of life areas assessed were the physical 
health, mental and psychological health, relationships and social 
activities, and finally the global health. These aspects were scored by 
the patient giving punctuation in a scale from 1 to 6, being 6 the 
maximum well-being and 1 the worse. The measurements of health 
outcome for these areas were the change in the score reported in 
baseline respect to the score reported at the end of follow-up. 
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Annex V: Data analysis code for ProAdh study in HIV infected patients 
 
* SPSS syntax for the data management and statistical analysis*. 
*** Sample description*. 
COMPUTE edat= DATEDIFF(Fechadeentrevista,FechadeNacimiento,"year") . 
EXECUTE. 
 
FREQUENCIES 
  VARIABLES= ViadeInfección 
  /ORDER=  ANALYSIS. 
 
FREQUENCIES 
  VARIABLES=num_tarvs_durante_studio edat 
 /FORMAT=NOTABLE 
  /PERCENTILES= 25 75 
  /STATISTICS=STDDEV MINIMUM MAXIMUM MEAN MEDIAN 
  /ORDER=  ANALYSIS. 
 
***Description by group*. 
SORT CASES BY Grupo. 
SPLIT FILE 
  SEPARATED BY Grupo. 
 
FREQUENCIES 
  VARIABLES= ViadeInfección 
  /ORDER=  ANALYSIS. 
 
FREQUENCIES 
  VARIABLES=num_tarvs_durante_studio edat 
 /FORMAT=NOTABLE 
  /PERCENTILES= 25 75 
  /STATISTICS=STDDEV MINIMUM MAXIMUM MEAN MEDIAN 
  /ORDER=  ANALYSIS. 
 
SPLIT FILE 
  OFF. 
 
*** Cost calculation*. 
*The expenditure on human resources and blood tests per visit and patient were recorded. 
File: “fecha entrevista+visitas seleccionadas.sav”*. 
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COMPUTE Temps_entrevista_visita_mesos= 
DATEDIFF(DataProgramada,Fechadeentrevista,"month") . 
EXECUTE. 
 
AGGREGATE 
  /OUTFILE='E:\IOMEGA\Copia de seguridad_8-7-09\FLS_8-7'+ 
 '-09\ProADH\ProADH_abril2012\suma coste visitas y analiticas'+ 
 ' seleccionadas.sav' 
  /BREAK=NHC 
  /Nom_first = FIRST(Nom) /Cognom1_first = FIRST(Cognom1) /Cognom2_first = 
  FIRST(Cognom2) /Grupo_mean = MEAN(Grupo) /CodigoPaciente_first = 
  FIRST(CodigoPaciente) /cost_analiticas_sum = SUM(cost_analiticas) 
 /coste_visita_prof_sum = SUM(coste_visita_prof) /coste_visita_infer_sum = 
  SUM(coste_visita_infer) /coste_psico_visita_estudio_sum = 
  SUM(coste_psico_visita_estudio) /Temps_entrevista_visita_mesos_max = 
  MAX(Temps_entrevista_visita_mesos). 
 
*File: suma coste visitas y analíticas seleccionadas.sav*. 
*Add the variable "coste_analiticas_corregido". The minimum expenditure due to blood test 
screening during the study is supposed to be €945.78 for the patients that have 12 months of 
follow-up. The baseline blood test costs was estimated at €421.22 and at €131.14 the blood 
tests performed at 3, 6, 9 and 12 months*. 
 
*In the data set used, the cART treatment cost was done taking into consideration the cost for 
every drug and the period of time of consumption. For each patient the cART and his/her date 
of starting and date of ending were recorded. 
The time under study that each patient takes a specific treatment combination should be 
calculated*. 
*Data file:demo+seguimiento+tarv15dec2012.sav*. 
COMPUTE Temps_tarv1_dias= DATEDIFF(periodo_vigencia_arv1,DataInicial,"day"). 
EXECUTE. 
COMPUTE Temps_tarv2_dias= DATEDIFF(periodo_vigencia_arv2,DataInicial_arv2,"day"). 
EXECUTE. 
COMPUTE Temps_tarv3_dias= DATEDIFF(periodo_vigencia_arv3,DataInicial_arv3,"day"). 
EXECUTE. 
COMPUTE Temps_tarv4_dias= DATEDIFF(periodo_vigencia_arv4,DataInicial_arv4,"day"). 
EXECUTE. 
COMPUTE Temps_tarv5_dias= DATEDIFF(periodo_vigencia_arv5,DataInicial_arv5,"day"). 
EXECUTE. 
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*To be able to perform the following calculations, missing values were substituted by 0 *. 
COMPUTE Temps_total= 
Temps_tarv1_dias+Temps_tarv2_dias+Temps_tarv3_dias+Temps_tarv4_dias+Temps_tarv5_di
as. 
EXECUTE. 
 
*cART cost by patient during the study period of time**. 
*To be able to perform the following calculations, missing values in the variable 
“precio_tarv_dia” were substituted by 0 *. 
 
COMPUTE cost_TARV_temps_estudi=Temps_tarv1_dias*precio_tarv_dia+ 
Temps_tarv2_dias*precio_tarv_dia_arv2+Temps_tarv3_dias*precio_tarv_dia_arv3+Temps_tarv
4_dias*precio_tarv_dia_arv4+Temps_tarv5_dias*precio_tarv_dia_arv5. 
EXECUTE. 
 
*Concomitant treatment cost calculation*. 
COMPUTE cost_TConcom_temps_estudi=Temps_total*cost_dia_tto_concomitant.  
EXECUTE. 
*****. 
 
*Add the cost for human resources use*. 
COMPUTE 
cost_recursoshumanos_temps_estudi=coste_visita_prof_sum+coste_visita_infer_sum+coste_p
sico_visita_estudio_sum.  
EXECUTE. 
 
COMPUTE 
cost_total_temps_estudi=cost_TARV_temps_estudi+cost_TConcom_temps_estudi+coste_anali
ticas_corregido+cost_recursoshumanos_temps_estudi.  
EXECUTE. 
 
COMPUTE cost_total_per_mes=cost_total_temps_estudi/12.  
EXECUTE. 
 
*** Cost description*. 
SORT CASES BY Grupo. 
SPLIT FILE 
  SEPARATED BY Grupo. 
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FREQUENCIES 
  VARIABLES=cost_TARV_temps_estudi cost_TConcom_temps_estudi 
  coste_analiticas_corregido cost_recursoshumanos_temps_estudi cost_total_per_mes 
 /FORMAT=NOTABLE 
  /PERCENTILES= 25 75 
  /STATISTICS=STDDEV MINIMUM MAXIMUM MEAN MEDIAN 
  /ORDER=  ANALYSIS. 
 
SPLIT FILE 
  OFF. 
 
*** Health outcomes calculation*. 
RECODE 
  DiffCD4_w0_48 
  (SYSMIS=SYSMIS)  (Lowest thru 99.99=0)  (99.9999 thru Highest=1)  INTO  
DiffCD4_w0_48_cat . 
EXECUTE. 
VALUE LABEL   DiffCD4_w0_48_cat  0'Aument inferior a 100 cels' 1'Aument superior o igual a 
100 cels'. EXECUTE. 
COMPUTE MOSHIVP1_w0_48= MOSHIVP1_48-MOSHIVP1_0. 
EXECUTE. 
 
COMPUTE MOSHIVP2_w0_48= MOSHIVP2_48-MOSHIVP2_0. 
EXECUTE. 
COMPUTE MOSHIVP3_w0_48= MOSHIVP3_48-MOSHIVP3_0. 
EXECUTE. 
COMPUTE MOSHIVP4_w0_48= MOSHIVP4_48-MOSHIVP4_0. 
EXECUTE. 
 
RECODE 
  MOSHIVP1_w0_48 
  (SYSMIS=SYSMIS)  (Lowest thru -0.01=0)  (0 thru Highest=1)  INTO  MOSHIVP1_w0_48_cat. 
EXECUTE. 
VALUE LABEL   MOSHIVP1_w0_48_cat  0'No mejora' 1' Igual o mejora'. EXECUTE. 
 
RECODE 
  MOSHIVP2_w0_48 
  (SYSMIS=SYSMIS)  (Lowest thru -0.01=0)  (0 thru Highest=1)  INTO  MOSHIVP2_w0_48_cat. 
EXECUTE. 
VALUE LABEL   MOSHIVP2_w0_48_cat  0'No mejora' 1' Igual o mejora'. EXECUTE. 
163 
 
 
RECODE 
  MOSHIVP3_w0_48 
  (SYSMIS=SYSMIS)  (Lowest thru -0.01=0)  (0 thru Highest=1)  INTO  MOSHIVP3_w0_48_cat. 
EXECUTE. 
VALUE LABEL   MOSHIVP3_w0_48_cat  0'No mejora' 1' Igual o mejora'. EXECUTE. 
 
RECODE 
  MOSHIVP4_w0_48 
  (SYSMIS=SYSMIS)  (Lowest thru -0.01=0)  (0 thru Highest=1)  INTO  MOSHIVP4_w0_48_cat. 
EXECUTE. 
VALUE LABEL   MOSHIVP4_w0_48_cat  0'No mejora' 1' Igual o mejora'. EXECUTE. 
 
*** Health outcomes description*. 
SORT CASES BY Grupo. 
SPLIT FILE 
  SEPARATED BY Grupo. 
 
FREQUENCIES 
  VARIABLES= CV_indect_w48_50indetect 
  /ORDER=  ANALYSIS. 
 
FREQUENCIES 
  VARIABLES= DiffCD4_w0_48_cat  
  /ORDER=  ANALYSIS. 
 
FREQUENCIES 
  VARIABLES=MOSHIVP1_w0_48_cat 
MOSHIVP2_w0_48_cat 
MOSHIVP3_w0_48_cat 
MOSHIVP4_w0_48_cat   
  /ORDER=  ANALYSIS. 
 
SPLIT FILE 
  OFF. 
 
*** Health outcomes comparison by group*. 
CROSSTABS 
  /TABLES= CV_indect_w48_50indetect  
DiffCD4_w0_48_cat  
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MOSHIVP1_w0_48_cat 
MOSHIVP2_w0_48_cat 
MOSHIVP3_w0_48_cat 
MOSHIVP4_w0_48_cat  BY Grupo 
  /FORMAT= AVALUE TABLES 
  /STATISTIC=CHISQ 
  /CELLS= COUNT ROW COLUMN 
  /COUNT ROUND CELL. 
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Annex VI:  Numerical example for a cohort simulation using a Markov 
model  
 
Parameters that fulfill the transition probability matrix, A: 
pww 0.7 
pws 0.29 
pwd 0.01 
psw 0.5 
pss 0.4 
psd 0.1 
pdw 0 
pds 0 
pdd 1 
 
Utility contribution of each health state per cycle 
uw 1 
us 0.5 
ud 0 
 
Cost contribution of each health state per cycle  
cw 20 
cs 200 
cd 0  
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Table VI.1. Two-cycle Markov trace for a 3-state Markov model with health states: 
Well, Sick and Dead. P0=(1,0,0). Column 1 show the cycle number (k), columns 2 to 4 
show the proportion of the cohort in each of the 3 health states at each cycle k (Pk), the 
last 4 columns show utility (and cost) contribution in each cycle and cumulative utilities 
in the simulation time 
 
Cycle 
(k, 
in years) 
Well Sick Dead Cycle utility Cumulative 
utility 
Cycle 
cost 
Cumulative 
cost 
0 1 0 0 0.5 0.5 10 10 
1 0.7 0.29 0.01 0.845 1.345 72 82 
2 0.635 0.319 0.046 0.7945 2.1395 76.5 158.5 
#At cycle 0, the utility and the cost were multiplied by 0.5 to take into account that 
some individuals transit in the middle of the cycle, which is known as the half-cycle 
correction. 
¤ To obtain discounted expected utility (or cost) values the cycle utility (or cost) would 
be divided by its discount factor (1+r)k. Not applied to the table calculations, i.e., 
undiscounted values for utility and cost are shown. 
 
When k is displayed in years, it can be said that, on average, the cohort 
contributes 0.845 quality-adjusted during the first cycle. Note that at 
cycle 0 the maximum utility value is 0.5 because the half-cycle 
correction is used. 
If the simulation were run until all cohort fall in the dead health state the 
cumulative “utility” in the last cycle would represent the quality-adjusted 
life expectancy of the cohort. Similarly, the cumulative costs n the last 
cycle represent the average lifetime costs of the cohort. 
Summing the health state probabilities for a particular state for all cycles 
results in the average length of time that the cohort spent in that health 
state. 
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Annex VII:  Input parameters for the bazedoxifene versus raloxifene´s 
model 
 
Treatment, incidence and risk fracture, and mortality 
Treatments efficacy  
The Osteoporosis Study109 was a 3-year, randomized, double-blind, 
placebo- and active-controlled trial, including 7,492 healthy 
postmenopausal osteoporotic women aged between 55 to 85 years. All 
women were at least 2 years postmenopausal and had osteoporosis. 
Women were assigned to treatment randomly, stratifying by prevalent 
vertebral fracture status to ensure similar distribution of subjects with 
and without prevalent vertebral fracture across treatment groups. The 
treatment groups where 20 mg bazedoxifene daily (N=1,886), 40 mg 
bazedoxifene daily (N=1,872), 60 mg raloxifene daily (N=1,849), or 
placebo (N=1,885) for 36 months. From the total number of eligible 
patients the percentage of patients that completed the study was 66% of 
patients receiving bazedoxifene 20 mg or 40 mg daily, 68% of patients 
receiving bazedoxifene 60 mg daily and 67% of patients receiving 
placebo. The clinical trial included participants among whom 
approximately 56% in each treatment group had at least one vertebral 
fracture at baseline, and the majority of these had one mild vertebral 
fracture. In this study patients were compared who either received 20 
mg bazedoxifene daily or 60 mg raloxifene daily. 
For osteoporosis patients without fractures, a relative risk (RR) reduction 
for vertebral fractures of 35% (95% confidence interval [CI], 0.32-1.30) 
was seen in patients treated with bazedoxifene versus 41% (95% CI, 
0.29-1.21) for patients treated with raloxifene (Table VII.1). RR 
reductions were 45% (95% CI, 0.32-0.94) for bazedoxifene versus 43% 
(95% CI, 0.34-0.97) for raloxifene in patients with prior vertebral 
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fractures (Table VII.2). No differences in the incidence of non-vertebral 
fractures were observed between both treatments in women without 
prior fractures, although the reduced RR in patients with previous 
fractures was 46% with bazedoxifene and 8% with raloxifene. 
 
Incidence and fracture risk 
Country and age-specific normal populations’ incidences were used when 
possible. A vertebral fracture can be classified as a clinical fracture (i.e., 
symptomatic fractures that come to clinical attention) or as 
morphometric, which includes all fractures both symptomatic and 
asymptomatic. For this study, the morphometric definition of a fracture 
was used as it provided more specific incidence data with an age 
standardized incidence ratio of 10.2 (95% CI 4.7-15.7) per 1,000 
inhabitants for the Southern European female population because clinical 
fracture data were lacking108.  
Incidence rates of non-vertebral fractures (ratio 24.2 non-vertebral 
fractures per 1,000 female inhabitants) were obtained from Marín et al 
(2006)200 and consisted mostly of wrist fractures (36.7%) and hip 
fractures (14.9%). Population fracture incidence rates were adjusted to 
reflect the risk in both treatment groups.  
The probability of having a first fracture, a second fracture, or remaining 
healthy is determined by the RR of vertebral or non-vertebral fractures 
affected by treatment with bazedoxifene or raloxifene based on the 
Osteoporosis Study109 (Tables VII.1 and VII.2).  
 
Mortality 
Age-specific normal population mortality rates were obtained from the 
Spanish national statistics agency110. These were adjusted in the model 
to take into account mortality associated with fractures105, 201-204. In this 
analysis, we derived estimates of the excess mortality after vertebral 
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fractures from a study based on Spanish patients who showed an 
increase in mortality between 20% and 34% in 5 years after its 
fracture205. The RR in the year after a vertebral fracture was estimated 
at 5.4 and was similar in subsequent years. The RR of mortality in the 
year after a non-vertebral fracture was 20206. RRs of excess mortality in 
subsequent years after a non-vertebral fracture were estimated at 30 
due mostly to hip fractures, though there are studies which claim there is 
little or no relation between co-morbid conditions and post-fracture 
mortality102. Based on this study, a RR of 10 was assumed for patients 
that sustained a non-vertebral fracture in subsequent years, as these not 
only involved hip fractures but also wrist fractures. 
 
Table VII.1. Transition Probabilities for Bazedoxifene 20 mg/day 
 
Well Vertebral 
fracture 
Non-
vertebral 
fracture 
Healthy 
vertebral 
fracture 
Healthy non-
vertebral 
fracture 
Dead 
Well 0.94479a 0.00901b,c 0.024 b,d 0 0 0.022 e  
Vertebral 
fracture 0 0 0 0.9768120a 0 0.023188 e 
Non-vertebral 
fracture 0 0 0.1384667 b,f 0 0.8351333a 0.0264 g  
Healthy 
vertebral 
fracture 0 
0.0275706 
b,h   0.1986292 b,i  0.7506122a 0 0.023188 j 
Healthy non-
vertebral 
fracture 0 
0.0103615 
b  0.0528313 h  0 0.9126072a 0.0242 k  
Dead 0 0 0 0 0 1 
aResidual probability; b Silverman et al.109; c Felsenberg et al.108; d Marin et al.200; e 
MSPI110; f Christodoulou et al. 207; g SNAMFAP206; h SEIOMM93; i Naves et al.208; j 
AIAQS205; k Borgstrom et al.105. All probabilities without notes are based on assumption. 
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Table VII.2. Transition Probabilities for Raloxifene 60 mg/day 
 
Well Vertebral 
fracture 
Non-
vertebral 
fracture 
Healthy 
vertebral 
fracture 
Healthy non-
vertebral 
fracture 
Dead 
Well 0.944994a 0.008806 b,c ,23] 0.024 b,d 0 0 0.022 e 
Vertebral 
fracture 
0 0 0 0.9768120
a 
0 0.023188 e 
Non-vertebral 
fracture 
0 0 0.1897467 b,f 0 0.7838533a 0.0264 g 
Healthy 
vertebral 
fracture 
0 0.0271577 b,h   0.2287228 b,i  0.7209315
a 
0 0.023188 j 
Healthy non-
vertebral 
fracture 
0 0.0100682b  0.0608356 h  0 0.90489624a 0.0242 k  
Dead 0 0 0 0 0 1 
aResidual probability; b Silverman et al.109; c Felsenberg et al.108; d Marin et al.200; e MSPI 
110; f Christodoulou  et al.207; g SNAMFAP206; h SEIOMM 93; i Naves et al208; j AIAQS 205; k 
Borgstrom et al.105 . All probabilities without notes are based on assumption. 
 
Cost and effectiveness input data 
Costs for osteoporosis treatment consisted of drug costs, diagnostic and 
follow-up tests, as well as physician visits. Costs were represented in 
2010 Euros (EUR) and discounted according to health economic 
guidelines, resulting in a 3% discount for costs and benefits209. Drug 
prices were derived from a Spanish drug-cost database210. Drug costs 
for bazedoxifene were assumed to be similar as for raloxifene. The 
monitoring of osteoporosis treatment was estimated to include one 
yearly physician visit and one year BMD measurement based on other 
studies and expert opinion211, 212. 
 
Event-related fracture resource utilization was obtained by expert 
consultation. Vertebral fractures were assumed to be associated with 
two days of hospitalization. Outpatient treatment comprised of two 
imaging procedures, three specialist visits, and concomitant medication 
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as analgesics during 90 days. Vertebral fracture costs resulted in 
approximately €3,878 per event. 
 
Non-vertebral fracture costs were assumed to consist of 50% hip 
fractures and 50% wrist fractures. Hip fractures were associated with 15 
hospitalization days and similar outpatient treatment to vertebral 
fractures, including additional rehabilitation costs during a 40-day period.  
Wrist fractures included four hospitalization days, surgery costs and 
outpatient treatment similar to that for hip fractures, with one less image 
procedure. Non-vertebral fracture costs were estimated at €7,478 per 
event (Table VII.3). 
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Table VII.3. Osteoporosis Treatment and Fractures: Resource Utilization in Units and 
Costs 
 Units Cost (EUR) 2010 
Osteoporosis treatment   
Drug costs  287a  
Conventional blood test 1 21b  
Bone density scan (DXA) 1 165c  
Visit to rheumatologist 1.5 69d  
Annual treatment costs  576  
Vertebral fracture   
Hospitalization vertebral fracture 
(average 2 days)   3,513.90e  
Radiography 1 32.80f  
Bone scan 1 232.34g  
Visit to orthopedist  2 44.10d  
Analgesics (2 tablets/day, 90 days)  0.06a  
Annual treatment costs   3,878  
Non-vertebral fracture   
Hip fracture   
Hospitalization hip fracture (average of 
15 days)   7,956.70e  
Visits to orthopaedist 3 44.10d  
Radiography 2 32.80f  
Rehabilitation (40 days)  52.87b  
Analgesics (2 tablets/day, during 90 
days)  0.06a  
Wrist fracture   
Surgery  1 96.97h  
Hospitalization wrist fracture (average 
of 4 days) 4 555.71d  
Visits to orthopedist  3 44.10d  
Radiography 3 32.8f0  
Rehabilitation (40 days)  52.87b  
Analgesics (2 tablets/day, during 90 
days)  0.06a  
Annual treatment costs (50% hip and 50% 
wrist)   7,478  
aVademecum210; bHospital Lluís Alcanyis213; cHospital de la Esperanza214; dINSALUD215 
;eFinnern et al.216; fCernuda217; gDOGC218 ; hDOGC220.  
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Adverse Events incidence 
Bazedoxifene and raloxifene have a number of associated adverse events 
(AEs), including leg cramps, venous thrombolytic events (VTEs) such as 
deep vein thrombosis (DVT), and breast cysts/fibrocystic breast 
disease109, 219. To account for these AEs costs and utilities for each 
health state were corrected based on their incidences (Table VII.4).  
 
Table VII.4. Adverse Events and Incidence Rates (%) per 1,000 Postmenopausal Women 
With Osteoporosis  
Adverse events  Incidence rates in % Bazedoxifene Raloxifene 
Leg crampsa 10.9 11.7 
Deep vein thrombosisb 0.4 0.4 
Breast cysts/fibrocystic breast diseasea 0.7 1.7 
aP-value for the comparison between treatments was <0.01. 
bP-value for the comparison between treatments was <0.05. 
 
Resource utilization associated with the treatment of AEs such as leg 
cramps, deep vein thrombosis, and breast cysts or fibrocystic breast 
disease, was added to all health states based on the treatment-related 
incidence and expert validation (Table VII.5). Treatment of leg cramps 
and breast cysts or fibrocystic breast disease required one diagnostic 
test and one specialist physician visit per year. Deep vein thrombosis 
treatment included several diagnostic tests, a specialist physician visit, 
and the use of concomitant medication.  
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Table VII.5. Adverse Events: Resource Utilization in Units and Costs 
Adverse events  Units Cost (EUR) 2010 
Leg cramps   
Basic analyses: blood, biochemistry, 
ions 1 39a [59] 
Visit to specialist physician 1 46b [60] 
Annual treatment costs  85  
Deep vein thrombosis   
Basic analyses: blood, biochemistry, 
ions 1 39a [59] 
Doppler echocardiogram 1 70b [60] 
Plethysmography of legs 1 111b [60] 
Venography 1 79b [60] 
Visit to specialist physician 1 46b [60] 
Sodic Heparin (injections 5,000 
UI/mL, during 5 days)  1.83c [37] 
Warfarin (5 mg/day, 40 days )  2.30c [37] 
Annual treatment costs  349  
Breast cysts/fibrocystic breast 
disease 
  
Mammography 1 128b [60] 
Visit to specialist physician 1 46b [60] 
Annual treatment costs  174  
a DOGC (2009)220; b BOR (2009)221; c Vademecum (2011)210 
 
The total of healthcare costs for osteoporosis treatment and fractures 
per postmenopausal woman were very similar for both treatment groups 
and once corrected for the incidence of AEs, resulted in 1€ higher cost 
for raloxifene than for bazedoxifene (Table VII.6). Bazedoxifene was 
being evaluated to be introduced in the Spanish market, and its price was 
assumed the same as raloxifene, the difference in the adverse events 
incidence rate produced the cost difference between treatments. 
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Table VII.6. Annual Cost per Health State; general prices and adding cost for AES by 
treatment group 
Health state Cost (EUR) 2010 
Corrected costs for AEs 
Bazedoxifene Raloxifene 
Well 576 € 580 € 581 € 
Vertebral fracture  3,878 € 4,458 € 4,459 € 
Non-vertebral fracture  7,478 € 8,058 € 8,059 € 
Healthy post vertebral fracture  576 € 580 € 581 € 
Healthy post non-vertebral fracture 576 € 580 € 581€ 
EUR, Euros; AE, adverse event. 
 
Health related quality of life 
Utility weights were derived from a global longitudinal study among 
57,141 postmenopausal osteoporotic women aged 55 years and older that 
examined HRQoL in women who sustained fractures and the effect of 
fracture location on their HRQoL222. Utility values were evaluated using 
the EQ-5D and SF-36 subscales mapped to a country-specific 
preference based value. The reduction in HRQoL after a vertebral 
fracture was 38% lower than that observed in a healthy individual, and 
for non-vertebral fracture was 39% (based on reductions for hip and 
wrist fractures). The reduction in HRQoL in subsequent years after a 
vertebral fracture was 9% lower compared with that of a healthy 
individual and a reduction of 6% for hip and wrist fractures after a non-
vertebral fracture. 
 
VTEs, primarily DVT, were assumed to be associated with a 10% utility 
loss per year based on assumptions in previous publications 223, 224. No 
appropriate estimate was found for utility loss due to leg cramps and 
breast cyst or fibrocystic breast disease and a 10% HRQoL loss was 
assumed for them as it was documented for DVT. Based on the incidence 
rate of AEs for both treatments, utilities were corrected for HRQoL loss 
associated with AEs (Table VII.7). 
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Table VII.7. Utilities for postmenopausal population and utilities corrected by the AEs 
presence by treatment 
Health condition Utilitya  Corrected utility for AEs Bazedoxifeneb  Raloxifeneb  
Well 1 0.996 0.9954 
Vertebral fracture  0.620 0.61752 0.617148 
Non-vertebral fracture  0.651 0.647898 0.6475077 
Healthy post vertebral fracture  0.910 0.90636 0.905814 
Healthy post non-vertebral fracture 0.940 0.9358416 0.93527784 
HRQoL loss due to each AE of 
10%c,d * -0.1
 - - 
HRQoL, health related quality of life; AE, adverse event. 
*Includes assumption ;a Adachi et al.222; b Silverman et al.109;c Sobocki et al.223 ;d 
Zethraeus et al.224. 
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Annex VIII: Analysis worksheets for the bazedoxifene versus raloxifene 
model 
 
The simulation model to assess the cost-effectiveness of the two 
assessed treatments was implemented in Microsoft® Excel. 
The model input and output parameters are organized into 12 (the 
placebo scenario is not shown) Excel sheets: Frontpage, Results, Model 
and Probabilities, Bazedoxifene, Raloxifene, Costs and Utilities, Drug 
costs, Parameters, Simulation, CEA Curve, CEP, and CEAC. 
 
VIII.1 Frontpage 
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VIII.2 Results 
 
 
 
VIII.3 Model and Probabilities 
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VIII.4 Bazedoxifene cohort 
 
 
 
VIII.5 Raloxifene cohort 
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VIII.6 Costs and Utilities 
 
 
 
 
VIII.7 Drug costs 
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VIII.8 Parameters 
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VIII.9 Simulation 
Calculations replicated up to 1000 trials. 
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VIII.10 CEA Curve 
 
 
VIII.11 CEP 
 
 
VIII.12 CEAC 
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VIII.13 Macros for Microsoft Project using Visual Basic for Applications 
(VBA) 
' 
'The most of the calculations were implemented using formulae in the calculus sheets. The plots 
'were done using the chart menu. 
' 
 
Sub Analisis() 
' 
' Analisis Macro 
' Macro recorded 02/12/2010 
' 
' 
Application.ScreenUpdating = False 
 
Simulacion 
CEAcurva 
 
Sheets("Results").Select 
Range("A1").Select 
 
End Sub 
 
*****************. 
 
Sub CEAcurva() 
' 
' CEAcurva Macro 
' Macro recorded 01/12/2010 
' 
 
' 
Application.DisplayStatusBar = True 
Sheets("Simulation").Select 
Index = 0 
Trials = 58 
 
Do 
     
    Range("CW6").Select 
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    ActiveCell.Offset(Index, 0).Range("A1").Select 
    Selection.Copy 
    Range("CR1").Select 
    ActiveSheet.Paste 
    Range("CT4:CU4").Select 
    Application.CutCopyMode = False 
    Selection.Copy 
    Range("CX6").Select 
    ActiveCell.Offset(Index, 0).Range("A1").Select 
    Selection.PasteSpecial Paste:=xlValues, Operation:=xlNone, SkipBlanks:= _ 
        False, Transpose:=False 
        Index = Index + 1 
    Application.StatusBar = "Calculation " & Index & " of " & Trials 
         
Loop While Index < Trials 
 
Application.DisplayStatusBar = False 
Sheets("Simulation").Select 
Range("CM1").Select 
        
End Sub 
***********************************. 
 
 
Sub Simulacion() 
' 
' Simulacion Macro 
' 
' 
 
' 
 
Sheets("Main").Select 
Range("E19").Select 
ActiveCell.FormulaR1C1 = "1" 
Application.DisplayStatusBar = True 
Sheets("Simulation").Select 
Index = 0 
Trials = 1000 
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Do 
     
    Range("C4:CO4").Select 
    Selection.Copy 
    Range("C6:CO6").Select 
    ActiveCell.Offset(Index, 0).Range("A1").Select 
    Selection.PasteSpecial Paste:=xlValues, Operation:=xlNone, SkipBlanks:= _ 
            False, Transpose:=False 
    Index = Index + 1 
    Application.StatusBar = "Simulation " & Index & " of 1000 trials" 
         
Loop While Index < Trials 
 
Application.DisplayStatusBar = False 
Sheets("Main").Select 
Range("E19").Select 
ActiveCell.FormulaR1C1 = "0" 
Sheets("Simulation").Select 
Range("A1").Select 
 
End Sub 
 
*****************************.
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Annex IX: Cohort simulation and cost-effectiveness analysis code with R 
 
Once the health states, the probabilities for fulfilling the transition 
probabilities matrices, the costs, and utilities for each health state and 
the simulation stages are determined the cohort simulation can be 
performed. 
The code is displayed below. The same code is used for the sensitivity 
analysis, to generate different scenarios by changing the input values. 
 
###### Generalization Cohort Simulation for 2-stages ########## 
 
##### Functions 
# Function to perform the Markov model run 
cohortsim = function() 
 { 
#matrix that is going to contain the number of patients in each health state over the   
#simulation cycles. The number of columns is nhs and the number of rows are steps 
ncycle<-matrix(nrow = steps, ncol=nhs, byrow=TRUE, dimnames = list(c(1:steps), 
c("C.1", "C.2", "C.3"))) 
     
 # 1st cycle of the simulation 
 ncycle[1,]<-Nstartv%*%mtrans1 
 
 #1st phase simulation 
 b<-steps1-1 
      for (i in 1:b) 
  
      {  
   ncycle[i+1,]<-ncycle[i,]%*%mtrans1 
       } 
 
 #2nd phase simulation 
 Nstartv<-ncycle[steps1,] 
 ncycle[steps1+1,]<-Nstartv%*%mtrans2 
 
 b<-steps2-1 
 
      for (i in 1:b) 
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      {  
   ncycle[i+1+steps1,]<-ncycle[i+steps1,]%*%mtrans2 
       } 
  
 cat("Patients at each health state per cycle\n") 
 print(ncycle) 
   
 }  
 
 
 
# Allocate cost and utilities 
  costuts = function() 
    { 
cost<- matrix(c(cost1,cost2,cost3), nrow = 1, ncol=nhs, byrow=TRUE, dimnames = 
list(c("row1"),c("C.1", "C.2", "C.3"))) 
ut<- matrix(c(ut1,ut2,ut3), nrow = 1, ncol=nhs, byrow=TRUE, dimnames = 
list(c("row1"),c("C.1", "C.2", "C.3"))) 
 
#imputation of the cost (and utilities) for the patients in each health status. [lenght it is 
#time horizon, here not used. 3 months cycles. Simulation lasts X 
#months=steps*3months] 
 # steps<-length(ncycle)/3 
 
costcycle<-matrix(nrow = steps, ncol=nhs, byrow=TRUE, dimnames = list(c(1:steps), 
c("C.1", "C.2", "C.3"))) 
utcycle<-matrix(nrow = steps, ncol=nhs, byrow=TRUE, dimnames = list(c(1:steps), 
c("C.1", "C.2", "C.3"))) 
  
   for (i in 1:steps) 
  {  
  for(j in 1:nhs) 
 
       {  
   costcycle[i,j]<-cost[j]%*%ncycle[i,j] 
   utcycle[i,j]<-ut[j]%*%ncycle[i,j] 
        } 
  } 
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 cat("Total cost for all patients at each health status\n") 
 print(costcycle) 
 cat("Total utilities for all patients at each health status\n") 
 print(utcycle) 
 aux<-cbind(costcycle,utcycle) 
 
    }  
 
 
##### Define input parametres 
#Treatment A: MRV-454 Tropile test 
#Total health state number 
nhs<-3 
 
#Total number of clinical phases that are going to be simulated 
nphases<-2 
 
#Total number of individuals in the simulated cohort 
N<-100000 
 
#The state where the (a concret number of) individuals are starting in the simulated cohort. The 
#sum of the individuals in each health state should equal N. Nstartv has nrow=1 and ncol=nhs 
 
Nstartv<- matrix(c(N,0,0), nrow = 1, ncol=nhs, byrow=TRUE,dimnames = list(c("row1"),c("C.1", 
"C.2", "C.3"))) 
      
 
#Each phase should have a transition probabilities matrix (mtrans), then the same number of 
#mtrans than nphases are required 
 
 
mtrans1<-matrix(c(0.9298,0.07,0.0002,0.36,0.6398,0.0002, 0,0,1), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
mtrans2<-matrix(c(0.9773,0.0225,0.0002,0.01,0.9898,0.0002,0,0,1), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
 
 
#Simulate steps through the Markov Chain (Attention! Zero time point should be inclused, this is 
#reflected by adding an extra step) 
steps<-13 
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steps1<-3 
steps2<-steps-steps1 
 
# Allocate cost and utilities 
# The cost for 1 patient in each health state are 1, 2, 3  
cost1<-3161.13 
cost2<-3161.13 
cost3<-0 
# The Utilities for 1 patient in each health state are 1, 2, 3 
ut1<-0.83 
ut2<-0.79 
ut3<-0 
 
#Treatment B: MRV-454 tropism test 
mtrans1<-matrix(c(0.9048,0.095,0.0002,0.2628,0.737,0.0002,0,0,1), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
mtrans2<-matrix(c(0.98338,0.01643,0.00020,0.00730,0.99250,0.0002,0,0,1), nrow = nhs, 
ncol=nhs, byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
 
# The cost for 1 patient in each health state are 1, 2, 3 
cost1<-3067.38 
cost2<-3067.38 
cost3<-0 
# The Utilities for 1 patient in each health state are 1, 2, 3 
ut1<-0.83 
ut2<-0.79 
ut3<-0 
 
#Treatment C: MRV-PS (geno2pheno) test 
mtrans1<-matrix(c(0.9048,0.095,0.0002,0.216,0.7838,0.0002,0,0,1), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
mtrans2<-matrix(c(0.98630,0.01350,0.00020,0.00600,0.99380,0.00020,0,0,1), nrow = nhs, 
ncol=nhs, byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
 
# The cost for 1 patient in each health state are 1, 2, 3 
cost1<-3051.13 
cost2<-3051.13 
cost3<-0 
# The Utilities for 1 patient in each health state are 1, 2, 3 
ut1<-0.83 
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ut2<-0.79 
ut3<-0 
 
 
##### Call functions and see output at the screen. 
#Read the parameters for one of the therapeutic strategies and call the functions 
 
#Read parameters for treatment A 
ncycle<- cohortsim(); 
cost_utcycle<- costuts(); 
treatA<-cbind(ncycle, cost_utcycle) 
treatA<-data.frame(treatA) 
names(treatA) <- 
c("nstat1A","nstat2A","nstat3A","cstat1A","cstat2A","cstat3A","ustat1A","ustat2A","ustat3A") 
 
#Read parameters for treatment B 
ncycle<- cohortsim(); 
cost_utcycle<- costuts(); 
treatB<-cbind(ncycle, cost_utcycle) 
treatB<-data.frame(treatB) 
names(treatB) <- 
c("nstat1B","nstat2B","nstat3B","cstat1B","cstat2B","cstat3B","ustat1B","ustat2B","ustat3B") 
 
#Read parameters for treatment B 
ncycle<- cohortsim(); 
cost_utcycle<- costuts(); 
treatC<-cbind(ncycle, cost_utcycle) 
treatC<-data.frame(treatC) 
names(treatC) <-
c("nstat1C","nstat2C","nstat3C","cstat1C","cstat2C","cstat3C","ustat1C","ustat2C","ustat3C") 
 
 
##### Data management 
#Simulated time, in years. It has to be coherent with the discount tax units 
#Simulation of 12 cycles of 3 months 
 
time_sim<-seq(0,by=0.25, length.out=steps) 
out<-cbind(treatA,treatB,treatC,time_sim) 
summary(out) 
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write.table(out,"C:\\Documents and Settings\\nperez\\Escritorio\\Maraviroc_redo\\output.txt", dec 
= ".", row.names = TRUE,col.names = TRUE) 
 
data<-read.table("C:\\Documents and Settings\\nperez\\Escritorio\\Maraviroc_redo\\output.txt", 
header=T, dec=".") 
summary(data) 
 
 
##### Cost-effectiveness analysis 
#Summaryze cost-effectiviness information 
#The code for treatment A is shown, the sema has to be done for treatment B and C by 
#changing the A by B or C in the value names. 
 
#CEA: Calculations for treatment A 
 
#Cost  (Non discounted) 
 data$cA<-( data$cstat1A+ data$cstat2A+ data$cstat3A) 
resumcA<-sum( data$cA)/N 
 
#Cost  (Discounted ->discount tax 3%, introduced as 0.03) 
 data$cAdisc<-( data$cstat1A+ data$cstat2A+ data$cstat3A)/((1+0.03)^time_sim) 
resumcAdisc<-sum( data$cAdisc)/N 
 
#Utility  (Non discounted) 
 data$uA<-( data$ustat1A+ data$ustat2A+ data$ustat3A) 
resumuA<-sum( data$uA)/N 
 
#Utility  (Discounted ->discount tax 3%, introduced as 0.03) 
 data$uAdisc<-( data$ustat1A+ data$ustat2A+ data$ustat3A)/((1+0.03)^time_sim) 
resumuAdisc<-sum( data$uAdisc)/N 
 
#Life years (Non discounted) 
 data$lyA<-(data$nstat1A+data$nstat2A) 
resumlyA<-sum( data$lyA)/N 
 
#Life years  (Discounted ->discount tax 3%, introduced as 0.03) 
 data$lyAdisc<-(data$nstat1A+data$nstat2A)/((1+0.03)^time_sim) 
resumlyAdisc<-sum( data$lyAdisc)/N 
 
resumcA 
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resumcAdisc 
resumuA 
resumuAdisc 
resumlyA 
resumlyAdisc 
 
# Difference between treatments A and B 
difcdiscAB<-resumcAdisc-resumcBdisc 
difcdiscAB 
difudiscAB<-resumuAdisc-resumuBdisc 
difudiscAB 
 
# Difference between treatments A and C 
difcdiscAC<-resumcAdisc-resumcCdisc 
difcdiscAC 
difudiscAC<-resumuAdisc-resumuCdisc 
difudiscAC 
 
# Difference between treatments B and C 
difcdiscBC<-resumcBdisc-resumcCdisc 
difcdiscBC 
difudiscBC<-resumuBdisc-resumuCdisc 
difudiscBC 
 
#Labelling output of the difference between costs and utilities (can be done analogously for 
#AvsC and BvsC 
AvsB <- if ((resumcAdisc>resumcBdisc)&(resumuAdisc<resumuBdisc)) 'Dominant' else if 
((resumcAdisc<resumcBdisc)&(resumuA>resumuBdisc)) 'Dominated' else 'Non conclusive'  
 AvsB 
 
Results<-matrix(c(resumcA, resumcB,resumcAdisc,resumcBdisc, resumuA,resumuB, 
resumuAdisc, resumuBdisc,resumlyA,resumlyB,resumlyAdisc,resumlyBdisc), nrow = 6, ncol=2, 
byrow=TRUE, dimnames = list(c("resum cost","Discounted cost","Resum utility","Discounted 
utility","resum ly ","Discounted ly disc"),c("Treatment A", "Treatment B"))) 
 
Results_diffs<-matrix(c(resumcA, resumcB,resumcAdisc,resumcBdisc, resumuA,resumuB, 
resumuAdisc, resumuBdisc,resumlyA,resumlyB,resumlyAdisc,resumlyBdisc, resumcA-
resumcB,resumcAdisc-resumcBdisc, resumuA-resumuB, resumuAdisc-resumuBdisc,resumlyA-
resumlyB,resumlyAdisc-resumlyBdisc), nrow = 6, ncol=3, byrow=TRUE, dimnames = 
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list(c("resum cost","Discounted cost","Resum utility","Discounted utility","resum ly ","Discounted 
ly disc"),c("Treatment A", "Treatment B", "Difference"))) 
 
#Cost efficacy plot for the treatments assessed 
x<-c(resumuA,resumuB) 
y<-c(resumcA,resumcB) 
plot(x,y, xlab="Utilities", ylab="Cost(€)", main="Cost Efficacy pot",pch=15, col="blue")  
y1<-c(3715,3722) 
x1<-c(0.98562,0.98572) 
points(x1, y1, pch=16, col="green") 
 
 
The following code is used to generate the input parameters for the 
probabilistic sensitivity analysis. The use of the code is the following: 
first, the functions should be read, after reading the input parameters for 
the therapeutic strategies assessed the funcions can be executed, and, 
finally, the output information can be saved. 
 
 
##### Functions 
### Execute the functions needed for distribution assignation 
 
#Assign theoretical distributions to the parameters 
#Probabilities and utilities follow a Beta distribution 
#Costs follow a Gamma distribution 
 
#Assign SD to the values 
### 2.1.1 SD to the probabilities 
#nhs is the total health states (HS) 
#mat is the matrix or vector containing the transition probabilities between HS. 
SDmat<-function(nhs,mat){ 
   mat<-as.vector(t(mat)) 
   SDmat<-array(NA,length(mat)) 
       for (i in 1:length(mat)) {if((mat[i]<0.1)){SDmat[i]<-0.005} 
            if(mat[i]<0.001){SDmat[i]<-mat[i]} 
            if(mat[i]>0.1){SDmat[i]<-0.05} 
            }  
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      print(SDmat) 
       
   } 
 
#2.2 Funtions for parameters on the distributions 
 
#parameters for the Beta- Function 
alpha_b<-function(value,sd) {a<-value*(value*(1-value)/(sd*sd)-1) 
      #print(a) 
     } 
 
beta_b<-function(value,sd) {b<-value*(1-value)/(sd*sd)-1-(value*(value*(1-value)/(sd*sd)-1)) 
      #print(b) 
     } 
 
### Function that gives the probabilities of transiton and the utilities (both follow a beta 
#distribution) 
# In the beta_trials functions the parameters for the beta distribution are generated, the columns 
have the name o btrials (parameters for the trials that follow a beta distribution) 
 
beta_trials<-function(ntrials,mat,s){ 
    mat<-as.vector(t(mat)) 
    btrials<-array(NA,ntrials) 
    aux<-seq(1, ntrials, by = 1) 
    for(i in 1:length(mat)) { if(mat[i]==0){btrials<-array(0,ntrials)} 
               if(mat[i]==1){btrials<-array(1,ntrials)} 
               if((mat[i]>0)&(mat[i]<1)){btrials<-
rbeta(ntrials, alpha_b(mat[i],s[i]), beta_b(mat[i],s[i]), ncp = 0)}  
         aux<-cbind(aux,btrials) 
      } 
     #print(aux) 
     beta_trials<-aux   
     } 
   
 
#parameters for the Gamma- Function 
alpha_g<-function(value,sd) {a<-((value/sd)^2) 
      #print(a) 
     } 
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beta_g<-function(value,sd) {b<-(sd*sd)/value 
      #print(b) 
     } 
 
 
### Function that gives the costs (follow a Gamma distribution) 
#in the gamma_trials functions the parameters for the beta distribution are generated, the 
columns have the name o gtrials (parameters for the trials that follow a Gamma distribution) 
 
gamma_trials<-function(ntrials,mat,s){ 
    gtrials<-array(NA,ntrials) 
    aux<-seq(1, ntrials, by = 1) 
    for(i in 1:length(mat)) { if(mat[i]==0){gtrials<-array(0,ntrials)} 
                if(mat[i]>0){gtrials<-
rgamma(ntrials,alpha_g(mat[i],s[i]), 1/beta_g(mat[i],s[i]))}  
         aux<-cbind(aux,gtrials) 
       } 
     #print(aux) 
     gamma_trials<-aux   
     } 
 
 
##### Read input parameters 
nhs<-3 
mtrans1<-matrix(c(0.9298,0.07,0.0002,0.36,0.6398,0.0002, 0,0,1), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
mtrans2<-matrix(c(0.9773,0.0225,0.0002,0.01,0.9898,0.0002,0,0,1), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
 
 
##we need to read the components of the matrix as an array 
mat1<-as.vector(t(mtrans1)) 
mat2<-as.vector(t(mtrans2)) 
 
# The cost for 1 patient in each health state are 1, 2, 3 
cost1<-3161.13 
cost2<-3161.13 
cost3<-0 
 
# The Utilities for 1 patient in each health state are 1, 2, 3 
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ut1<-0.83 
ut2<-0.79 
ut3<-0 
 
ntrials<-1000 
 
###  SD to the costs 
#Gamma distribution for the cost 
#As long as the number of nhs 
#SD of cost is going to be taken to the 10% of the value. 
SDcost1<-cost1*0.1 
SDcost2<-cost2*0.1 
SDcost3<-cost3*0.1 
 
### SD to the utilities 
#Beta distribution 
#As many SDut1, SDut2... as the number of nhs 
SDut1<-ifelse(ut1>0.1, 0.05, 0.005) 
SDut2<-ifelse(ut2>0.1, 0.05, 0.005) 
SDut3<-ifelse(ut3>0.1, 0.05, 0.005) 
 
 
##### Call functions and safe the output 
###For the phases of simulation considered. In our case we have 2. 
probs_trials1<-beta_trials(ntrials,mtrans1,SDmat(nhs,mtrans1)) 
probs_trials2<-beta_trials(ntrials,mtrans2,SDmat(nhs,mtrans2)) 
 
#Costs and SD are introduced in an array for the use of the function gamma_trials 
costs<-array(c(cost1,cost2,cost3)) 
SDcosts<-array(c(SDcost1,SDcost2,SDcost3)) 
costs_trials<-gamma_trials(ntrials,costs,SDcosts) 
 
### Function that gives the utilities 
uts<-array(c(ut1,ut2,ut3)) 
SDuts<-array(c(SDut1,SDut2,SDut3)) 
uts_trials<-beta_trials(ntrials,uts,SDuts) 
 
###Bind all the information of the parameters in a data frame 
#Probability Simulation Parameters 
probsimpar<-cbind(probs_trials1,probs_trials2[,-1], costs_trials[,-1],uts_trials[,-1]) 
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#Attention! Names depend on the treatment branch and on the total nhs.  
probsimparA<-data.frame(probsimpar) 
names(probsimparA) <- 
c("trial","prob11A1","prob12A1","prob13A1","prob21A1","prob22A1","prob23A1","prob31A1","pro
b32A1","prob33A1","prob11A2","prob12A2","prob13A2","prob21A2","prob22A2","prob23A2","pr
ob31A2","prob32A2","prob33A2","cost1A","cost2A","cost3A","ut1A","ut2A","ut3A") 
write.table(probsimparA,"C:\\Documents and 
Settings\\nperez\\Escritorio\\Maraviroc_redo\\probsimparA.txt", dec = ".", row.names = 
TRUE,col.names = TRUE) 
 
# The code is the same for treatment B and C. Input parameters and value labels should be 
#changed 
 
 
CEA_output of n trials 
The cohort simulation is going to be performed n times (to generate n 
trials) using the input parameters generated by means of the parametrical 
distributions. The funcitons “cohortsim” and “costuts” as implemented 
before are going to be used. 
 
 
##### Input parameters 
#Parameters (For cohortsim and some of them for costuts) 
#Total health state number 
nhs<-3 
#Total number of clinical phases that are going to be simulated 
nphases<-2 
#Total number of individuals in the simulated cohort 
N<-100000 
 
#The state where the (a concret number of) individuals are starting in  the simulated cohort. The 
sum of the individuals in each health state should equal N. Nstartv has nrow=1 and ncol=nhs 
Nstartv<- matrix(c(N,0,0), nrow = 1, ncol=nhs, byrow=TRUE,dimnames = list(c("row1"),c("C.1", 
"C.2", "C.3"))) 
 
#Required parameters for CEA for ntrials 
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# Parameters for the ntrials are stored at "probsimpar*.txt" 
# For treatment A at data1, treatment B at data 2 and treatment C at data 3 
data1<-read.table("C:\\Documents and 
Settings\\nperez\\Escritorio\\Maraviroc_redo\\probsimparA.txt", header=T, dec=".") 
data2<-read.table("C:\\Documents and 
Settings\\nperez\\Escritorio\\Maraviroc_redo\\probsimparB.txt", header=T, dec=".") 
data3<-read.table("C:\\Documents and 
Settings\\nperez\\Escritorio\\Maraviroc_redo\\probsimparC.txt", header=T, dec=".") 
 
data<-cbind(data1,data2,data3) 
summary(data) 
 
#Number of trials should be the same as in the generation of parameters 
ntrials<-1000 
 
#Simulate steps through the Markov Chain (Initial time point should be included, remember to 
#add an extra step) 
steps<-13 
steps1<-3 
steps2<-steps-steps1 
 
 
##### Cohort simulation for n trials 
attach(data) 
 
all_summaries<- data.frame(uA=numeric(0), lyA=numeric(0), cA=numeric(0), uB=numeric(0), 
lyB=numeric(0), cB=numeric(0),uC=numeric(0), lyC=numeric(0), cC=numeric(0)) 
 
t=1 
 
#for t in 1:ntrials 
for (t in 1:ntrials) { 
#Treatment A 
mtrans1<-matrix(c(prob11A1[t], prob12A1[t], prob13A1[t], prob21A1[t], prob22A1[t], 
prob23A1[t], prob31A1[t], prob32A1[t], prob33A1[t]), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
mtrans2<-matrix(c(prob11A2[t], prob12A2[t], prob13A2[t], prob21A2[t], prob22A2[t], 
prob23A2[t], prob31A2[t], prob32A2[t], prob33A2[t]), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
cost1<-cost1A[t] 
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cost2<-cost2A[t] 
cost3<-cost3A[t] 
ut1<-ut1A[t] 
ut2<-ut2A[t] 
ut3<-ut3A[t] 
 
ncycle<- cohortsim(); 
cost_utcycle<- costuts(); 
 
treatA<-cbind(ncycle, cost_utcycle) 
 treatA<-data.frame(treatA) 
names(treatA) <- 
c("nstat1A","nstat2A","nstat3A","cstat1A","cstat2A","cstat3A","ustat1A","ustat2A","ustat3
A") 
 
 
#Treatment B 
mtrans1<-matrix(c(prob11B1[t], prob12B1[t], prob13B1[t], prob21B1[t], prob22B1[t], 
prob23B1[t], prob31B1[t], prob32B1[t], prob33B1[t]), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
mtrans2<-matrix(c(prob11B2[t], prob12B2[t], prob13B2[t], prob21B2[t], prob22B2[t], 
prob23B2[t], prob31B2[t], prob32B2[t], prob33B2[t]), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
cost1<-cost1B[t] 
cost2<-cost2B[t] 
cost3<-cost3B[t] 
ut1<-ut1B[t] 
ut2<-ut2B[t] 
ut3<-ut3B[t] 
 
ncycle<- cohortsim(); 
cost_utcycle<- costuts(); 
 
treatB<-cbind(ncycle, cost_utcycle) 
 treatB<-data.frame(treatB) 
names(treatB) <- 
c("nstat1B","nstat2B","nstat3B","cstat1B","cstat2B","cstat3B","ustat1B","ustat2B","ustat3
B") 
 
#Treatment C 
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mtrans1<-matrix(c(prob11C1[t], prob12C1[t], prob13C1[t], prob21C1[t], prob22C1[t], 
prob23C1[t], prob31C1[t], prob32C1[t], prob33C1[t]), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
mtrans2<-matrix(c(prob11C2[t], prob12C2[t], prob13C2[t], prob21C2[t], prob22C2[t], 
prob23C2[t], prob31C2[t], prob32C2[t], prob33C2[t]), nrow = nhs, ncol=nhs, 
byrow=TRUE, dimnames = list(c("row1", "row2", "row3"),c("C.1", "C.2", "C.3"))) 
cost1<-cost1C[t] 
cost2<-cost2C[t] 
cost3<-cost3C[t] 
ut1<-ut1C[t] 
ut2<-ut2C[t] 
ut3<-ut3C[t] 
 
ncycle<- cohortsim(); 
cost_utcycle<- costuts(); 
 
treatC<-cbind(ncycle, cost_utcycle) 
 treatC<-data.frame(treatC) 
names(treatC) <- 
c("nstat1C","nstat2C","nstat3C","cstat1C","cstat2C","cstat3C","ustat1C","ustat2C","ustat
3C") 
 
#Simulated time, in years. It has to be coherent with the discount tax units 
#Simulation of 12 cycles of 3 months. 
 
time_sim<-seq(0,by=0.25, length.out=steps) 
out<-cbind(treatA,treatB,treatC,time_sim) 
 
### CEA: Calculations. 
# Treatment A 
#Utility  (Non discounted) 
 out$uA<-( out$ustat1A+ out$ustat2A+ out$ustat3A) 
resumuA<-sum( out$uA)/N 
 
#Life years (Non discounted) 
  out$lyA<-(out$nstat1A+out$nstat2A) 
resumlyA<-sum( out$lyA)/N 
 
#Cost  (Non discounted) 
 out$cA<-( out$cstat1A+ out$cstat2A+ out$cstat3A) 
204 
 
resumcA<-sum( out$cA)/N 
 
#Treatment B 
#Utility  (Non discounted) 
  out$uB<-( out$ustat1B+ out$ustat2B+ out$ustat3B) 
resumuB<-sum( out$uB)/N 
 
#Life years (Non discounted) 
out$lyB<-(out$nstat1B+out$nstat2B) 
resumlyB<-sum( out$lyB)/N 
 
#Cost  (Non discounted) 
 out$cB<-( out$cstat1B+ out$cstat2B+ out$cstat3B) 
resumcB<-sum( out$cB)/N 
 
#Treatment C 
#Utility  (Non discounted) 
  out$uC<-( out$ustat1C+ out$ustat2C+ out$ustat3C) 
resumuC<-sum( out$uC)/N 
 
#Life years (Non discounted) 
out$lyC<-(out$nstat1C+out$nstat2C) 
resumlyC<-sum( out$lyC)/N 
 
#Cost  (Non discounted) 
  out$cC<-( out$cstat1C+ out$cstat2C+ out$cstat3C) 
resumcC<-sum( out$cC)/N 
 
### Save the summary of a CEA calculation per every trial 
all_summaries[t,]<-c(resumuA, resumlyA, resumcA, resumuB, resumlyB, resumcB, 
resumuC, resumlyC, resumcC) 
t=t+1 
                            } #closes the repetition for the number of trials selected 
  
#Save the output of the simulation for the n trials 
write.table(all_summaries,"C:\\Documents and 
Settings\\nperez\\Escritorio\\Maraviroc_redo\\all_summaries.txt", dec = ".", row.names = 
TRUE,col.names = TRUE) 
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Plots for PSA  
The following code can be used or plotting the Cost-effectiveness 
analysis (CEA) and the Cost-effectiveness acceptability curves (CEAC) 
resulting of the probability sensitivity analysis performance. 
 
CEA_PSA<-read.table("C:\\Documents and 
Settings\\nperez\\Escritorio\\Maraviroc_redo\\all_summaries.txt", dec = ".", header = TRUE) 
names(CEA_PSA) 
summary(CEA_PSA) 
dim(CEA_PSA) 
attach(CEA_PSA) 
 
 
##### Cost-effectiveness plane 
#Trofile vs 454 
CEA_PSA$Incr_costAB<-CEA_PSA$cA-CEA_PSA$cB 
CEA_PSA$Incr_utAB<-CEA_PSA$uA-CEA_PSA$uB 
 
#454 vs PS 
CEA_PSA$Incr_costBC<-CEA_PSA$cB-CEA_PSA$cC 
CEA_PSA$Incr_utBC<-CEA_PSA$uB-CEA_PSA$uC 
 
#Trofile vs PS  
CEA_PSA$Incr_costAC<-CEA_PSA$cA-CEA_PSA$cC 
CEA_PSA$Incr_utAC<-CEA_PSA$uA-CEA_PSA$uC 
 
plot(CEA_PSA$Incr_costAB,CEA_PSA$Incr_utAB,xlab="Incremental utility gain", 
ylab="Incremental cost(€)", main="Cost effectiveness plane (A vs 
B)",type="p",lty=3,lwd=2.5,col="blue") 
abline(h=0, v=0) 
abline(h =c(-5,0,5), v = c(-30000,-20000,-10000,0,10000,20000,30000,40000), col ="gray60", 
lty=3) 
points(mean(CEA_PSA$Incr_costAB), mean(CEA_PSA$Incr_utAB), pch = 23, bg = "red") 
mean(CEA_PSA$Incr_costAB) 
mean(CEA_PSA$Incr_utAB) 
 
plot(CEA_PSA$Incr_costBC,CEA_PSA$Incr_utBC,xlab="Incremental utility gain", 
ylab="Incremental cost(€)", main="Cost effectiveness plane (B vs 
C)",type="p",lty=3,lwd=2.5,col="blue") 
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abline(h=0, v=0) 
abline(h =c(-5,0,5), v = c(-30000,-20000,-10000,0,10000,20000,30000,40000), col ="gray60", 
lty=3) 
points(mean(CEA_PSA$Incr_costBC), mean(CEA_PSA$Incr_utBC), pch = 23, bg = "red") 
mean(CEA_PSA$Incr_costBC) 
mean(CEA_PSA$Incr_utBC) 
 
 
plot(CEA_PSA$Incr_costAC,CEA_PSA$Incr_utAC,xlab="Incremental utility gain", 
ylab="Incremental cost(€)", main="Cost effectiveness plane (A vs 
C)",type="p",lty=3,lwd=2.5,col="blue") 
abline(h=0, v=0) 
abline(h =c(-5,0,5), v = c(-30000,-20000,-10000,0,10000,20000,30000,40000), col ="gray60", 
lty=3) 
points(mean(CEA_PSA$Incr_costAC), mean(CEA_PSA$Incr_utAC), pch = 23, bg = "red") 
mean(CEA_PSA$Incr_costAC) 
mean(CEA_PSA$Incr_utAC) 
 
 
##### Cost effectiveness acceptability curve 
#Define Ceiling ratio 
#CEA_PSA$cratio<-100000 
vary_cratio<-seq(from = 0, to = 100000, by = 100) 
cratioplot<-array(NA,(100000/100)) 
 
plotingCEAC<- data.frame(cratioplot=numeric(0),prob_A=integer(0), prob_B=integer(0), 
prob_C=integer(0)) 
i=1 
for (i in 1:(100000/100)) 
  { 
  cratioplot<-array(vary_cratio[i],(100000/100)) 
   
  #Create a indicator variable for the treatment which is more cost effective 
#Multiplied by 100 because the values are very similiar (utilities differs in the 3rd 
#position after 0) *100 enlarge differences 
  CEA_PSA$NMB_Aaux<-((CEA_PSA$uA*cratioplot)-CEA_PSA$cA)*100 
  CEA_PSA$NMB_Baux<-((CEA_PSA$uB*cratioplot)-CEA_PSA$cB)*100  
  CEA_PSA$NMB_Caux<-((CEA_PSA$uC*cratioplot)-CEA_PSA$cC)*100 
   
  for (j in 1:length(CEA_PSA$NMB_Aaux)){ 
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CEA_PSA$max[j]<-
max(CEA_PSA$NMB_Aaux[j],CEA_PSA$NMB_Baux[j],CEA_P
SA$NMB_Caux[j]) 
           }   
  CEA_PSA$probCEA_A<-ifelse(CEA_PSA$max==CEA_PSA$NMB_Aaux,1,0) 
  CEA_PSA$probCEA_B<-ifelse(CEA_PSA$max==CEA_PSA$NMB_Baux,1,0) 
  CEA_PSA$probCEA_C<-ifelse(CEA_PSA$max==CEA_PSA$NMB_Caux,1,0) 
   
 
plotingCEAC[i,]<-     c(cratioplot[1], 
mean(CEA_PSA$probCEA_A), mean(CEA_PSA$probCEA_B), 
mean(CEA_PSA$probCEA_C))   
  i=i+1 
 
  } 
 
 
write.table(plotingCEAC,"C:\\Documents and 
Settings\\nperez\\Escritorio\\Maraviroc_redo\\plotingCEAC.txt", dec = ".", row.names = 
TRUE,col.names = TRUE) 
 
plot(plotingCEAC$cratioplot/1000, plotingCEAC$prob_A,xlab="Value of ceiling ratio (K 
€)",ylab="Probability cost-effective",xlim=c(0,100),ylim=c(0.00,1.00),type='l',lty=1,col=2,lwd=2) 
lines(plotingCEAC$cratioplot/1000, plotingCEAC$prob_B,lty=3,col=3,lwd=2) 
lines(plotingCEAC$cratioplot/1000, plotingCEAC$prob_C,lty=5,col=4,lwd=2) 
legend(70,0.99, c("A-Trofile","B-454","C-PS"),lty=c(1,3,5),col=c(2,3,4),lwd=2) 
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Annex X:  Input parameters for the model of HIV tropism testing 
 
Table X.1. Transition probabilities matrices by co-receptor test and phase of HIV 
viremia control 
Trofile-ES test and treated with MRV  
 Week 0 to 24 week (MT1) >24 weeks (MT2) 
  VL≤50 VL>50 Dead VL≤50 VL>50 Dead 
VL≤50 0.9298 0.0700 0.0002 0.9773 0.0225 0.0002
VL>50 0.3600 0.6398 0.0002 0.0100 0.9898 0.0002
Dead 0 0 1 0 0 1
Roche 454 test and treated with MRV 
 Week 0 to 24 week (MG1) >24 weeks (MG2) 
  VL≤50 VL>50 Dead VL≤50 VL>50 Dead 
VL≤50 0.9048 0.0950 0.0002 0.9834 0.0164  0.0002 
VL>50 0.2628 0.7370 0.0002 0.0073 0.9925  0.0002 
Dead 0 0 1 0 0 1
PS test and treated with MRV 
 Week 0 to 24 week (MPS1) >24 weeks (MPS2) 
 VL≤50 VL>50 Dead VL≤50 VL>50 Dead 
VL≤50 0.9048 0.0950 0.0002 0.9863 0.0135  0.0002 
VL>50 0.2160 0.7838 0.0002 0.0060 0.9938  0.0002 
Dead 0 0 1 0 0 1
MT1: Probabilities used for the simulation of the cohort of patients 
allocated in the Trofile-ES test in the time from zero to 24 weeks. 
MT2: Idem than MT1 for the time from 24 weeks to 144 weeks. 
MG1: Probabilities used for the simulation of the cohort of patients 
allocated to the 454 Roche test in the time from zero to 24 weeks. 
MG2: Idem than MG1 for the time from 24 weeks to 144 weeks. 
MPS1: Probabilities used for the simulation of the cohort of patients 
allocated to the population sequencing test in the time from 0 to 24 weeks. 
MPS2: Idem than MPS1 for the time from 24 weeks to 144 weeks. 
 
The simulation was run using the MT1, MG1 and MPS1 for the first 2 
cycles (equivalent to 24 weeks) and the next cycles the patients in each 
health status travel according to the transition probabilities in matrices 
MT2, MG2 and MPS2 up to 3 years of follow-up (12 cycles) or death. 
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It is relevant to take into account that the prevalence of HIV infected 
patients with X4 coreceptor corresponds to the population of patients 
who had an “improperly” received MRV. 
 
Cost and utility input data 
The direct cost of the hospital medical supplies where used. The 
reported proportion of adverse events also was used to increment the 
treatment cost. 
 
Table X.2. The imputed costs per patient and a period of 3 months 
Concept Cost (€) 
ARV (3months)  3033  
Trofile-ES test (3 months)+ 125 
Roche 454 (3 months)+  31,25 
PS (3 months)+ 15 
Cost increase for adverse event 
(mean per patient per 3 months)* 
71  
* 1 extra medical visit: €59 Euros+ concomitant treatment €12 
+The cost of the test was divided into the number of cycles simulated. Trofile-ES cost 
was €1000, Roche 454 test cost was €250 and PS test cost was €120. 
 
Utility weights range between 0 and 1, being 1 the higher utility. The 
applied utilities for each state were derived from the published article of 
Sanders et al.225. The utilities were calculated taking into consideration 
the adverse events frequency reported form the MERIT study: 4.2% of 
patients reported the presence of adverse events for the MRV group. 
The utility score was decreased in 0.02 units for the presence of adverse 
events. 
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Annex XI: Costs: Definitions and concepts 
 
There are three types of cost: direct, indirect, intangible. Their 
definitions are given below. 
 The direct costs are those associated with the medical recovery of 
the patient. They can be quantified as the value of resources 
(products and/or services) used directly when providing the 
treatment. It includes pharmaceutical products, hospital care, 
physician care, nursing services, etc. They also include the costs 
of resources consumed directly to produce a certain health 
outcome, for instance physician’s, nurse’s, or pharmacist’s time, 
equipment, etc. Other direct, non-medical, costs include the 
products and/or services that are needed to obtain care, although 
they do not directly contribute to health care. For instance, 
transportation to the hospital or hiring a baby sitter so a parent can 
visit the doctor. 
 The indirect costs list include those resulting from a patient being 
unable to perform normal activities due to illness, change in health 
status and mortality such as loss of earnings, loss of productivity 
or family time devoted to the patient’s care. 
 To facilitate quantifying the benefit of certain medical treatments 
and measures, studies in the field of health care economics also 
consider intangible costs that cannot be directly measured in 
monetary form; it would be even unethical to try it. Intangible 
effects, such as pain, joy, or physical limitations are assessed 
using the patient’s biopsychosocial health related quality of life 
after the accident; health related quality of life in this context 
includes physical health as well as social contacts and emotional 
health226. 
Two important concepts associated with the costs assessment: 
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 The concept of opportunity cost is fundamental to the 
economist's view of costs. Since resources are scarce relative 
to needs, the expenditure on a given health care intervention 
prevents to spend the same money on something else. When 
dealing with the opportunity cost we have to figure out if the 
whole set of benefits gained with the new therapy (treatment B) 
could buy a larger health benefit in the cheaper therapy 
(treatment A) or in some other part of the health care system. 
The comparative nature of health economics reflects that the 
interest is in the incremental analysis of costs and benefits. 
Either cost-effectiveness or cost-utility studies permit to 
compare the opportunity costs of the interventions assessed. 
 The marginal cost refer to the cost change when comparing 
between therapeutic strategies, the fixed costs should not be 
included in the marginal cost calculation. For instance, if 
treatment B enables patients to be discharged from hospital a 
day earlier than treatment A, the additional costs for the 
treatment A will only include the costs of the patient’s meals, 
treatment and perhaps nursing time of the extra day. These are 
the marginal costs, where the resource use actually changes 
substantially, but all the fixed capital charges for a hospital bed, 
which go into the average cost, e.g. costs of laboratories, 
kitchens, and building maintenance, will be largely unchanged 
when the patient is not admitted in the hospital. Incremental 
analysis is concerned with the marginal and not the average 
costs. Marginal costs are often very difficult to measure, and 
the use of average costs can be justified. In this particular 
example, if enough bed days are saved by the widespread 
adoption of treatment B to reduce bed numbers and to close 
wards. 
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Annex XII:  Input parameters for the PNH model  
Advers events profile, direct and indirect costs related to PNH 
The profile of adverse events and events related to PNH where obtained 
from Hillmen et al.162 study and their direct costs of them are listed in 
the Table XII.1.  
 
Table XII.1. Drug costs to handle with adverse events and events related to PNH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The percentages of individuals suffering the adverse events in both 
groups of treatment were used in the estimation of the mean direct costs 
that suppose to treat them. The direct costs per patient year are 
reported in Table XII.2. 
Adverse Event Drug Cost 
Headache 1.86 € 
Nasopharingitis 1.92 € 
Respiratory tract infection 2.41 € 
Back pain 2 € 
Nausea 1.52 € 
Cough 4.04 € 
Diarrhea 1.21 € 
Arthralgia 12.63 € 
Abdominal pain 0 € 
Dizziness 4.31 € 
Vomiting 1.52 € 
Fatigue 3.36 € 
Viral infection 10 € 
Events related to PNH  
Trombosis 41.98 € 
Chronic Kidney Disease-stage 1-3 4.54 € 
Chronic Kidney Disease stage 4-5 1,171.80 € 
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Table XII.2. Summary of direct costs (€) per patient year 
Costs Eculizumab Standard of care Difference 
Drug costs 318,842 18,468 300,374 
Administration costs 559 272 287 
AE and events related to HPN cost 72 83 -11 
Total 319,473 18,823 300,650 
 
The indirect costs derived of the patient’s resources expenses to receive 
the PNH care (drugs administering, waiting time, time and cost of 
travelling to the ambulatory care clinic and productivity loss) were 
evaluated. The disaggregated items and their costs are listed in Table 
XII.3.  
Table XII.3. Indirect costs by treatment group 
 Eculizumab Standard of care 
Diagnoses Age 37 37
Mean survival time after the diagnoses (years) 40 15
Cost of the drug administering time 
Travelling time per ambulatory visit 1 1
Waiting 0.50 0.50
Administration time 1 8
Required visits 27 8
Total time use 1,890 1,140
Time value (€/hour) 13.36 € 13.36 €
Total time cost 25,250.40 € 15,230.40 €
Travel costs for administration 
Cost per km 0.52 € 0.52 €
Round trip (km) 50 50
Cost per round trip 26 € 26 €
Number of travels 27 8
Total travel cost 702 € 208 €
Productivity loss* 
Loss in productive time (annual) 0 € 13
Time economic value (annual wages) 27,792 € 27,792 €
Human resources lost 0 € 361,296 €
Travel cost for medical visits 
Cost per km 0.52 € 0.52 €
Round trip (km) 50 50
Cost per round trip 26 € 26 €
Number of travels 4 8
Total travel cost 104 € 208 €
*The productivity loss is computed as years lost in human resources due to death, and using 65 years-old as  
the age of retirement. 
All costs are expressed in Euros (€, 2010). Resource unitary costs were 
collected from literature and Spanish public costs database updated to 
2010 value with Consumer Price Index227. 
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Annex XIII:  Analysis worksheets for the PNH model 
 
Model implemented in Microsoft® Excel to estimate the costs of PNH. 
Excel sheets: Introduction, Efficacy, Adverse Events, Key Trial Data, 
Treatment Inputs, Treatment cost, Cost of Adverse Events, Results, 
Inputs I, Results DI, Simple BI, Simple BI total cost. 
 
XIII.1. Introduction 
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XIII.2. Efficacy 
 
 
XIII.3. Adverse Events 
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XIII.4. Key Trial Data 
 
 
XIII.5. Treatment Inputs  
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XIII.6. Treatment cost  
 
 
XIII.7. Cost of Adverse Events  
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XIII.8. Results 
 
 
XIII.9. Inputs I  
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XIII.10. Results DI  
 
 
XIII.11. Simple BI  
 
 
XIII.12. Simple BI total cost 
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Annex XIV:  Medical Outcomes Study (MOS) 
 
Medical Outcomes Study (MOS)–Short Form (SF) with 12 items 
questionnaire (SF-12v2), was used to derive disutility values. One of the 
most widely used generic quality-of-life instruments is the SF-36. The 
SF-36 was developed from the RAND Corporation’s Health Insurance 
Experiments in the United States228. The SF-36 measures the HRQoL 
with 36 items, along eight dimensions and one physical component 
summary score and one mental component summary score. The SF-12 is 
a 12 items instrument that appears to be a practical alternative to the 
SF-36 for the purpose of large group comparisons229, 230. 
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Annex XV: Data analysis and DALYs calculation code with SPSS 
*** DALYs Calculation***. 
#DALY Calculation code implemented jointly with L. Kaskens. 
 
#### Deaths for patients suffering Osteoporosis with bone fractures. 
DATASET ACTIVATE Conjunto_de_datos1. 
RECODE edadn (SYSMIS=SYSMIS) (0 thru 69.99=0) (70 thru 74.99=0.000008) (75 thru 
79.99=0.000111)  (80 thru 84.99=0.000363) (85 thru 102=0.0001716) INTO deaths_owithf. 
EXECUTE. 
 
#### Deaths for patients suffering Osteoporosis without bone fractures. 
RECODE edadn (SYSMIS=SYSMIS) (0 thru 59.99=0) (60 thru 69.99=0.000001) (70 thru 
74.99=0.000000) (75 thru 79.99=0.000002)  (80 thru 84.99=0.000009) (85 thru 102=0.00004) 
INTO deaths_owithoutf. 
EXECUTE. 
 
IF(grupo_4cat=0) deaths=deaths_owithf. 
EXECUTE. 
IF(grupo_4cat=1) deaths=deaths_owithoutf. 
EXECUTE. 
IF ((grupo_4cat=2) OR (grupo_4cat=3)) deaths=0. 
EXECUTE. 
 
#Queda igual que en el fichero del 16-2. 
RECODE edadn (SYSMIS=SYSMIS) (0=84.56) 
(1=83.81) (2=82.83) (3=81.84) (4=80.85) (5=79.86) (6=78.87) (7=77.87) (8=76.88) (9=75.89) 
(10=74.90) (11=73.90) (12=72.91) (13=71.91) (14=70.92) (15=69.92) (16=68.94) (17=67.94) 
(18=66.96) (19=65.97) (20=64.98) (21=64.00) (22=63.01) (23=62.02) (24=61.03) (25=60.04) 
(26=59.06) (27=58.07) (28=57.08) (29=56.09) (30=55.11) (31=54.12) (32=53.13) (33=52.15) 
(34=51.17) (35=50.19) (36=49.21) (37=48.23) (38=47.25) (39=46.28) (40=45.30) (41=44.33) 
(42=43.37) (43=42.41) (44=41.45) (45=40.49) (46=39.54) (47=38.59) (48=37.64) (49=36.70) 
(50=35.76) (51=34.83) (52=33.90) (53=32.96) (54=32.03) (55=31.11) (56=30.19) (57=29.27) 
(58=28.35) (59=27.43) (60=26.52) (61=25.61) (62=24.70) (63=23.80) (64=22.90) (65=22.01) 
(66=21.13) (67=20.25) (68=19.36) (69=18.50) (70=17.64) (71=16.77) (72=15.93) (73=15.12) 
(74=14.32) (75=13.52) (76=12.75) (77=11.99) (78=11.24) (79=10.52) (80=9.83) (81=9.18) 
(82=8.54) (83=7.93) (84=7.36) (85=6.81) (86=6.29) (87=5.83) (88=5.39) (89=4.98) (90=4.61) 
(91=4.23) (92=3.92) (93=3.62) (94=3.34) (95=3.10) (96=2.89) (97=2.70) (98=2.47) (99=2.23) 
(100=1.94) INTO life_expectancy. 
EXECUTE. 
 
RECODE edadn (SYSMIS=SYSMIS) (0=0.1) 
(1 thru 4=2.6) (5 thru 9=7.5) (10 thru 14=12.5) (15 thru 19=17.5) (20 thru 24=22.5) (25 thru 
29=27.5) (30 thru 34=32.5) (35 thru 39=37.5) (40 thru 44=42.5) (45 thru 49=47.5) (50 thru 
54=52.5) (55 thru 59=57.5) (60 thru 64=62.5) (65 thru 69=67.5) (70 thru 74=72.5) (75 thru 
79=77.5) (80 thru 84=82.5) (85 thru 105=90) INTO Avg_age_death. 
EXECUTE. 
 
COMPUTE Duration_years=life_expectancy. 
EXECUTE. 
 
FREQUENCIES VARIABLES=PCS_US 
MCS_US 
  /FORMAT=NOTABLE 
  /NTILES=4 
  /STATISTICS=STDDEV VARIANCE MINIMUM MAXIMUM MEAN 
  /ORDER=ANALYSIS. 
 
#Our sample values- Reference Franks et al. 
COMPUTE restar_PCS=43.091387640576535. 
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EXECUTE. 
COMPUTE restar_MCS=47.56822530680328. 
EXECUTE. 
 
DATASET ACTIVATE Conjunto_de_datos1. 
COMPUTE EQ5DS_bis=(0.84690-0.08)+(PCS_US-restar_PCS)*0.01261+(MCS_US-
restar_MCS)*0.00759+(-0.00009*(PCS_US-restar_PCS)**2)+(-0.00015*((MCS_US-
restar_MCS)**2)+(-0.00015*(PCS_US-restar_PCS)*(MCS_US-restar_MCS))). 
EXECUTE. 
 
#Utility. 
COMPUTE utility=EQ5DS_bis. 
EXECUTE. 
COMPUTE disability_weight=1-utility. 
EXECUTE. 
 
COMPUTE YLL_rate0_agewt0=(deaths*1)*(0*0.1658*((EXP(-0.04* 
Avg_age_death))/0.04**2)*((EXP(-0.04* life_expectancy))*(-0.04*( life_expectancy+ 
Avg_age_death)-1)-(-0.04* Avg_age_death-1))+((1-0)* life_expectancy)). 
EXECUTE. 
COMPUTE YLL_rate0_agewt1=(deaths*1)*(1*0.1658*((EXP(-0.04* 
Avg_age_death))/0.04**2)*((EXP(-0.04* life_expectancy))*(-0.04*( life_expectancy+ 
Avg_age_death)-1)-(-0.04* Avg_age_death-1))+((1-1)* life_expectancy)). 
EXECUTE. 
COMPUTE YLL_rate3_agewt0=deaths*1*(0*((0.1658*EXP(0.03*Avg_age_death))/(-
0.07**2))*((EXP(-0.07*( life_expectancy+ Avg_age_death))*(-0.07*( life_expectancy+ 
Avg_age_death)-1))-(EXP(-0.07* Avg_age_death)*(-0.07* Avg_age_death -1)))+((1-
0)/0.03)*((1-EXP(-0.03* life_expectancy)))). 
EXECUTE. 
COMPUTE YLL_rate3_agewt1=-1*(deaths*1*(1*((0.1658*EXP(0.03*Avg_age_death))/(-
0.07**2))*((EXP(-0.07*( life_expectancy+ Avg_age_death))*(-0.07*( life_expectancy+ 
Avg_age_death)-1))-(EXP(-0.07* Avg_age_death)*(-0.07* Avg_age_death -1)))+((1-
1)/0.03)*((1-EXP(-0.03* life_expectancy))))). 
EXECUTE. 
 
   
COMPUTE YLD_rate0_agewt0=(1*disability_weight)*(0*0.1658*((EXP(-
0.04*edad_diag))/0.04**2)*((EXP(-0.04*Duration_years))*(-0.04*(Duration_years+edad_diag)-
1)-(-0.04*edad_diag-1))+((1-0)*Duration_years)). 
EXECUTE. 
COMPUTE YLD_rate0_agewt1=(1*disability_weight)*(1*0.1658*((EXP(-
0.04*edad_diag))/0.04**2)*((EXP(-0.04*Duration_years))*(-0.04*(Duration_years+edad_diag)-
1)-(-0.04*edad_diag-1))+((1-1)*Duration_years)). 
EXECUTE. 
COMPUTE YLD_rate3_agewt0=((1*disability_weight)*(0*((0.1658*EXP(0.03*edad_diag))/(-
0.07**2))*((EXP(-0.07*(Duration_years+edad_diag))*(-0.07*(Duration_years+edad_diag)-1))-
(EXP(-0.07*edad_diag)*(-0.07*edad_diag-1)))+((1-0)/0.03)*((1-EXP(-0.03*Duration_years))))). 
EXECUTE. 
COMPUTE YLD_rate3_agewt1=-1*((1*disability_weight)*(1*((0.1658*EXP(0.03*edad_diag))/(-
0.07**2))*((EXP(-0.07*(Duration_years+edad_diag))*(-0.07*(Duration_years+edad_diag)-1))-
(EXP(-0.07*edad_diag)*(-0.07*edad_diag-1)))+((1-1)/0.03)*((1-EXP(-0.03*Duration_years))))). 
EXECUTE. 
 
COMPUTE DALY_rate0_Agewt0=YLL_rate0_agewt0+YLD_rate0_agewt0. 
EXECUTE. 
COMPUTE DALY_rate0_Agewt1=YLL_rate0_agewt1+YLD_rate0_agewt1. 
EXECUTE. 
COMPUTE DALY_rate3_Agewt0=YLL_rate3_agewt0+YLD_rate3_agewt0. 
EXECUTE. 
COMPUTE DALY_rate3_Agewt1=YLL_rate3_agewt1+YLD_rate3_agewt1. 
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EXECUTE. 
 
##Remove the  DALYs for the patients with age at diagnose missing. n=632. 
## Remove patients with previous fracture that were in the Group of "osteopenia" or "normal". 
 
FREQUENCIES VARIABLES=DALY_rate0_Agewt0 DALY_rate0_Agewt1 DALY_rate3_Agewt0 
DALY_rate3_Agewt1 
  /FORMAT=NOTABLE 
  /NTILES=4 
  /STATISTICS=STDDEV MINIMUM MAXIMUM MEAN MEDIAN 
  /ORDER=ANALYSIS. 
 
*** Recode into a new group variable*. 
IF (grupo_4cat=0) grupo_3cat=0. 
EXECUTE. 
IF (grupo_4cat=1) grupo_3cat=1. 
EXECUTE. 
IF ((grupo_4cat=2) OR (grupo_4cat=3)) grupo_3cat=2. 
EXECUTE. 
value labels grupo_3cat 0'Osteoporosis con fractura' 1'Osteoporosis sin fractura' 2'Normal o 
Osteopenia'. EXECUTE. 
 
 
***Table 6.1***. 
*Socio-demographics, clinical characteristics and participant background for all included women 
and by study group*. 
**[Conjunto_de_datos2] E:\IOMEGA\Copia de seguridad_8-7-09\Freelance\Pfizer - DALYs 
osteoporosis_LK_Jul13\Database and sintaxis\DALY results - 4\Marzo 29\Results 
1\Database29marzo2012_Corregido_table1.sav 
*. 
**Description**. 
FREQUENCIES 
  VARIABLES=grupo_3cat 
  /ORDER=  ANALYSIS . 
 
FREQUENCIES 
  VARIABLES=edadn imcn cign edad_diag  dxan Nfrfo frmosteo 
tiemdiagn/FORMAT=NOTABLE 
  /STATISTICS=STDDEV MEAN 
  /ORDER=  ANALYSIS . 
 
FREQUENCIES 
  VARIABLES=edad_grupo sit_labn niv_estn 
habitatn tabacon alcohn frfo3 dmn h_artn 
art_reumn anor_nern hiperparan hipertiron hepat_cron sind_malabn  
  /ORDER=  ANALYSIS . 
 
*Description and comparision by group*. 
SORT CASES BY grupo_3cat . 
SPLIT FILE 
  LAYERED BY grupo_3cat . 
 
FREQUENCIES 
  VARIABLES=edadn imcn cign edad_diag  dxan Nfrfo frmosteo 
tiemdiagn/FORMAT=NOTABLE 
  /STATISTICS=STDDEV MEAN 
  /ORDER=  ANALYSIS . 
SPLIT FILE 
  OFF. 
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ONEWAY 
  edadn imcn cign edad_diag  dxan Nfrfo frmosteo tiemdiagn BY grupo_3cat 
  /MISSING ANALYSIS . 
 
CROSSTABS 
  /TABLES=edad_grupo sit_labn 
niv_estn habitatn tabacon alcohn frfo3 dmn h_artn 
art_reumn anor_nern hiperparan hipertiron hepat_cron sind_malabn BY grupo_3cat 
  /FORMAT= AVALUE TABLES 
  /STATISTIC=CHISQ 
  /CELLS= COUNT  COLUMN 
  /COUNT ROUND CELL . 
* Osteoporosis therapy background by study group*. 
CROSSTABS 
 /TABLES=med_higien calcion calcio_dn ejercn tra_farmn bifosfon sermn otron BY grupo_3cat 
  /FORMAT= AVALUE TABLES 
  /STATISTIC=CHISQ 
  /CELLS= COUNT  COLUMN 
  /COUNT ROUND CELL . 
 
 
***Figure 6.1***. 
### Overall DALYs both undiscounted and discounted by the study groups 
 
FREQUENCIES VARIABLES= DALY_rate0_Agewt0 DALY_rate0_Agewt1 DALY_rate3_Agewt0 
DALY_rate3_Agewt1 
  /FORMAT=NOTABLE 
  /NTILES=4 
  /STATISTICS=STDDEV VARIANCE MINIMUM MAXIMUM MEAN 
  /ORDER=ANALYSIS. 
 
SORT CASES BY grupo_3cat . 
SPLIT FILE 
  LAYERED BY grupo_3cat . 
 
FREQUENCIES VARIABLES= DALY_rate0_Agewt0 DALY_rate0_Agewt1 DALY_rate3_Agewt0 
DALY_rate3_Agewt1 
  /FORMAT=NOTABLE 
  /NTILES=4 
  /STATISTICS=STDDEV VARIANCE MINIMUM MAXIMUM MEAN 
  /ORDER=ANALYSIS. 
 
SPLIT FILE 
  OFF. 
 
 
***Figure 6.2**. 
#### ANOVAs for the DALY. 
 
#All women <>65 years old 
ONEWAY DALY_rate0_Agewt0 BY edadn_cat65 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt1 BY edadn_cat65 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY edadn_cat65 
  /STATISTICS DESCRIPTIVES  
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  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt1 BY edadn_cat65 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
 
#Anova for the variables grupo_3cat. 
ONEWAY DALY_rate0_Agewt0 BY grupo_3cat 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt1 BY grupo_3cat 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY grupo_3cat 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt1 BY grupo_3cat 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
 
##by age < 65 and age > 65 and 4 groups of classification: OBF, OWBF, Ot  and Normal. 
IF ((grupo_4cat=0) AND (frcv1=0)) grupo_65=00. 
EXECUTE. 
IF ((grupo_4cat=0) AND (frcv1=1)) grupo_65=01. 
EXECUTE. 
IF ((grupo_4cat=1) AND (frcv1=0)) grupo_65=10. 
EXECUTE. 
IF ((grupo_4cat=1) AND (frcv1=1)) grupo_65=11. 
EXECUTE. 
IF ((grupo_4cat=2) AND (frcv1=0)) grupo_65=20. 
EXECUTE. 
IF ((grupo_4cat=2) AND (frcv1=1)) grupo_65=21. 
EXECUTE. 
IF ((grupo_4cat=3) AND (frcv1=0)) grupo_65=30. 
EXECUTE. 
IF ((grupo_4cat=2) AND (frcv1=1)) grupo_65=31. 
EXECUTE. 
value labels grupo_65 00'Osteoporosis con fractura<65' 01'Osteoporosis con fractura=>65' 
10'Osteoporosis sin fractura<65' 11'Osteoporosis sin fractura=>65' 20'Osteopenia<65' 
21'Osteopenia=>65' 30'Normal<65' 31'Normal=>65'. EXECUTE. 
 
ONEWAY DALY_rate0_Agewt0 BY grupo_65 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt1 BY grupo_65 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY grupo_65 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt1 BY  grupo_65 
  /STATISTICS DESCRIPTIVES  
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  /PLOT MEANS 
  /MISSING ANALYSIS. 
 
 
***Figure 6.3**. 
* DALYs loss, with and without discount by the presence of a risk factor. Mean and 95% 
confidence intervals. 
 
USE ALL. 
COMPUTE filter_$=(grupo_3cat=0 & grupo_3cat=1). 
VARIABLE LABEL filter_$ 'grupo_3cat=0 & grupo_3cat=1 (FILTER)'. 
VALUE LABELS filter_$  0 'No seleccionado' 1 'Seleccionado'. 
FORMAT filter_$ (f1.0). 
FILTER BY filter_$. 
EXECUTE . 
 
T-TEST 
  GROUPS = frfo1(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = DALY_rate0_Agewt0 DALY_rate3_Agewt0 
  /CRITERIA = CI(.95) . 
T-TEST 
  GROUPS = frfo4(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = DALY_rate0_Agewt0 DALY_rate3_Agewt0 
  /CRITERIA = CI(.95) . 
T-TEST 
  GROUPS = frfo2(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = DALY_rate0_Agewt0 DALY_rate3_Agewt0 
  /CRITERIA = CI(.95) . 
T-TEST 
  GROUPS = frfo3(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = DALY_rate0_Agewt0 DALY_rate3_Agewt0 
  /CRITERIA = CI(.95) . 
T-TEST 
  GROUPS = art_reumn(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = DALY_rate0_Agewt0 DALY_rate3_Agewt0 
  /CRITERIA = CI(.95) . 
T-TEST 
  GROUPS = fam_osteon(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = DALY_rate0_Agewt0 DALY_rate3_Agewt0 
  /CRITERIA = CI(.95) . 
T-TEST 
  GROUPS = frfo8(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = DALY_rate0_Agewt0 DALY_rate3_Agewt0 
  /CRITERIA = CI(.95) . 
T-TEST 
  GROUPS = sermnn(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = DALY_rate0_Agewt0 DALY_rate3_Agewt0 
  /CRITERIA = CI(.95) . 
 
FILTER OFF. 
USE ALL. 
EXECUTE . 
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***Table 6.2**. 
* Variables associated with DALY loss, undiscounted and discounted; adjusted by BD and 
previous osteoporosis BF. 
 
#Undiscounted DALYs 
 
ONEWAY DALY_rate0_Agewt0 BY dxan 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt0 BY frfo4 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt0 BY imc_20_cat 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt0 BY frfo2 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt0 BY frfo3 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt0 BY art_reumn 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt0 BY fam_osteon 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate0_Agewt0 BY frfo8 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
 
**Final model*. 
UNIANOVA DALY_rate0_Agewt0  BY frfo4 art_reumn fam_osteon frfo8 WITH dxan 
  /METHOD=SSTYPE(3) 
  /INTERCEPT=INCLUDE 
  /PRINT=PARAMETER DESCRIPTIVE 
  /CRITERIA=ALPHA(.05) 
  /DESIGN=frfo4 art_reumn fam_osteon frfo8 dxan . 
 
#Discounted DALYs 
 
ONEWAY DALY_rate3_Agewt0 BY dxan 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY frfo4 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY imc_20_cat 
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  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY frfo2 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY frfo3 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY art_reumn 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY fam_osteon 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
ONEWAY DALY_rate3_Agewt0 BY frfo8 
  /STATISTICS DESCRIPTIVES  
  /PLOT MEANS 
  /MISSING ANALYSIS. 
 
**Final model*. 
UNIANOVA DALY_rate3_Agewt0  BY frfo4 art_reumn frfo8 WITH dxan 
  /METHOD=SSTYPE(3) 
  /INTERCEPT=INCLUDE 
  /PRINT=PARAMETER DESCRIPTIVE 
  /CRITERIA=ALPHA(.05) 
  /DESIGN=frfo4 art_reumn frfo8 dxan . 
 
*** Missing data analysis ***. 
**4 March de 2013, file: “missing_data_analysis.sps”**. 
 
FREQUENCIES 
  VARIABLES=DALYs_available 
  /ORDER=  ANALYSIS . 
 
**Comparing the variables at TABLE 6.4.1: ptes with DALY missing vs. DALY available**. 
*Socio-demographic data*. 
 
T-TEST 
  GROUPS = DALYs_available(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = edadn 
  /CRITERIA = CI(.95) . 
CROSSTABS 
  /TABLES=edad_grupo sit_labn niv_estn habitatn BY DALYs_available 
  /FORMAT= AVALUE TABLES 
  /STATISTIC=CHISQ 
  /CELLS= COUNT ROW COLUMN 
  /COUNT ROUND CELL . 
 
*Clinical characteristics* 
T-TEST 
  GROUPS = DALYs_available(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = imcn cign 
  /CRITERIA = CI(.95) . 
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CROSSTABS 
  /TABLES=tabacon alcohn gramosn  BY DALYs_available 
  /FORMAT= AVALUE TABLES 
  /STATISTIC=CHISQ 
  /CELLS= COUNT ROW COLUMN 
  /COUNT ROUND CELL . 
 
**Background* 
CROSSTABS 
  /TABLES=dmn h_artn art_reumn anor_nern hiperparan hipertiron hepat_cron sind_malabn  
BY DALYs_available 
  /FORMAT= AVALUE TABLES 
  /STATISTIC=CHISQ 
  /CELLS= COUNT ROW COLUMN 
  /COUNT ROUND CELL . 
 
***Osteoporosis data*. 
T-TEST 
  GROUPS = DALYs_available(0 1) 
  /MISSING = ANALYSIS 
  /VARIABLES = edad_diag dxan Nfrfo Frmosteo tiemdiagn 
  /CRITERIA = CI(.95) . 
CROSSTABS 
  /TABLES=imc_20_cat  BY DALYs_available 
  /FORMAT= AVALUE TABLES 
  /STATISTIC=CHISQ 
  /CELLS= COUNT ROW COLUMN 
  /COUNT ROUND CELL . 
 
 
********** Logistic regression***. 
**All variables***. 
LOGISTIC REGRESSION VARIABLES  DALYs_available 
  /METHOD = ENTER edadn sit_labn 
niv_estn 
habitatn  
imcn cign 
tabacon 
alcohn 
gramosn 
dmn 
h_artn 
art_reumn 
anor_nern 
hiperparan 
hipertiron 
hepat_cron 
sind_malabn 
 edad_diag 
dxan 
Nfrfo 
Frmosteo 
tiemdiagn 
  /CONTRAST (sit_labn)=Indicator(1) 
  /CONTRAST (niv_estn)=Indicator(1) 
  /CONTRAST (habitatn)=Indicator(1) 
  /CONTRAST (tabacon)=Indicator(1) 
  /CONTRAST (alcohn)=Indicator(1) 
  /CONTRAST (gramosn)=Indicator(1) 
  /CONTRAST (dmn)=Indicator(1) 
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  /CONTRAST (h_artn)=Indicator(1) 
  /CONTRAST (art_reumn)=Indicator(1) 
  /CONTRAST (anor_nern)=Indicator(1) 
  /CONTRAST (hiperparan)=Indicator(1) 
  /CONTRAST (hipertiron)=Indicator(1) 
  /CONTRAST (hepat_cron)=Indicator(1) 
  /CONTRAST (sind_malabn)=Indicator(1) 
  /PRINT = GOODFIT CI(95) 
  /CRITERIA = PIN(.05) POUT(.10) ITERATE(20) CUT(.5) . 
 
 
**Assess and avoid multicolinearity**. 
LOGISTIC REGRESSION VARIABLES  DALYs_available 
  /METHOD = ENTER edadn sit_labn 
niv_estn 
habitatn  
imcn 
tabacon 
gramosn 
dmn 
h_artn 
art_reumn 
anor_nern 
hiperparan 
hipertiron 
hepat_cron 
sind_malabn 
 edad_diag 
dxan 
Nfrfo 
Frmosteo 
tiemdiagn 
  /CONTRAST (sit_labn)=Indicator(1) 
  /CONTRAST (niv_estn)=Indicator(1) 
  /CONTRAST (habitatn)=Indicator(1) 
  /CONTRAST (tabacon)=Indicator(1) 
  /CONTRAST (gramosn)=Indicator(1) 
  /CONTRAST (dmn)=Indicator(1) 
  /CONTRAST (h_artn)=Indicator(1) 
  /CONTRAST (art_reumn)=Indicator(1) 
  /CONTRAST (anor_nern)=Indicator(1) 
  /CONTRAST (hiperparan)=Indicator(1) 
  /CONTRAST (hipertiron)=Indicator(1) 
  /CONTRAST (hepat_cron)=Indicator(1) 
  /CONTRAST (sind_malabn)=Indicator(1) 
  /PRINT = GOODFIT CI(95) 
  /CRITERIA = PIN(.05) POUT(.10) ITERATE(20) CUT(.5) . 
 
**Final model include all the significative ones, removing from the multivariate model the non 
significative ones (one by one) 
**Avoiding multicolinearity and without including Dexa**. 
*** Selected model to be reported in the reviewer answer ****. 
LOGISTIC REGRESSION VARIABLES  DALYs_available 
  /METHOD = ENTER imc_20_cat Nfrfo Frmosteo 
  /CONTRAST (imc_20_cat)=Indicator(1) 
  /PRINT = GOODFIT CI(95) 
  /CRITERIA = PIN(.05) POUT(.10) ITERATE(20) CUT(.5) . 
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